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Abstract 
Fungal infections are increasing in frequency throughout the world. The development 
of new diagnostic and treatment strategies has not kept pace with this increase. Anti-
fungal treatment options are limited to azoles and echinocandins, which are limited in 
spectrum, and the polyenes, which are toxic to human cells [1]. As treatments are 
limited in efficacy, there is a high incidence of recurrence and high mortality. The 
pathogenic yeasts Cryptococcus neoformans and Cryptococcus gattii, provide an 
excellent system for determining the spectrum of fungal growth and infection, from 
environmental saprotrophic growth, to self-limiting infection and through to severe 
primary infection. C. neoformans and C. gattii are the primary causative agents of 
cryptococcosis [2], however, the biological processes of in vivo Cryptococcus 
pathogenesis, and the host response to infection, at the molecular level remain a 
mystery.  
Unlike bacterial pathogens, where a single gene can determine virulence, fungal 
pathogens require a minimum set of interacting virulence-associated properties for 
establishing and maintaining infection [3, 4]. The interplay between these during the 
infectious process is difficult to unravel by conventional genetic methods. Global 
approaches using proteomics allow differential gene expression to be investigated at a 
whole organism level. Furthermore, as proteins are targets for diagnostic tests and 
drug interventions, proteome approaches are the most rapid, reliable and powerful 
means of identifying potentially useful targets [5-9]. However, at this point in time, 
there is an absence of proteomic analyses of in vivo fungal infection. This is likely a 
result of the inherent technical issues associated with the fungal proteomics and 
mammalian pulmonary infection models.  
  
 
 iii 
This study focused on using comparative proteomic techniques to elucidate the 
proteins vital to Cryptococcus pathogenesis and the mammalian host response to 
pulmonary infection. Cryptococcus cells obtained from pulmonary infection and rat 
lung tissue represented technically challenging sample types that required significant 
protocol development prior to comparative analysis. Combined with the use of a 
mammalian model of infection, this subjected the data that were obtained to a number 
of experimental caveats. Despite the impediments to experimentation, the advances 
made in protocol development by this study allowed for the first in vivo analysis of 
intracellular Cryptococcus protein expression. This result provided proof of concept 
for global "–omics" analysis of Cryptococcus from an in vivo sample. In addition, 
qualitative data were obtained that offered insights into fungal pathogenesis at the 
protein level and highlighted a number of Cryptococcus proteins that could be 
exploited as drug targets.  
The application of iTRAQ to rat lung tissue provided the first demonstration of the 
global host lung protein response to pulmonary infection with Cryptococcus of 
differing species and virulence levels. iTRAQ comparative proteomic analysis 
suggested that the basic responses to pulmonary infection with Cryptococcus of 
different species and different virulence levels are uniform, regardless of disease 
outcome. While the identified lung proteins did not indicate the eventual outcome of 
disease, the analysis permitted inferences to be drawn regarding the potential 
therapeutic use of a number of differentially expressed proteins. The elucidation of 
the host response to infection with Cryptococcus was further pursued via Bio-Plex 
comparative cytokine analysis. This analysis found that pulmonary infection with 
virulent Cryptococcus progressed despite increased expression of cytokines, 
chemokines and growth factors that classically result in infection inhibition and/or 
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eradication. This study indicates that protection from the threat of infection and 
disease progression with highly virulent strains of Cryptococcus requires the 
development of novel anti-Cryptococcus therapeutic agents. 
The identification of intracellular Cryptococcus proteins and host lung proteins and 
systemic cytokines of biological relevance to pulmonary cryptococcosis provides 
proof of the ability of comparative proteomics to elucidate future drug targets, 
biomarkers and diagnostic markers from in vivo mammalian infection models. The 
studies’ most significant achievement has been the advances made in protocol 
development. It is hoped that these advances will lead to further, potentially 
quantitative, analysis of fungal pathogens under in vivo conditions, along with 
continued development of novel therapeutic and diagnostic options for pathogenic 
fungi. 
 
  
  
 
 v 
Abbreviations 
1-D SDS-PAGE One dimensional/sodium dodecyl sulphate/polyacrylamide gel 
electrophoresis 
2-D PAGE Two dimensional/polyacrylamide gel electrophoresis 
2-D nanoLC ESI 
MS/MS 
Two dimensional/nano-liquid chromatography/electrospray 
ionization/tandem mass spectrometry 
ACN Acetonitrile 
AIDS Acquired immunodeficiency syndrome 
C7BzO 3-(4-Heptyl)phenyl-3-
hydroxypropyl)dimethylammoniopropanesulfonate 
cm   Centimetre(s) 
ddH2O Double distilled water 
DIGE Difference gel electrophoresis 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DTT Dithiothreitol 
ELISA Enzyme-linked immunosorbent assay 
G-CSF  Granulocyte-colony stimulating factor 
GalXM Galactoxylomannan 
GM-CSF  Granulocyte macrophage-colony stimulating factor 
GXM Glucuronoxylomannan 
HIV Human immunodeficiency virus 
IDA  Information dependent acquisition mode 
IEF Isoelectric focusing 
IFN  Interferon 
IL  Interleukin 
IPG Immobilised pH gradient 
iTRAQ  Isobaric tags for relative and absolute quantitation 
kDa  Kilodalton(s) 
LDS Lithium dodecyl sulphate 
LiCl Lithium chloride 
LPS  Lipopolysaccharide 
M  Molar 
m/z Mass to charge ratio 
MES 2-(N-morpholino)ethanesulfonic acid 
MHC  Major histocompatibility complex 
min(s)  Minute(s) 
MIP  Macrophage inflammatory protein 
mL  Millilitre 
mm  Millimetre 
mM  Millimolar 
MMTS  Methyl methanethiosulfonate 
mRNA Messenger ribonucleic acid 
NK cells Natural Killer cells 
PBS  Phosphate buffered saline 
PBS-T Phosphate buffered saline with Tween 20 
pI Isoelectric point 
PVDF Polyvinylidene fluoride 
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RANTES  Regulated upon activation, normal T cell expressed and secreted 
RNA  Ribonucleic acid 
SCX HPLC Strong cation-exchange/high-performance liquid 
chromatography 
SD  Standard deviation 
SDS  Sodium dodecyl sulphate 
TBP Tributylphosphine 
TBS Tris-buffered saline 
TCEP   Tris(2-carboxyethyl)phosphine 
TEAB  Tetraethylammonium bromide 
TGF  Transforming growth factor 
TNF  Tumour necrosis factor 
TOF-MS  Time-of flight mass spectrometer 
VEGF  Vascular endothelial growth factor 
x g  Units of centrifugal force, i.e. earth’s gravitational acceleration 
α  Alpha 
β  Beta 
γ  Gamma 
δ  Delta 
µm  Micron 
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Chapter One 
Introduction 
This introduction includes a brief description of the current understanding of the C. 
neoformans-C. gattii species complex including the basic characteristics required for 
pathogenesis and the major virulence factors involved in pathogenesis. In addition, 
this introduction will encompass a brief review of the proteomic techniques 
applicable to the study of the C. neoformans-C. gattii species complex during both in 
vitro growth and in vivo mammalian infection.  
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1.1. The C. neoformans-C. gattii species complex 
Fungi are ubiquitous in both the natural and urban environment. It has been estimated 
that the fungal Kingdom contains 1.5 million fungal species [10] of which 
approximately 140,000 have been formally identified by taxonomists [11]. Despite 
their ubiquitous nature, less than 0.01% of fungi species are capable of causing human 
disease [12, 13]. Included in this selective group of pathogenic fungi are the 
Cryptococcus neoformans and Cryptococcus gattii yeast species. Cryptococcus 
belongs to the Filobasidella clade of the Tremellales (Order Tremellomycetes) (figure 
1.1) [14]. The genus Cryptococcus contains around 37 recognised fungal species, the 
majority of which do not cause disease in mammals [15]. The C. neoformans-C. gattii 
species complex includes C. neoformans var. neoformans, C. neoformans var. grubii 
and C. gattii, which are the most common causative agents of cryptococcosis [16, 17]. 
C. neoformans and C. gattii are free-living in the environment and do not require an 
infective step in their lifecycle to propagate.  C. neoformans and C. gattii are not 
considered zoonotic pathogens [18] and this appears to be true apart from a handful of 
zoonotic transfer cases involving immune-suppressed patients [19, 20]. Rather, 
mammals acquire the organism from environmental sources. Disease as a result of C. 
neoformans or C. gattii infection, known as cryptococcosis, generally begins in the 
lungs before haematogenous dissemination to other organs, with a predilection for the 
central nervous system (figure 1.2) [16, 21]. The result of brain invasion is 
cryptococcal meningoencephalitis that is always fatal without antifungal therapy. In 
fact, mortality remains at almost 20% despite aggressive antifungal therapy [22]. 
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Figure 1.1: Scanning electron microscopy of C. neoformans 
Scanning electron microscopy of A) C. neoformans grown in rich media, B – D) C. neoformans 
obtained from pulmonary infection (scale bar from B applies to C and D) (from [23]). 
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Figure 1.2: The cryptococcal virulence pathway  
Cryptococcus survives in the environment where it can interact with animals or microbial predators. 
Inhaled desiccated yeast cells or spores establish mammalian pulmonary infection. The fungus can then 
spread from the lungs and enter the central nervous system (CNS) through the microcapillaries of the 
blood–brain barrier. Dashed arrows indicate that pathways are hypothetical (from [24]). 
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C. neoformans and C. gattii are so closely related, having diverged from each other 
approximately 37-49 million years ago [25], that until recently they were considered 
varieties of a single species (figure 1.3) [26-28]. Despite the fact that the two species 
share all known major virulence factors [16], there are numerous differences between 
the species with regard to ecology, epidemiology, pathobiology, biochemistry and 
genetics [27]. A clear distinction between the two Cryptococcus species is that C. 
neoformans is primarily an opportunistic pathogen that causes a self-limiting 
asymptomatic, chronic disease whereas C. gattii produces a relentlessly progressive 
infection that readily results in the death of otherwise healthy hosts [29, 30]. C. gattii 
is therefore classified as a primary pathogen. A further defining discrepancy between 
the two species is that C. neoformans has a worldwide distribution in association with 
avian guano while C. gattii has traditionally been considered to be geographically 
restricted to tropical and sub-tropical climates in association with Eucalypt trees [31-
33]. However, a recent outbreak of C. gattii induced cryptococcosis in the temperate 
climate of Vancouver Island, British Columbia, Canada is challenging this proposed 
geographical restriction [32, 34].  
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Figure 1.3: Schematic phylogeny of the C. neoformans-C. gattii species complex 
For C. neoformans, two monophyletic lineages, corresponding to variety grubii and neoformans 
consistently present along with the hybrid population. Serotypes correspond to genotypes. For C. gattii, 
four monophyletic lineages corresponding to the previously described genotypic groups are 
consistently found. Serotypes and genotype do not correlate. The molecular types VNIV and VGII 
form the basal clades within the C. neoformans and C. gattii branches of the phylogenetic tree, 
respectively (from [35]). 
 
Cryptococcus classification is based on serotype, as determined by specific capsular 
antigens, and by molecular genotyping, which further defines diversity at the sub-
species and sub-variety level. The C. neoformans-C. gattii species complex is divided 
into the following serotypes: C. neoformans var. neoformans = serotype D, C. 
neoformans var. grubii = serotype A, a mixed C. neoformans = serotype AD (diploid 
hybrid) and C. gattii = serotype B or C. The development of modern molecular 
technologies and genomic analyses resulted in the confirmation of C. neoformans and 
C. gattii as separate species [36]. Genotyping has been performed using a variety of 
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molecular techniques such as PCR fingerprinting, AFLP, RFLP, RAPD and MLST. 
Molecular genotyping further defines diversity within serotypes. C. neoformans var. 
grubii (serotype A) includes molecular types VNI and VNII. C. neoformans var. 
neoformans (serotype D) comprises molecular type VNIV and the hybrid serotype 
AD is molecular type VNIII. C. gattii (serotypes B and C) is divided into molecular 
types VGI, VGII, VGIII and VGIV [37], with no clear correlation between the 
serotypes and genotypes. Genetic subtypes exist within some molecular types, for 
example VGII is subdivided into subtypes VGIIa, VGIIb and VGIIc. The molecular 
genotyping of the C. neoformans-C. gattii species complex not only provides a more 
precise classification method, it also provides the scientific community with a tool to 
aid our understanding of the relationships both within and between geographic areas. 
 
1.2. C. gattii and the cryptococcosis outbreak on Vancouver Island 
C. gattii was first identified in 1970 after being isolated from a leukemic patient [38]. 
Since that time it has been shown to differ from C. neoformans in phenotypic 
characteristics, natural habitat, epidemiology, clinical manifestations of disease and 
response to antifungal therapy [28]. Despite increasing evidence of C. gattii as an 
emerging primary human pathogen, during the past 4 decades this pathogenic 
organism has remained understudied. This can be largely attributed to the fact that 
less than 1% of cryptococcosis cases worldwide are a result of infection with C. gattii 
[35]. Furthermore, it was previously believed that the organism was geographically 
restricted to tropical and subtropical environs. A recent outbreak of cryptococcosis in 
human and animal hosts as a result of C. gattii has increased the rate of C. gattii 
related cryptococcosis cases and has resulted in the reassessment of the geographic 
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range limits of this fungal pathogen. The outbreak and spread of what appears to be a 
hyper-virulent clone of C. gattii has stimulated interest in the scientific investigation 
of this pathogenic organism. The outbreak was first acknowledged in 1999 on 
Vancouver Island, British Columbia, Canada, and is continuing to spread into 
northwestern United States of America with fatal consequences (figure 1.4) [32, 39-
41]. The vast majority of C. gattii isolates involved in the outbreak have been 
identified as belonging to the VGII molecular type [35]. These VGII isolates have 
been further separated into two subtypes, a major hyper-virulent form that is common 
in environmental and clinical isolates (VGIIa) and a rare, less virulent minor form 
(VGIIb) [37, 42, 43]. The obvious question arises as to how and why these subtypes, 
and especially VGIIa, have become such a pathogenic threat in relatively recent times. 
 
Figure 1.4: Map of the Pacific Northwest  
Shows human and veterinary C. gattii cases (including marine mammals) by place of residence or 
detection, and locations of environmental isolation of C. gattii during 1999–2008 (from [40]). 
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1.3. The association between the global environment and the 
emergence of fungal pathogens 
Human infections and diseases are intricately linked to the global environment [44]. 
The exact consequences of the alteration of the global environment via the effects of 
global warming on the emergence, or re-emergence, of infectious diseases are as to 
this date only theoretical and are heavily dependent on the complex interaction 
between the host population and the causative agent [44, 45]. It is postulated that 
global warming could lead to human migration, crowding, famine, water 
contamination, changes in vector ecology, the spread of infectious diseases to 
environs which where previously unsuitable and the straining/breakdown of public 
health services [44, 46]. Global warming could have some very real detrimental 
effects to mammalian hosts in the case of fungal diseases, such as cryptococcosis.  
Fungi cause relatively few diseases in mammals, despite being major pathogens of 
plants, other fungi, rotifers, insects and amphibians [47]. Mammals have a high 
resistance to fungal infections as a result of a combination of possessing a complex 
immune system and endothermy. Body temperatures above that of environmental 
temperatures create a thermally restrictive barrier for the majority of fungi. Fungi 
have only come into prevalence as human pathogens as a result of increasing rates of 
impaired immunity due to medical interventions and the onset of the HIV/AIDS 
epidemic in the late 20th century. It has been hypothesised that global warming could 
increase geographic range of pathogenic species and select for adaptive 
thermotolerance, that is, the ability to grow at and above mammalian body 
temperatures [48]. Both C. gattii and C. neoformans are infective organisms that 
display thermotolerance, and the opening of new environmental niches to these 
potentially deadly organisms could have serious consequences for public health. The 
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risk of newly emerging fungal pathogens will be magnified by the apparent lack of 
effective antifungal drugs and the absolute lack of vaccines. A better understanding of 
fungal pathogenesis is paramount to the identification of novel drug targets and the 
development of antifungal drugs and possibly vaccines. 
 
1.4. Cryptococcal pathogenesis 
1.4.1. Host invasion 
There is a general consensus that cryptococcal cells most commonly enter the host via 
the respiratory tract.  Infection is initiated when the fungal propagules enter the 
alveolar space. Infections can also be initiated in other tissues via trauma and may 
also be acquired via the gastrointestinal tract [49]. Fungal propagules 1-2 µm in 
diameter result in the highest rate of deposition in the respiratory spaces of the lungs 
[50]. Above this size penetration and deposition efficiency decreases due to the fact 
that fewer particles escape upper respiratory trapping and expulsion. Below this size 
lobular deposition is retarded due to the fact that gravitational settlement within the 
alveolar space decreases. Cryptococcal cells fit this size criterion when in the form of 
desiccated haploid yeast cells (<2 µm diameter) or as basidiospores (1-3 µm diameter) 
[51].  
 
1.4.2. Intracellular survival and dissemination 
Many aspects of cryptococcal pathogenesis are poorly understood.  This is especially 
true of C. gattii pathogenesis. However, there is broad consensus in the literature that 
subsequent to deposition in the alveolar spaces, highly virulent strains of 
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Cryptococcus are able to surmount the initial host defence barrier, namely alveolar 
macrophages, and disseminate utilising unique pathogenic strategies. It has been 
demonstrated experimentally that the interaction of cryptococcal cells with host 
phagocytes, including macrophages and monocytes, is vital for the persistence and 
proliferation of cryptococcal disease. Indeed it has been determined that these 
pathogenic fungi replicate inside and escape alive from phagocytic cells, the very 
cells that are designed to eradicate infection [52-54]. It is during facultative 
intracellular infection that cryptococcal cells undergo microevolution and phenotypic 
switching resulting in the enhanced expression of key virulence factors that increase 
the pathogenicity of the infectious particles [55]. These virulence factors are 
paramount to cryptococcal host infection and dissemination. These aspects of 
cryptococcal infection will be discussed at greater length in a following section.  
In addition to replication within phagocytes, it has been recently demonstrated that 
cryptococcal cells have the ability to undergo lateral transfer between phagocytes, 
moving directly from infected to uninfected phagocytes (figure 1.5). Although this is 
a rare event that has only been observed within in vitro systems, it has been 
hypothesised that direct cell-to-cell spread may occur repeatedly during Cryptococcus 
infections, allowing the pathogen to remain concealed from the immune system and 
protecting it from exposure to antifungal agents [56, 57]. This strategy would not only 
allow the fungus to persist within the host during latent infections, but also provides a 
plausible model for the mode of the spread of infection, whereby phagocytes act as 
the vehicle for dissemination of Cryptococcus cells throughout the host [58, 59]. 
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Figure 1.5: Cell-to-cell transfer of C. neoformans leads to infection of previously 
uninfected cells  
The thin arrow indicates the cryptococcal cell that is being transferred while the wide arrow points to 
the cryptococcal cell that has been fully transferred to the previously uninfected macrophage cell (from 
[56]). 
 
1.4.3. Invasion of the central nervous system 
Although cryptococcal cells have the capability to infect any organ, the infection of 
the central nervous system is one of the most common clinical manifestations and is 
the leading cause of death from cryptococcosis. The apparent neurotropism observed 
during cryptococcal infection is the result of C. neoformans and C. gattii being able to 
utilise catecholamines, a compound the brain is rich in, as a carbon source. 
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Cryptococcus cells are thought to invade the brain and cerebrospinal fluid via 
circulating blood [60]. In order to penetrate into the brain, cryptococcal cells must 
transverse the endothelium of the blood-brain barrier or the epithelium of the blood-
cerebrospinal fluid barrier. The exact method by which this process occurs is one of 
the least understood steps of cryptococcosis. It is known that microbial pathogens 
may cross the blood-brain barrier transcellularly (passage through the brain micro-
vascular endothelial cells), paracellularly (passage between the cells of an epithelium) 
and/or by means of infected immune cells (also known as the Trojan horse 
mechanism whereby infected immune cells carry the pathogen across the blood brain 
barrier) (figure 1.6) [61]. Multiple studies have provided evidence for both the 
transcellular [62] and Trojan horse mechanism [58, 59] of brain invasion, however the 
role of paracellular passage remains uncertain. 
 
Figure 1.6: Possible methods that Cryptococcus uses to transverse the 
endothelium of the blood-brain barrier or the epithelium of the blood-
cerebrospinal fluid barrier (from [35]). 
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1.5. Factors key to cryptococcal infection 
The factors that make C. neoformans and C. gattii a pathogen are divided into two 
major groups, namely the characteristics required for the fungi to establish infection 
and survive in the human host and the virulence factors that increase the degree of 
pathogenicity [51]. The basic characteristics for pathogenicity are absolutely essential 
for the survival of C. gattii and C. neoformans within animal and human hosts. Thus, 
these basic characteristics are paramount for the initiation and progression of 
cryptococcal disease. 
 
1.5.1. Basic characteristics of pathogenesis 
1.5.1.1. The infectious propagule 
To enter the alveolar spaces of the lungs, so as to establish pulmonary infection, an 
organism must produce viable forms that are smaller than 4 µm in diameter. Although 
the exact nature of the infectious propagules responsible for cryptococcosis remains 
unknown, they have been hypothesised to be dehydrated yeast cells or basidiospores 
[63]. The typical vegetative form of C. neoformans and C. gattii is the yeast form with 
a cell diameter ranging from 2.5 - 10 µm, depending on environmental conditions 
[16]. Thus, cells in the lower region of this size range are capable of entering the 
alveolar spaces of the lungs. Basidiospores range in size from 1 - 3 µm and hence are 
also capable of entering the alveolar spaces of the lungs. Basidiospores are produced 
during sexual reproduction between α- and a-mating types, an event that has not been 
observed directly in nature but readily occurs on appropriate media [63].  
An organism’s ability to generate spores depends on the presence of appropriate 
mating partners and the fertility of the strains (figure 1.7). In specific cases, the degree 
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of strain fertility, and thus its ability to undergo sexual reproduction, has been 
correlated to the virulence of the strain [64-66]. There is also evidence that an 
organism’s ability to undergo sexual reproduction and thus sexual recombination 
facilitates its ability to adapt to new environments and be more tolerant of harsh 
environs via an increased capability of generating genetic diversity [66-68]. Thus, 
there is a direct relationship between fertility and virulence in Cryptococcus. This 
concept is especially interesting with regard to C. gattii virulence and the Vancouver 
Island outbreak. It has also been demonstrated that viable basidiospores are produced 
during monokaryotic fruiting events that occur when cells are under nitrogen 
starvation (figure 1.7) [69]. Monokaryotic fruiting was once believed to be linked 
exclusively to the MATα locus and thus a-mating type strains, which posses the MATa 
locus, were once thought to be unable to produce haploid fruiting bodies. Recent 
research has proven that this is not the case, rather that both α- and a-mating types can 
undergo monokaryotic fruiting events [70]. Regardless of the nature of the infectious 
propagule, it is known that if a cryptococcal strain is unable to produce small 
infectious propagules it cannot be pathogenic [51].  
 
Figure 1.7: Model of the Cryptococcus lifecycle showing basidiospore production  
(from [24]).  
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1.5.1.2. Growth under in vivo conditions 
In order to cause infection in humans, C. neoformans and C. gattii isolates must be 
able to efficiently grow at 37 °C in an atmosphere of approximately 5 % CO2 at a pH 
of 7.3 to 7.4. It has been established that many cryptococcal genes are regulated by 
temperature; however, the exact mechanisms by which cryptococcal species tolerate 
high-temperature growth are not entirely understood. A number of studies have 
identified approximately 50 genes that are either induced or up-regulated by high 
temperature growth, of which over a dozen have been identified as being necessary 
for high-temperature growth [71-73]. The gene encoding the calcineurin A catalytic 
subunit is one such essential gene. This serine-threonine specific phosphatase is 
activated by Ca2+-calmodulin and is involved in stress responses in yeasts. 
Calcineurin A mutants are unable to survive at 37 °C, in 5 % CO2 or at alkaline pH 
[74].  It has been predicted that calcineurin A would not represent a likely candidate 
for drug therapy due to Cryptococcus calcineurin sharing striking identity with other 
calcineurins, including human calcineurin [74]. Calcineurin inhibitors, which are the 
mainstay of post-transplantation immunosuppression [75], are inherently toxic, 
especially to the kidneys [76]. However, the fact that calcineurin A is a basic 
requirement of Cryptococcus survival in the host and thus an absolutely necessary 
feature for the pathogenicity of the organism continues to drive research attempting to 
harness calcineurin as an anti-fungal agent [74, 77].  
 
1.5.2. Virulence factors 
Virulence factors act to increase the degree of pathogenicity of a microbe. C. 
neoformans and C. gattii have been found to share all known major virulence factors, 
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a number of which have been well defined. Although virulence factors do not serve as 
potential targets in the hunt for a definitive cure for cryptococcal disease, inhibitors 
and vaccines designed to act upon the components of the cryptococcal virulence 
phenotype may be useful in the treatment and/or prevention of cryptococcosis [78]. 
There appears to be a general consensus that capsule synthesis, cryptococcal products 
(exopolysaccharides, mannoproteins etc.), melanin production, mannitol production 
and phenotypic switching are the major virulence factors during cryptococcal 
infection. Cryptococcal infection has been further associated with phospholipase [78], 
a myriad of proteases, urease [79], thiol peroxidise [80] and superoxide dismutase 
activity [81]. A review of every potential virulence factor is beyond the scope of this 
introduction. Thus, the focus will be on the major virulence factors of cryptococcal 
infection. 
1.5.2.1. The Cryptococcus capsule 
The capsule is widely regarded as the main virulence factor of C. neoformans and C. 
gattii (figure 1.8). Indeed, experimental evidence demonstrates that acapsular mutant 
strains are typically avirulent whilst encapsulated isolates have varying degrees of 
virulence [82, 83]. Until recently there had been no identified correlation between 
capsule thickness and the virulence of a strain [84]. Pool et al. (2013) demonstrated 
that, in the context of neuro-pathogenesis, hypercapsular strains of Cryptococcus were 
less virulent that strains that produced less capsule, and that neuro-virulence is related 
to total capsule accumulation rates and total capsule volume rather than the amount of 
capsule produced per organism [85]. The correlation between capsule thickness and 
Cryptococcus virulence during pulmonary infection, however, remains enigmatic.  
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Figure 1.8: C. gattii obtained from pulmonary infection showing the very large 
Cryptococcus capsule. 
 
The cryptococcal capsule has been associated with chemotactic effects on leukocytes 
that protect the organism from host defences, with complement depletion in the host 
that creates a favourable environment for the cryptococcal cells, and also with altered 
cytokine production, which compromises the protective responses of the host [86]. It 
has also been determined that glucuronoxylomannan (GXM), the major component of 
the cryptococcal capsule, has immunosuppressive effects. GXM promotes T-cell 
apoptosis, indicating that GXM is a negative regulator that suppresses self-reactive 
lymphocytes [87].   
The cryptococcal capsule is a complex structure that displays variable density and 
porosity and is highly plastic depending on the ionic strength of the aqueous 
environment [88, 89]. The capsule is composed primarily of polysaccharides. The 
major polysaccharide component is the high molecular weight GXM (1.2-1.5 × 106 
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Da), which accounts for approximately 88 % of the capsule mass.  The polysaccharide 
galactoxylomannan (GalXM) (1.5 × 105 Da) accounts for roughly 7 % of capsule 
mass and is considered a minor capsular component along with mannoproteins. 
Cryptococcus capsule synthesis strategies could theoretically generate an infinite 
number of structural combinations. This structural heterogeneity is a result of 
differing molar ratios of xylose, the extent of O-acetylation and the glucuronic acid 
positional differences in the primary capsule constituent GXM. The biological 
consequence is the production of a powerful avoidance strategy for interactions with 
host immune systems and phagocytic environmental predators [90]. The 
polysaccharide capsule is non-covalently anchored to the cell wall via α-1,3-glucan  
(figure 1.9) [91]. This was demonstrated via the observation that mutants lacking cell 
wall α-1,3-glucan no longer display capsule polysaccharide on their surfaces, 
although they do continue to shed this material into the environment. These mutant 
cells were further found to grow slowly and were temperature sensitive. These results 
strongly suggest that the cryptococcal capsule is important for cellular survival [92].   
 
Figure 1.9: Electron microscopy of the cell wall-capsule interface.  
Depicts an arc of cell wall separating the cellular interior from the capsule fibres emanating upwards 
(from [93]) 
Cell wall 
Cellular 
interior 
Capsule 
fibres 
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The cryptococcal capsule is also a dynamic structure, the thickness of which is 
modulated in response to environmental conditions. In typical environmental 
conditions and under standard in vitro conditions the capsule thickness is often 2.5 - 
10 µm. However, during in vivo infection, or under specific capsule-inducing 
conditions in vitro [94, 95], capsule thickness can be up to 100 µm [96]. It is thought 
that capsule enlargement is mediated at the level of individual polysaccharide 
molecules whereby new polysaccharide molecules, with larger effective diameter, are 
added near the capsule edge (figure 1.10) [97-99]. Capsule enlargement is associated 
with reduced susceptibility to both oxidative and antifungal killing, demonstrating the 
importance of capsule enlargement as a mechanism of intracellular survival [100]. 
The CAP59 gene has been identified to be essential for the extracellular trafficking 
and/or secretion of polysaccharides, however, the exact mechanism of CAP59 
remains unknown [101]. The high-energy cost of capsule growth is offset by a 
significant reduction of fungal susceptibility to oxidative and antifungal killing [102]. 
This demonstrates the importance of capsule enlargement as a mechanism of 
intracellular survival [100].  
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Figure 1.10: Images depicting cryptococcal cells with different capsule sizes and 
a schematic representation of capsule enlargement.  
India ink staining of a) cells with a small capsule and b) cells with an enlarged capsule. Scanning 
electron microscopy of c) small-capsule cells and d) enlarged-capsule cells. Scale bars = 5 µm. 
Confocal microscopy of e) small-capsule cells and f) enlarged-capsule cells after coating the capsule 
with an IgM mAb to GXM (12A1) and detection with a goat anti-mouse IgM antibody conjugated to 
rhodamine (red fluorescence). The cell wall is visible by staining with calcofluor (blue fluorescence). 
3D image reconstruction of g) small-capsule cells shown in part e); and h) enlarged-capsule cells 
shown in part f). i) Schematic showing the self-assembly and distal elongation of the capsule. New 
polysaccharide (red) is added to existing polysaccharide (blue) (from [103]).  
 
 
  Chapter One 
 
 22 
1.5.2.2. Melanin production 
Melanin production has been described as one of the three major Cryptococcus 
virulence factors, along with polysaccharide capsule and growth at 37 °C. The brown-
to-black melanin-like pigment was first described by Staib in 1962 [104] and is a 
result of phenoloxidase (also known as laccase) activity (figure 1.11) [105]. Melanin 
production has been correlated to a number of functions involved in fungal protection 
including protection from oxygen and nitrogen derived oxidants, impeding 
phagocytosis, impeding the T-cell mediated immune response, maintaining cell wall 
structure and protecting Cryptococcus from UV light, X-ray or gamma radiation, heat, 
cold and amphotericin B [106]. Ngamskulrungroj and Meyer (2009) demonstrated 
that the major Vancouver Island outbreak genotype, VGIIa, produced more melanin at 
in vitro physiological temperature than the minor Vancouver Island outbreak 
genotype, VGIIb [106]. 
 
Figure 1.11: Non-melanin- and melanin-forming colonies of C. gattii on 3,4-
dihydroxyphenylalanine (L-DOPA) media after 7 days at 25 °C (from [35]). 
 
Another intriguing element regarding melanin production and pathogenesis is that the 
melanin synthesis pathway has the ability to utilise catecholamines, a compound that 
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is enriched in the brain. This may provide an explanation for the evident neurotropism 
observed during C. neoformans and C. gattii infection. Catecholamines, however, 
cannot act as a sole carbon source, suggesting that the brain serves as a survival niche 
rather than a preferred nutritional niche during cryptococcosis [107]. To date, the role 
of melanin as a virulence factor has been limited to in vitro studies and there is little 
evidence demonstrating the presence of melanin in vivo. Further investigation is 
required to delineate the role of melanin production regarding virulence in mammals.   
 
1.5.2.3. Mannitol production 
Wong et al. (1990) demonstrated that C. neoformans produces large amounts of 
mannitol in vitro and in vivo [108]. Mannitol expression has been associated with 
increased resistance to heat, osmotic stress and damage by reactive oxygen 
intermediates. Moreover, low mannitol production has been linked to decreased 
pathogenicity [109]. Mannitol has been hypothesised to contribute to pathogenicity by 
two means. Firstly, high concentrations of mannitol in the central nervous system may 
contribute to brain oedema. Secondly, mannitol is an effective free hydroxyl radical 
scavenger, providing a link to mannitol production as a means to protect the organism 
against oxidative damage [51, 108]. Further studies are required to deduce the exact 
role of mannitol during cryptococcal infection. 
 
1.5.2.4. Cryptococcal products 
Measurable levels of cryptococcal products, including glucuronoxylomannan, 
galactoxylomannan and mannoproteins, are present in bodily fluids during 
cryptococcal infection. Indeed, the detection of cryptococcal antigens in serum or 
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spinal fluid is diagnostic for cryptococcosis and it has been demonstrated that there is 
a direct correlation between cryptococcal antigen levels in body fluids and severity of 
disease [110]. Cryptococcal exopolysaccharides, which are structurally different from 
capsular polysaccharides, have been found to exhibit potent immunosuppressive 
properties in vitro and in vivo [111]. These specific cryptococcal products have been 
demonstrated to negatively affect leukocyte migration to the site of infection, and to 
induce T-cell apoptosis and regulatory T-cells, resulting in dampened anti-
cryptococcal humoral as well as cell-mediated immune responses [87]. Moreover, 
high concentrations of cryptococcal products have the potential to alter the osmolarity 
of the cerebral spinal fluid leading to increased intracranial pressure resulting in 
headaches, visual loss and early death [112]. Thus, is has been suggested that more 
consideration should be given to the impact of high levels of cryptococcal products in 
body fluids on the progression of disease [51].  
 
1.5.2.5. Phenotypic switching 
Phenotypic switching has been observed in both prokaryotes and eukaryotes. It 
involves the stochastic switching between two or more alternative and heritable 
phenotypes. It results from spontaneous alterations in gene expression that arises at 
higher frequencies than standard spontaneous mutation rates. It differs from random 
spontaneous mutations in that the process is reversible and readily detectable. 
Phenotypic switching is usually adopted by pathogens to escape recognition by the 
host immune system and/or to adapt to a novel, hostile host environment [113].  
Fries and Casadevall (1998) first observed phenotypic switching in C. neoformans 
[114]. They showed that C. neoformans has the ability to undergo microevolution 
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during chronic infections. The most crucial aspect of phenotypic switching to fungal 
pathogenesis is that the microevolutionary changes that occur have lead to observable 
changes in virulence by causing changes in capsule or cell wall morphology [115-
118]. Phenotypic switching is clearly observable in C. gattii pulmonary infections 
where the cells are found to switch reversibly between two colony/cell morphologies. 
During pulmonary infection, cells switch to a mucoid colony phenotype that reflects 
enlargement of the polysaccharide capsule, which affords the cells with enhanced 
intracellular survival. The ability of Cryptococcus to cause chronic infections even 
after prolonged antifungal treatment therapy has been attributed to phenotypic 
switching [118]. It should be noted at this point that the process of phenotypic 
switching during pulmonary infection in C. gattii was the cause of significant 
technical issues encountered during this project. 
 
1.6. The origin and maintenance of virulence factors: Is cryptococcal 
infection a case of readymade virulence? 
C. neoformans and C. gattii do not require host cellular machinery for replication, 
dissemination and survival [55, 119]. However, these environmental saprotrophs, 
which are typically found in soil and trees, have the incredibly rare ability to cause 
respiratory disease and a potentially fatal meningoencephalitis in both human and 
animal hosts. Thus, the question arises as to why these organisms possess an unusual 
and sophisticated strategy for the facultative intracellular parasitism observed during 
cryptococcosis [120].  
To date a significant amount of evidence has been gathered that suggests that 
Cryptococcus virulence originated as a result of environmental selective pressure. 
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Firstly, it has been proposed that the intracellular replication and dissemination of C. 
neoformans and C. gattii within animal hosts may have evolved from the ability of the 
fungus to survive inside amoebae. Amoebae feed on microorganisms in a similar way 
to phagocytosis by macrophages. Indeed, it has been hypothesised that amoebae could 
be the earliest form of macrophage and perhaps gave rise, by an undetermined 
evolutionary pathway, to the modern macrophage [121]. Thus, it has been proposed 
that C. neoformans and C. gattii acquired the ability to cause disease in human and 
animal hosts as the result of the defence mechanisms developed to evade 
environmental predators [122]. Secondly, the fact that environmental isolates can 
cause animal infections indicates that virulence factors have been developed in the 
absence of prior interaction with host animals [119]. Furthermore, a multitude of 
‘virulence factors’ appear to have ‘dual use’ capabilities that afford survival 
advantages in both animal hosts and in the environment [35]. Thus, it is becoming 
increasingly evident that virulence factors were probably not specially developed to 
enable host infection; rather, they are ‘ready made’ due to environmental selective 
pressures. It is likely that animals represent an inadvertent host rather than a primary 
niche. 
 
1.7. The host response to infection 
1.7.1. Physical barriers of the lung 
The inhalation of Cryptococcus propagules is considered the initial point of exposure 
of Cryptococcus to the host immune system. Physical protection from pulmonary 
infection is provided by airway turbulence and proper ciliary function [16, 123]. 
Combined, these physical barriers retain the majority of inhaled yeast forms in the 
  Chapter One 
 
 27 
upper airways, preventing fungal deposition in the alveoli. Fungal basidiospores 
and/or hypocapsular forms of Cryptococcus are able to circumvent these physical 
barriers and reach the alveolar space [124]. Fungi that do reach the lung parenchyma 
are normally controlled by the host immune response without extra-pulmonary 
dissemination. The immune system either eliminates the infective agent completely or 
restricts it to the lung within granulomas, where it has been found to persist in a latent 
state indefinitely. If the infection is not eliminated or contained, pneumonitis and/or 
dissemination may result [123]. This part of the introduction will briefly discuss how 
the innate and adaptive immune system responds to cryptococcal infection. 
 
1.7.2. The innate immune response 
The innate immune response acts as a major barrier to cryptococcal infection. This is 
especially true for immune compromised individuals. Physical barriers, such as the 
skin and nasal mucosa, and the anti-cryptococcal activity of serum and saliva, have 
been identified as innate immune factors that inhibit the establishment of infection 
[125-131]. Specifically for the lung, antimicrobial substances in surfactant have been 
identified to contribute to innate resistance against inhaled Cryptococcus. The exact 
role of surfactant and collectins (primitive opsonins found in surfactant and serum 
found to bind acapsular but not encapsulated cells) in innate immunity remains 
enigmatic, however, evidence suggests that these proteins play a role in the early 
pulmonary antifungal defence mechanisms [132]. While these innate factors have the 
potential to discourage cryptococcal infection, the complement system and the 
phagocytic effector cells resident in the lung have been identified as the major 
contributors in the nonspecific host immune system response to pulmonary infection. 
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It is the interaction of the pathogen with these innate immune factors that determines 
the outcome of infection [86, 133].  
 
1.7.3. The complement system 
The complement system is an anti-pathogen cascade of serum proteins that can be 
activated by the classical (antibody mediated), lectin or alternative (microbial-surface-
mediated) pathway. The complement system plays a vital role in host defence from 
infection of the lung. Local complement sources in the lung appear to play an 
important role in the very early stages of infection, providing immediate protection 
from infection along the delicate epithelium of the lung [134]. By opsonising the 
infective agent, the lung complement system attracts both immune effector cells and 
serum complement. The disruption of the complement system, especially the 
alternative pathway [135], has been found to result in reduced survival time during 
cryptococcal infection for a number of animal models. Thus, the lung complement 
system performs vitally important preparations for the subsequent host defence 
response. 
The cryptococcal capsule appears to act as an inhibitor of complement induced host 
immune responses [136, 137]. Interestingly, studies have demonstrated that total C3 
(which plays a central role in the complement system) accumulation on the cellular 
surface of C. gattii strains is half that of C. neoformans strains [138, 139], despite 
having an overall higher binding efficiency [140]. These observable differences in 
complement activation between C. gattii and C. neoformans have been suggested to 
be influential with regard to the increased virulence observed for C. gattii.  
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1.7.4. Cell mediated immunity 
The success or failure of the host defence against cryptococcal infection is critically 
regulated by cell-mediated immunity and especially T lymphocytes [35, 141-144]. 
The exact mechanisms of cryptococcal elimination by T lymphocytes remains 
enigmatic, however it is thought that lymphocytes act to indirectly clear the infection 
via the production of cytokines (produced mainly by CD4+ T cells) that enhance the 
elimination of the pathogen by natural effector cells, in particular macrophages [145, 
146]. The balance between Th1 (a proinflammatory response that stimulates the 
cellular immune system), Th2 (an anti-inflammatory response that stimulates the 
humoral immune system) and Th17 (recruitment, activation and migration of 
neutrophils) patterns of cytokine production in response to cryptococcal exposure to 
the immune system markedly influences the outcome of infection [86]. It has become 
apparent that the predominant synthesis of Th1 and Th17 cytokines over Th2 
cytokines protects mice from cryptococcal infection. The loss of the Th1 response, 
either as a result of HIV infection [147] or experimental depletion [148], leads to a 
high susceptibility to cryptococcal infection. Similarly, Th2-dominant anti-
inflammatory conditions exacerbate infection [149]. Phagocytic effector cells and 
primary lymphocytes such as natural killer T cells and γδ T cells maintain the balance 
of Th1/Th2/Th17 cytokine production during cryptococcal infection [150-153].  
Macrophages are involved in antigen presentation, cytokine production and 
phagocytosis during cryptococcosis. Macrophages have been established as the 
phagocyte that initially encounters inhaled Cryptococcus and acts as the primary 
phagocytic cell at all times during infection [154-157]. There are three distinct 
outcomes of Cryptococcus phagocytosis by macrophages: 1) the yeast is killed; 2) the 
yeast remains latent inside the macrophage; or 3) the yeast grows unchecked within 
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the macrophage leading to macrophage lysis (figure 1.12) [35]. The outcome is a 
direct result of the presence or absence of T-cell mediated immune response and 
whether the macrophages have been activated by Th1 cytokines or Th2 cytokines.  
 
Figure 1.12: Macrophage parasitism by Cryptococcus.  
Following phagocytosis, there are three distinct outcomes; 1) the yeast is killed; 2) the yeast remains 
latent inside the macrophage; or 3) the yeast grows unchecked within the macrophage leading to 
macrophage lysis. Released cells can infect more macrophages or establish extracellular dominance. 
Non-lytic escape pathways are also observed for Cryptococcus, during which the yeast cells are 
expelled by macrophages without causing death of either party 4) or the intracellular yeast cells are 
directly delivered to a neighbouring macrophage via lateral transfer 5) (from [158]). 
 
Th1 cytokine activated macrophages are more efficient at eliminating intracellular 
cryptococcal cells than macrophages activated by Th2 cytokines [123, 159, 160]. 
Macrophages activated by Th1 cytokines possess a variety of antifungal mechanisms, 
including oxidative and nitrosative bursts and granuloma formation. Granulomatous 
inflammation is a prerequisite for the successful resolution of infection with 
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Cryptococcus [16, 161]. Granuloma formation is a result of intact T cell function (and 
thus is common in non-HIV associated cryptococcosis) where macrophages form a 
histiocytic ring around Cryptococcus cells. These macrophages also have the potential 
to from multinucleated cells to engulf heavily encapsulated fungal cells [35]. 
Granuloma formation has been found to be the most effective host response to 
localise the infection and prevent dissemination [162]. The Th2-polarised host 
response, which up-regulates the expression of genes involved in tissue repair and 
results in activation changes in phagocytic effector cells, leads to the inhibition of 
phagocyte activity and increased susceptibility to infection. The absence of a T-cell 
mediated immune response results in the intracellular survival and proliferation of 
Cryptococcus cells [86].   
 
1.7.5. Antibodies 
Antibodies produced against Cryptococcus have been found to enhance the fungistatic 
and fungicidal activity of macrophages. For instance, antibody produced against 
capsular GXM increases nitric oxide production in macrophages [163] and antibody-
treated mice have a more intense granulomatous inflammatory response than control 
animals [16, 35]. Despite the presence of Th1 cytokines and antibody in immune 
competent individuals, certain strains of Cryptococcus are able to survive inside 
macrophages. This is most likely a result of the survival advantages provided by 
cryptococcal virulence factors and the host switching to a Th2 polarised response 
during late stage infection to avoid tissue damage as a result of the early 
proinflammatory Th1 response [35]. It is this persistence of this latent population of 
Cryptococcus cells that can lead to the development of cryptococcosis later in life if 
the host immune system becomes compromised [30]. 
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1.7.6. The direct antifungal effects of T lymphocytes 
It is well established that as well as acting as vital regulators of the immune response, 
NK cells and T lymphocytes (CD4+ and CD8+) function as cytotoxic cells during 
cryptococcosis. Studies have observed that these cells have the ability to directly bind 
to and inhibit the growth of Cryptococcus in the absence of MHC restriction [155, 
164]. This antifungal activity is dependent on the production and secretion of the 
proteins granulysin and perforin.  These proteins are pore-forming effector molecules 
that are stored in secretory vesicles (granules) of T lymphocytes and NK cells [35]. 
The expression and insertion of these proteins into the target cell’s plasma membrane 
leads to apoptosis. NK cells utilise perforin as the main contributor to the elimination 
of Cryptococcus cells [165] while CD4+ and CD8+ cells utilise granulysin [166, 167].  
Successful immune defence against Cryptococcus infection is dependent on 
complement opsonisation of the pathogen, a functioning T-cell mediated immune 
response driven by CD4+ cells, and the direct antifungal/cytotoxic activity of 
lymphocytes. Normally the efficient activation of these immune effector functions 
results in either the destruction of the infectious agent or containment of the fungus in 
a latent state. Proliferation and possible dissemination can result if an individual 
becomes immuno-compromised or the specific cryptococcal strain possesses 
virulence factors (capsule, phenotypic switching) that are able to circumvent or 
overcome the host immune responses.  
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1.8. Cryptococcosis diagnosis, therapy and treatment 
1.8.1. Diagnosis 
There are several methods for the diagnosis of cryptococcosis that can be grouped 
into two classes: radiological diagnosis and laboratory diagnosis. Body imaging via 
radiography, CT and MRI scans can provide the first indication/evidence of disease 
and can also identify the focus of infection [168]. When using radiological methods of 
diagnosis it must be taken into account that pulmonary cryptococcosis caused by C. 
gattii can mimic lung cancer [169]. The laboratory diagnostic techniques include the 
direct examination of the fungus in body fluids or tissue, histopathology of infected 
tissues [170, 171], serological studies and culture of the fungus from body fluids or 
tissue [49].  
 
1.8.2. Therapy and treatment 
The Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 
Update by the Infectious Diseases Society of America provides excellent guidelines 
for specific therapeutic options during cryptococcal infection [172]. Preliminary 
guidelines were first produced in 2000 [173]. The 2010-updated version provides 
detailed discussions on management, therapy and treatment recommendations for 
specific sites of infection and risk groups/populations. This document suggests that 
the principles for induction, consolidation and suppressive/maintenance treatment are 
the same for C. neoformans and C. gattii. It does state, however, that “the 
management of C. gattii infection in immunocompetent hosts needs to be specifically 
addressed” with more intensive diagnostic and follow-up examination recommended 
[174].  
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1.8.3. Antifungal agents 
To date amphotericin B combined with flucytosine represents the most potent 
fungicidal regimen and as such remains the treatment option of choice for 
disseminated or constrained severe cryptococcal disease [173, 175]. Despite their 
effectiveness both amphotericin B and flucytosine have severe and potentially lethal 
side effects. Therapeutic doses of intravenously administered amphotericin B are 
associated with multiple organ damage, especially severe and irreversible 
nephrotoxicity [176]. When delivered via liposomes, which causes the drug to be 
fungal specific, the side effects associated with amphotericin B are much reduced. 
Liposomes are disrupted upon binding to fungal cell walls and since mammalian cells 
lack a cell wall, lipid formulations of amphotericin B are significantly less toxic to 
mammals [177, 178]. Flucytosine has adverse effects on liver function, renal function, 
the central nervous system, causing skin reactions and anaphylaxis [179]. The 
antifungal advantages of the amphotericin B and flucytosine drug combination are 
offset by the generation of potentially lethal side effects.  
 
1.8.4. Resolving cryptococcosis requires the development of novel 
antifungals and therapies 
Since the first independent isolation of C. neoformans, from peach juice in Italy by 
Sanfelice [180] and from the tibial lesion of a patient in Germany by Busse [181] and 
Buschke [182] in 1894, the clinical relevance of cryptococcal disease has continued to 
gain in prominence. In 2009, Park et al. estimated that 957,900 cases of cryptococcal 
meningitis occur each year with approximately 624,700 of the cases resulting in death 
at 3 months post infection [183]. Coupled with the emergence of hyper-virulent 
strains of C. gattii that have the ability to proliferate outside of their predicted 
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ecological niche, it is evident that the pathogenic yeasts C. neoformans and C. gattii 
deserve further investigation [184]. Treating fungal disease remains a challenge due to 
the numerous similarities between the cellular machinery of fungi and humans that 
result in the majority of effective antifungal drugs having toxic side effects. As a 
result there are fewer drugs available for the treatment of fungal diseases compared 
with bacterial and viral diseases. There is a growing demand for the discovery of 
novel anti-Cryptococcus drug targets that are non-toxic or have a low toxicity to 
mammals. The discovery of these targets requires the elucidation of the molecular 
responses of the fungal and host responses to pulmonary infection. In this study, a 
proteomic approach was used to acquire a better understanding of these complex 
responses to fungal infection. What follows is a description of the proteomic 
techniques applicable to this endeavour.      
 
1.9. Proteomics: the study of protein structure and function 
Genetic information provided by genome sequences can be analysed utilising three 
distinct approaches: - the monitoring of the genome (genes) via genomics, the 
transcriptome (mRNA) via transcriptomics and the proteome (proteins) via 
proteomics. Although the genome and the transcriptome are relatively easy to analyse 
employing high-throughput techniques, it is evident that such analyses do not directly 
describe the molecules that function and interact in the cell, the proteins [185]. Hence 
genomic and transcriptomic approaches may lack the capability to comprehensively 
analyse the multifactorial process that is fungal pathogenesis during mammalian 
infection. Furthermore, transcriptomics suffers as a global investigative tool for gene 
expression due to its inability to detect posttranslational modifications and the fact 
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that the correlation between mRNA and protein expression levels is not always 
perfect [186-190].  
These shortcomings of genomic and transcriptomic analyses are addressed by 
proteomics, which encompasses the study of the functional output of the genome, that 
is, the proteome [191]. In the broadest sense, proteomics aims to systematically 
determine the amount, structure and function of the entire protein complement 
expressed by a genome, cell, tissue or organism, including their posttranslational 
modifications [185]. Theoretically proteomics allows the qualitative and quantitative 
analysis of the proteins that directly influence cellular biochemistry. Proteomics is 
presenting itself as the key technology for the study of complex and dynamic 
biological systems as it has the potential to provide a snapshot of the cellular state 
and/or system changes during growth, development and response to environmental 
factors.  
Despite the theoretical advantages, experimental proteomics represents a much greater 
technological challenge than genomics and transcriptomics. Consequently, to date, 
proteome-based studies have not yet been widely applied to pathogenic fungi [192]. 
This is a result of a multitude of factors, the most detrimental element being the 
extreme chemical complexity of the proteome. Furthermore, proteomics lacks a 
polymerase chain reaction equivalent and thus proteins cannot be amplified. As a 
result, comprehensive proteomic analysis requires highly sophisticated analytical 
machinery and software in order to detect a wide range of protein species that can be 
present at minute amounts. In practice, comprehensive ‘whole-cell’ proteomics is 
beyond the capacity of any combination of current proteomic technologies and 
consequently the identification and quantification of all the proteins in a biological 
system remains elusive [193]. Most proteomic studies adopt a simplification via 
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prefractionation approach based on either chemical attributes, such as solubility, or 
biological attributes, such as membrane preparations [194].  The nature of sample 
preparation and prefractionation is determined by the project aims and hypotheses and 
sample availability, however, the biological and medical importance of membrane 
proteins means that membrane preparation and analysis is a major part of many 
proteomic studies. 
The sheer number of prefractionation methods precludes any attempt at a review here, 
but the main goal of these techniques is complexity reduction [195]. Even the simplest 
organisms produce proteomes that are too complex and wide ranging in protein 
abundance to be analysed by a single separation step. Prefractionation methods aim to 
reduce the complexity from thousands to hundreds of proteins in each fraction. 
Subsequently, the core of most proteomics strategies is a protein or peptide separation 
method designed to further reduce the complexity of each fraction prior to mass 
spectrometry analysis. The goal at this stage is to present the mass spectrometer with 
a single protein at a time or a mixture of only a few proteins [194]. The two main 
separation approaches are based on liquid chromatography (LC) [196] or two-
dimensional electrophoresis (2-D PAGE) [197].  
 
1.9.1. Comparative proteomics 
The primary goal of comparative proteomics is to discover the quantitative and 
qualitative changes that underlie the cellular changes in response to a given 
experimental or biological scenario [198]. Traditional comparative proteomic 
experimental platforms have utilised dyes, fluorophores or radioactivity coupled with 
high-resolution protein separation to identify quantitative and qualitative changes 
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between protein samples. For the past four decades, two dimensional polyacrylamide 
gel electrophoresis (2-D PAGE) has been the technique of choice for the separation of 
the protein composition of a given sample [199]. This technique was first described 
by O’Farrell in 1975 [200]. 2-D PAGE utilises the orthogonal protein fractionation 
procedures of isoelectric focusing (IEF), where proteins are separated according to 
their isoelectric point, in the first dimension and sodium dodecyl sulphate 
polyacrylamide gel electrophoresis, where proteins are separated according to their 
molecular weight, in the second dimension.  
 
1.9.2. Two-dimensional polyacrylamide gel electrophoresis:  a 
fundamental proteomic technology  
The 2-D PAGE analysis platform was, until recent times, the most widely employed 
protein separation technique as it offers the unparalleled resolution of intact proteins 
coupled with the ability to simultaneously separate many thousands of proteins, and 
their modified forms, to homogeneity (figure 1.13). Furthermore, a number of groups 
have demonstrated that by applying the correct sample preparation and fractionation 
techniques it is possible to obtain large numbers of low abundance, membrane and 
alkaline proteins on 2-D PAGE gels [201, 202]. More importantly, the seemingly 
small number of genes in the human genome has reinforced the one gene-many post-
translational products paradigm and 2-D PAGE remains the only technique which 
offers sufficient resolution and quantitative range to address this at a proteomic level 
[203]. 2-D PAGE coupled with fluorescent staining provides an ideal image-based 
method for quantitative comparative proteomics [204]. 
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Figure 1.13: An example of the fractionation power of 2-D PAGE.  
This image shows separated Cryptococcus proteins from cultured C. gattii. Each spot represents an 
individual protein species. 
 
1.9.3. Difference in Gel Electrophoresis (DIGE) 
In 1997 Unlu et al. [205] introduced difference in gel electrophoresis (DIGE). This 
technology was designed to directly limit the amount of technical variation associated 
with comparative 2-D PAGE proteomics. DIGE is based on the fluorescence pre-
labelling of protein mixtures prior to 2-D PAGE [206]. Protein samples to be 
compared are labelled with up to three spectrally distinct, charge and mass-matched 
cyanine dyes known as CyDye DIGE fluors (which includes Cy2, Cy3 and Cy5) 
[207]. The labelled proteins samples are mixed and separated simultaneously on the 
same 2-D PAGE gel and visualised separately by exciting the different CyDyes at 
their specific excitation wavelengths [206]. Protein samples can be labelled via two 
markedly different methods. The first technique developed was minimal labelling that 
used amine reactive dye to label lysine residues. This method is referred to as minimal 
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labelling as the ratio of dye to protein is kept very low so that the only proteins 
visualised on a gel are those labelled with a single dye molecule; indeed only 1 to 5 % 
of total protein is labelled [205, 206]. The next generation of DIGE dyes targeted 
cysteine residues. This technique is known as saturation labelling as a high dye to 
protein ratio is used so as to label all available cysteine residues. Saturation dyes 
possess a maleimide reactive group that covalently binds to the thiol group of cysteine 
residues on a protein via a thioether linkage [208]. The saturation technique is far 
more sensitive than minimal labelling, being able to visualise proteins from a 5 µg 
protein sample. Indeed, saturation dyes are sensitive down to 15 pg of protein. In 
comparison 50 µg of protein sample is required for minimal labelling. Thus, the 
saturation method of labelling is also referred to as scarce sample labelling. 
The ability of DIGE to substantially reduce the effects of gel-to-gel variation is a 
result of the technology being able to separate more than one sample on a single two-
dimensional gel. Thus, samples of interest are separated and proteins detected and 
identified on a medium that has experienced identical experimental conditions. The 
capability of DIGE to include an internal standard during electrophoresis further 
increases the confidence that an observed difference is genuine [209]. The internal 
standard is a mixture of equal amounts of protein from each biological sample in the 
experiment. The internal standard is run on every gel, meaning that every sample 
within a gel can be normalised to the internal standard on that gel. Furthermore, every 
protein spot can be measured as a ratio to its corresponding spot present in the internal 
standard. Therefore, the confidence that a difference in fluorescence intensity between 
two samples is due to biological rather than experimental variation is increased. As a 
result, DIGE has the capability to generate statistically significant data using fewer 2-
D gels than conventional comparative differential display 2-D PAGE methods. 
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1.9.3.1. Technical issues associated with DIGE 
Despite the advantages of DIGE, the technique remains hampered by the inherent 
technical limitations associated with any 2-D PAGE analysis. These limitations 
include variable protein solubility [210], protein expression dynamic range problems 
[211] and low protein abundance issues [212]. Coupled with these global 2-D PAGE 
analysis issues, both minimal and saturation labelling techniques are subject to a 
number of significant DIGE-specific technical limitations. During minimal labelling, 
high dye substitutions result in significantly decreased protein solubility [205]. 
Therefore, the dye to protein ratio is very kept low in order to maintain protein 
solubility during electrophoresis [206]. Furthermore, it has been demonstrated that 
SYPRO Ruby dye staining detects 40 % more protein spots than minimal protein 
labelling with CyDye [213]. It is almost certain that the undetected proteins represent 
the lowest abundant species in the sample. These undetected proteins could include 
the very proteins that the researcher is attempting to detect [213]. The saturation 
labelling method also faces some significant limitations. The most evident issue is 
that not all protein species contain a cysteine residue. A protein that does not contain a 
cysteine residue cannot be labelled and will thus remain undetected. Furthermore, 
studies have found that saturation labelling can result in significantly increased 
protein insolubility [208]. Up to 40 % of high molecular weight proteins become 
insoluble upon labelling and on average 25 % of all protein material can be lost due to 
precipitation during the labelling process [208]. Moreover, detection sensitivity for 
both the minimal and saturation labelling techniques can also be hampered via 
fluorescence cross-talk between excitation/emission band-pass filters. The result is 
Cy5 labelled proteins being detected when illuminating at the optimal Cy3 excitation 
wavelength [214]. Thus, the ability of DIGE labelling systems to complete 
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meaningful comparative proteomics has been brought into question. If the technique 
is to become an efficient and effective method of comparative proteomics it is quite 
obvious that further research and development is required to optimise this technique. 
 
1.9.4. Further general limitations to the 2-D PAGE analysis platform 
Despite the advantages of the 2-D PAGE analysis platform, as with all experimental 
procedures there are a number of drawbacks to the fractionation technique. As with all 
proteomic procedures, 2-D PAGE is limited by low protein abundance and dynamic 
range issues. These issues can be combated with the use of a number of 
prefractionation techniques such as the use of narrow-range IPG strips that allow 
higher protein loads and improved resolution [215]. The overriding issue with 2-D 
PAGE is that this protein separation technique is sample greedy. 2-D gels of adequate 
protein spot intensity require at least 300 µg of protein, which may not be obtainable 
from in vivo experiments. For samples where obtainable protein yields are minimal, 
alternative techniques must be utilised. A further complicating factor for the 2-D 
PAGE experimental platform is that approximately 10% of the proteins in a typical 
proteome fall outside the 2-D PAGE solubility window. Additionally, very acidic and 
very alkaline proteins are notoriously difficult to focus during IEF [215]. Finally, 2-D 
PAGE has a generally low throughput of protein identifications when compared to 
alternative approaches such as liquid chromatography-mass spectrometry (LC-MS). 
Differential display comparative proteomics using the 2-D PAGE platform requires an 
individual MS run per spot identified with the differential display software. When 
compared to the hundreds of proteins identified with LC-MS the throughput 
limitations of the 2-D PAGE experimental platforms are obvious. These significant 
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inherent technical challenges, together with the low throughput nature of traditional 2-
D PAGE based comparative proteomic techniques, means there is an emerging trend 
towards using liquid chromatography coupled with tandem mass spectrometry (LC-
MS/MS) based technology platforms [193]. 
 
1.9.5. Alternative comparative proteomics techniques 
A hybrid approach to comparative proteomics that has gained favour in recent years is 
the combination of one-dimensional SDS-PAGE (1-D SDS-PAGE) with reversed 
phase LC-MS of peptides from in-gel digests. The advantages of this type of non-2-D 
PAGE gel approach include a reduced demand for sample compared to 2-D PAGE, an 
increased number of identifications, and the ability to combine highly solubilising 
techniques like 1-D SDS-PAGE as a separation method prior to LC-MS.  
The primary shortcoming of the LC-MS/MS platform is that mass spectrometry is not 
inherently quantitative. Accurate quantification requires the comparison of each 
individual peptide between experiments. This can be achieved in a number of ways. 
The most widely adopted approach, introduced in 1999 by three independent 
laboratories [216-218], is based on stable isotope labelling of peptides. This approach 
relies on the theory that a stable isotope-labelled peptide is chemically identical to its 
native counterpart and thus the two peptides also behave identically during 
chromatography and mass spectrometry. Isotope labels can be introduced 
metabolically, chemically, enzymatically or via the use of external standards using 
spiked synthetic peptides. A mass spectrometer has the ability to recognise the mass 
difference between the labelled and unlabelled peptides, and thus, quantification is 
achieved via comparing the respective signal intensities [193].  
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In the last five years the use of stable isotope labelling methods has driven an increase 
in non-gel approaches to quantitative proteomics. Both metabolic labelling and post-
extraction labelling target certain amino acids that are ‘mass-tagged’ using stable 
isotopes. Multiple samples can then be mixed and subsequently fractionated, 
separated and analysed by MS. The advantage of this is that several procedural and 
instrumental factors such as signal suppression are cancelled out when the compared 
samples are run under exactly the same conditions [219]. In the most automated 
approaches to these forms of proteomics, there are no protein separations at all. The 
entire sample, or multiplexed labelled sample, is enzymatically digested with trypsin 
and the complex mixture of peptides separated by two-dimensional LC. This usually 
involves strong cation exchange as the first dimension, followed by reversed phase 
LC-MS of each ion exchange fraction. Whilst this approach requires relatively low 
sample amounts and provides large numbers of peptides to the MS and can confirm 
that particular genes were expressed, the proteins are never observed as intact 
molecules. In addition, it does not adequately resolve multiple isoforms of proteins, 
thus under-estimating the complexity of any given proteome [220]. In recent times 
alternative strategies utilising label-free methods have been introduced [221-223]. 
These techniques compare multiple experiments via comparing the direct mass 
spectrometric signal intensity for a given peptide or by using the number of spectra 
matching to a peptide or protein as an indication of their respective amounts in a 
given sample. 
 
1.9.6. Isobaric tag for relative and absolute quantification (iTRAQ) 
iTRAQ is a novel mass spectrometry based technique that can accurately quantify 
proteins in absolute and relative terms [224]. iTRAQ is a post-extraction approach 
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that involves mass-tagging protein or peptide amino groups using the iTRAQ® 
reagents from Applied Biosystems (figure 1.14). The utilisation of iTRAQ overcomes 
the problem of low total protein yield encountered during sample preparation as it 
requires only 100 µg compared to the 300 µg demanded by the 2-D PAGE analysis 
platform. Furthermore, the iTRAQ reagent comes as a four-plex and eight-plex kit 
allowing several protein samples to be analysed simultaneously and compared on the 
same spectra. In comparison, the spectral counting analysis platform requires that 
each sample be run on the MS individually. This necessitates the inclusion of 
technical replicates due to the inherent variability associated with multiple MS/MS 
analyses over an extended time period. The multiplex nature of the iTRAQ 
technology removes the need to run technical replicates, improving time efficiency 
and lowering cost (at least in terms of MS runs).  
 
Figure 1.14: iTRAQ reagent structure (from [225]). 
 
The basic principle of the iTRAQ technology consists of the chemical derivatisation 
of proteolytic peptide mixtures using a set of amine-reactive reagents with distinct 
isotopic mass designs. The iTRAQ reagent ‘tags’ are isobaric, meaning they will not 
affect the overall protein sample mass across different samples as all changes in each 
  Chapter One 
 
 46 
individual protein mass are effectively the same. The iTRAQ reagent covalently 
attaches to the primary amine on amino acids such as those found in lysine and free 
N-terminal amines[226]. The isobaric ‘tags’ consist of a mass balance group, which 
provides the covalent link to primary amines, and a reporter group, that is released 
during MS/MS fragmentation and which provides the quantitative ion for each tag 
[226]. Once the labelling has occurred, the differentially labelled samples are 
combined and the peptides are separated by liquid chromatography and then analysed 
by tandem mass spectrometry (figure 1.15).  
 
Figure 1.15: iTRAQ workflow (from [225]). 
 
The reporter tags have differing mass to charge (m/z) ratios ranging from 113 to 121 
(excluding 120) and peptides of the same sequence from different samples, which are 
labelled with different tags, are eluted at the same chromatographic retention time 
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[227]. Differentially labelled peptides of the same sequence therefore appear as a 
single peak in MS scans. Relative quantitative information on iTRAQ-tagged peptides 
is obtained in MS/MS scans liberating the reporter groups as distinct isotope-encoded 
fragments [226]. Isotopic labelling at the peptide level, coupled with the specific mass 
design of the label, enables the simultaneous acquisition of qualitative and 
quantitative information [226]. 
 
1.9.6.1. Limitations of the iTRAQ technology 
As with all experimental protocols, the iTRAQ technology is not without its 
limitations. Pichler et al. (2010) found that the iTRAQ 4-plex identified a 
significantly higher number of peptides and proteins than the iTRAQ 8-plex [228]. It 
was concluded that the observed differences in peptide detection was a result of a 
combination of several factors, including the cleavage of the label itself and the 
possible disparate physiochemical properties of peptides depending on the type of 
derivatisation (iTRAQ labeled peptides are both bulkier and more hydrophobic than 
their underivatised counterparts – especially for the 8-plex). Protein ratios are 
calculated from the median of peptide ratios; thus, higher numbers of identified 
peptides improves the precision of protein ratios and the accuracy of protein 
quantification. It was concluded that due to its superior ability to identify peptides and 
proteins, 4-plex iTRAQ should be used in the place of the 8-plex iTRAQ [228]. This 
revelation reduces the high-throughput nature of the iTRAQ technology and demands 
more convoluted experimental design in the case of experiments with high sample 
number. However, the technique still has higher throughput and sensitivity than 2-D 
PAGE analysis and other comparative proteomic techniques.  
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1.9.7. Analysis of the host immune response 
Immunoproteomics is defined as the analysis of circulating antibodies that reflect the 
molecular imprint of antigens. These antibodies represent the subset of proteins that 
induce an immune response in the host [229, 230]. Immunoproteomic-based 
technologies are grouped into three broad groups: gel-based, gel-free (gel-free 
fractionation such as liquid chromatography followed by protein array) and inverse 
immunoproteomics. As this project will focus on gel-based techniques only these will 
be described. Gel-based techniques use either 1-D PAGE or 2-D PAGE for protein 
separation followed by protein transfer to a nitrocellulose or polyvinylidene fluoride 
membrane. Towbin et al. (1979) first introduced gel-to-membrane protein transfer, 
also known as immunoblotting or Western blotting [231].  
The selective identification of proteins that react with the host immune system 
reduces the necessity of examining the entire proteome. Immunoproteomics, however, 
is heavily dependent on optimised protein isolation techniques and is also highly 
sensitive to non-protein contaminants (cell wall, polysaccharide, DNA etc.) [232]. 
This sensitivity is especially relevant for the analysis of pathogenic Cryptococcus 
species, which produce polysaccharide capsule, especially during in vivo pulmonary 
infection. The technical limitations of coupling immunoproteomics with the 
Cryptococcus sample type were identified and resolved by Jobbins et al. [232], who 
used circulating antibodies from an infected host to detect 31 disease-associated 
antigens from Cryptococcus proteins separated by  2-D PAGE. The identification of 
disease-associated antigens can be used to identify targets for therapy, diagnostic 
biomarkers and indicators of prognosis.  
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1.9.8. The Bio-Plex suspension array system 
The Bio-Plex suspension array system was developed by Bio-Rad for the detection 
and measurement of cytokines, chemokines and growth factors. These cell-signalling 
proteins are expressed and secreted by a myriad of cells, including those of the 
immune system. The detection and quantitative measurement of these proteins can 
provide insight to the physiological state/responses of the host to cryptococcal 
infection. This technology is based on the flow cytometric analysis of fluorescently 
dyed microspheres (6.5 µm magnetic beads) that possess distinct spectral addresses. 
The assay is essentially an immunoassay, similar in principle to a sandwich ELISA, 
formatted on magnetic beads (figure 1.16). Capture antibodies, which target the 
desired biomarker, are covalently bound to the magnetic beads that react with sample 
containing the biomarker of interest. After washing, a biotinylated detection antibody 
is then introduced and subsequently reacts with the biomarker of interest to form the 
sandwich complex. The detection of the complex is achieved by the addition of the 
fluorescent indicator phycoerythrin in the form of a streptavidin-phycoerythrin 
conjugate. Data from these reactions are acquired by dual laser flow cytometery. A 
red laser (635 nm) illuminates the specific fluorescent dyes within each bead so as to 
provide assay identification while a green laser (532 nm) excites the phycoerythrin to 
generate a reporter signal that is detected by a photomultiplier tube. The Bio-Plex 
manager software then presents the data as median fluorescence intensity and 
concentration (pg/mL) (figure 1.17).  
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Figure 1.16: Bio-Plex sandwich immunoassay (from [233]).  
 
 
Figure 1.17: Bio-Plex suspension array system workflow (from [234]). 
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The Bio-Plex suspension array system allows for the simultaneous detection and 
measurement of over 100 different molecules in a single well of a 96 well microplate.  
The clear advantages of Bio-Plex are that the assay is a multiplex system (the rat 
cytokine kit can essentially run 23 ELISAs at once), it is not greedy on sample 
(requiring only 50 µL of serum per sample while Western blots require at least 250 
µL serum per sample) and it generates results in a time frame of hours rather than 
approximately three days to complete the 2-D PAGE Western blot protocol.  
 
1.10. Project outline 
Fungal infection and disease are increasing on a worldwide scale. The outbreak of a 
hypervirulent strain of C. gattii on Vancouver Island in 1999 highlighted the need for 
the development of novel, more effective Cryptococcus-specific antifungal agents 
[235]. Current antifungal therapies are limited in scope and spectrum, are frequently 
toxic [236] and are very expensive. Furthermore, treatment does not always 
completely eradicate the pathogen and antifungal drug resistance is an emerging issue. 
The development of novel antifungal agents requires the elucidation of the in vivo 
molecular responses of both the fungus and the host to pulmonary fungal infection.  
Pulmonary infection with C. neoformans and C. gattii provided a suitable model to 
investigate these molecular processes as inoculation resulted in the development of 
fungal burdens large enough to permit the use of comparative proteomic analysis 
techniques.  Furthermore, this study had access to Cryptococcus strains of differing 
virulence, which resulted in different levels of pulmonary infection.   
The aim of this thesis was to use the pulmonary infection model to provide insight as 
to how virulent Cryptococcus establishes and maintains infection in the mammalian 
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host. More specifically, this project attempted to identify the fungal proteins that 
promote pathogenesis during pulmonary infection via comparative quantitative 
proteomics. In addition to studying changes in Cryptococcus protein expression 
during infection, the work described in this thesis attempted to identify the proteins 
involved in the host response to fungal pulmonary infection via the comparative 
quantitative analysis of host lung proteins and serum cytokines. This thesis provides 
the first attempt at the comparative proteomic analysis of a pathogenic fungal species 
and the dynamic host response during mammalian infection. 
 
1.10.1. Hypothesis and aims – fungal pathogenesis 
The work outlined in this thesis was undertaken with the hypotheses that:  
1. Mammalian pulmonary infection would induce specific protein changes in the 
intracellular proteome of Cryptococcus;  
2. A comparative proteomic analyses would identify specific proteins that 
provide virulent Cryptococcus strains with survival advantages over less 
virulent strains; and  
3. This analysis would lead to the development of novel therapeutic or diagnostic 
targets.  
 
The aims of this study were therefore: 
• To investigate and develop suitable proteomic techniques for the analysis of 
Cryptococcus from pulmonary infection. 
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• To use these techniques to identify and describe the fungal proteins essential 
for the establishment and progression of Cryptococcus pulmonary infection. 
 
1.10.2. Hypothesis and aims - host response 
The work outlined in this thesis was undertaken with the hypotheses that:  
1. Pulmonary infection with Cryptococcus would induce specific changes in the 
lung proteome and systemic changes in cytokine expression that would vary 
according to the virulence of the infecting strain; and 
2. Comparative proteomic analyses would identify specific host proteins and 
serum cytokines that could form future therapeutic or diagnostic targets.  
 
The aims of this study were therefore: 
• To use iTRAQ to detect and quantify lung proteins that change in expression 
in response to pulmonary infection by Cryptococcus strains of different 
virulence levels. 
• To use the Bio-Plex suspension array system to detect and quantify the 
systemic cytokines that change in expression in response to pulmonary 
Cryptococcus infection. 
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Chapter Two 
Materials and Methods 
This chapter lists the materials and equipment, reagents and chemicals and the 
solution formulations used in this project. This chapter also contains a description of 
the general methods used and cross-references to the appropriate sections of the 
results chapters that detail the specifics of the methodology used. 
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2.1. Fungal strains 
The fungal strains utilised to complete the work presented in this doctoral thesis are 
listed in Table 2.1.  
 
Table 2.1: Fungal strains 
Isolate 
designation 
Source/host Geographic 
source 
Serotype Molecular 
Type 
A1M R265 Bronchial alveolar 
lavage 
Duncan, 
Vancouver Island 
(B.C., Canada)  
B VGIIa 
A1M R272  Bronchial alveolar 
lavage  
Ladysmith, 
Vancouver Island 
(B.C., Canada)  
B VGIIb 
KN99α A cross of KNA14 and 
H99 crg1 (αA) 
backcrossed 10 times to 
H99 - bred to be a 
congenic α mating type 
strain of H99 [237] 
Duke University 
Medical Center, 
Durham (North 
Carolina, USA) 
A VNI 
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2.2. Materials and equipment, reagents and chemicals and solution 
formulations 
The materials and equipment used to complete the work presented in this thesis are 
contained in Table 2.2. Table 2.3 contains the source of the reagents and chemicals. 
The solution formulations are listed in Table 2.4.   
 
Table 2.2: Materials and equipment 
Materials/Equipment Company 
11 cm focusing tray with lid Proteome Systems, Australia 
11 cm IPG strip rehydration/equilibration tray  Bio-Rad, USA 
Alpha 1-4 LDplus Freeze Dryer Christ, Germany 
Bio-Plex 200 system with version 5.0 software Bio-Rad, USA 
Bio-Plex Pro II magnetic wash station Bio-Rad, USA 
Bio-Plex Pro™ Rat Cytokine 24-plex Assay Bio-Rad, USA 
Criterion™ Cell gel running apparatus Bio-Rad, USA 
Criterion™ XT Bis-Tris One Dimensional Precast, 
4-12%, 12 well, 40 µl, 1.0 mm polyacrylamide gel 
Bio-Rad, USA 
Criterion™ XT Bis-Tris Precast, 4-12%, IPG + 1 
well, 11 cm, 1.0mm polyacrylamide gel 
Bio-Rad, USA 
DT-50 tube with rotor-stator element IKA, Germany 
Extra thick blot paper  Bio-Rad, USA 
Micro Bio-Spin 6 columns, P6 in saline sodium 
citrate 
Bio-Rad, USA 
Micromax 230 centrifuge IEC, USA 
Nanosep 100K Omega centrifugal devices Pall Scientific, USA 
PROTEAN® IEF Cell Bio-Rad, USA 
0.45 µm PVDF Immobiline-P Transfer Membrane  Millipore Corporation, USA 
Ratek Orbital Mixer Incubator Ratek Instruments Pty. Ltd., 
Australia 
ROTANTA 96 R centrifuge Hettich Zentrifugen, Germany 
Sonicator 3000 Misonix, USA 
Trans-Blot® SD Semi-Dry Transfer Cell Bio-Rad, USA 
Typhoon Trio laser scanners GE Healthcare, UK 
ULTRA-TURRAX® tube drive workstation IKA, Germany 
Vacufuge™ Concentrator 5301 Eppendorf, Germany 
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Table 2.3: Reagents and chemicals 
Reagent/Chemical Supplier 
10X Flamingo™ protein staining solution Bio-Rad, USA 
20 XT MES running buffer Bio-Rad, USA 
Acetic Acid Chem-supply, Australia 
Acetone Sigma-Aldrich Co, USA 
Acetonitrile, LC-MS grade (ACN) Sigma-Aldrich Co, USA 
Acrylamide Bio-Rad, USA 
Agar Sigma-Aldrich Co, USA 
Amino-caproic acid Sigma-Aldrich Co, USA 
Ammonium Bicarbonate Sigma-Aldrich Co, USA 
Ammonium sulphate Sigma-Aldrich Co, USA 
Bacteriological Peptone Oxoid, England 
Bromophenol blue Sigma-Aldrich Co, USA 
C7BzO Sigma-Aldrich Co, USA 
Citric acid Sigma-Aldrich Co, USA 
Complete protease inhibitor cocktail tablets Roche, Germany 
Coomassie brilliant blue G250 Sigma-Aldrich Co, USA 
Dextrose Univar, USA 
Direct blue 71 Sigma-Aldrich Co, USA 
Dithiothreitol (DTT) Bio-Rad, USA 
Ethanol Sigma-Aldrich Co, USA 
Formic acid Sigma-Aldrich Co, USA 
Lithium Chloride Sigma-Aldrich Co, USA 
Methanol Sigma-Aldrich Co, USA 
Mineral oil, Biotechnology grade Bio-Rad, USA 
NuPAGE® 4X LDS Sample Buffer (pH 8.4) Invitrogen Corporation, USA 
Orange G IEF Dye Proteome Systems, Australia 
Phosphoric acid Sigma-Aldrich Co, USA 
Phosphate buffered saline Amresco, USA  
Precision Plus Unstained Protein Standards Bio-Rad, USA 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich Co, USA 
Sucrose Univar, USA 
Thiourea Sigma-Aldrich Co, USA 
Tributylphosphine (TBP) Sigma-Aldrich Co, USA 
Triethylammonium bicarbonate (TEAB) Sigma-Aldrich Co, USA 
Tris buffered Phenol, pH 8 Sigma-Aldrich Co, USA 
Tris-HCl, pH 6.8 Sigma-Aldrich Co, USA 
Tris(hydroxymethyl)aminomethane Sigma-Aldrich Co, USA 
Trypsin Gold, Mass spectrometry grade Promega Corporation, USA 
Urea Sigma-Aldrich Co, USA 
Yeast Extract Oxoid, England 
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Table 2.4: Solution formulations 
Solutions  Formulation 
1X Flamingo™ protein 
staining solution 
10X Flamingo™ protein staining solution diluted to 
1X with ddH2O 
1X NuPAGE® LDS Sample 
Buffer (pH 8.4) 
NuPAGE® 4X LDS Sample Buffer (pH 8.4) diluted 
to 1X with ddH2O 
1X XT MES running buffer 20X XT MES running buffer diluted to 1X with 
ddH2O 
2-D PAGE sample buffer  1% C7BzO (w/v), complete protease inhibitor 
cocktail in 2 M thiourea, 7 M urea, 40 mM Tris, 50 
mM LiCl  
Acrylamide stock 1 M Acrylamide in ddH2O 
Coomassie brilliant blue 
G250 staining solution 1  
0.12% Coomassie brilliant blue G250 (w/v), 20% 
Methanol (v/v), 10% Phosphoric acid (v/v) in ddH2O 
Coomassie brilliant blue 
G250 staining solution 2  
50% Ammonium sulphate in ddH2O 
Coomassie de-staining 
solution  
1% Acetic acid (v/v) in ddH2O 
Direct blue 71 stock  0.01% (w/v) in ddH2O 
Dithiothreitol stock 1 M Dithiothreitol in ddH2O 
In-gel trypsin digestion 
Coomassie de-stain solution  
50% Acetonitrile (v/v) in 50 mM Ammonium 
bicarbonate 
In-gel trypsin digestion 
enzyme solution  
5 µL trypsin per 395 µL of 50 mM NH4HCO3 
In-gel trypsin digestion 
peptide extraction solution  
50% Acetonitrile (v/v), 2% Formic acid (v/v) in 
ddH2O 
IPG equilibration solution  6 M urea, 0.25 M Tris-HCl (pH 6.8), Bromophenol 
blue, 10% SDS (w/v) in ddH2O 
iTRAQ sample buffer  1% SDS (w/v) in 100 mM TEAB 
Polyacrylamide gel fixing 
solution  
40% methanol (v/v), 10% Acetic acid (v/v) in ddH2O 
Pulmonary tissue 
homogenisation sample buffer 
1% C7BzO (w/v), complete protease inhibitor 
cocktail in 2 M thiourea, 7 M urea, 80 mM citric 
acid, 50 mM LiCl  
PVDF membrane washing 
solution  
40% Ethanol (v/v), 10% Acetic acid (v/v) in ddH2O 
Sucrose density cushion 
centrifugation 
0.5 g/mL in ddH2O 
Western blot buffer 1 10X 
stock  
400 mM Amino-caproic acid, 250 mM Tris in ddH2O 
Western blot buffer 2 10X 
stock 
250 mM Tris in ddH2O 
Western blot buffer 3 10X 
stock 
3 M Tris in ddH2O 
Yeast peptone dextrose agar  1% yeast (w/v), 2% peptone (w/v), 2% glucose (w/v), 
2% agar (w/v) in ddH2O 
Yeast peptone dextrose broth  1% yeast (w/v), 2% peptone (w/v), 2% glucose (w/v) 
in ddH2O 
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2.3. General methods 
This thesis presents individual studies that used a number of general experimental 
techniques. What follows is a description of these techniques. 
 
2.3.1. In vitro growth conditions 
Cryptococcus colonies were grown on yeast extract peptone dextrose (YPD) agar 
plates for two days at 37 °C (or until sufficient colonies had developed). The cells 
were then sub-cultured in 100 mL of YPD broth in a Ratek Orbital Mixer Incubator 
(Ratek Instruments Pty. Ltd., Victoria, Australia) at 37 °C, 200 rpm to mid-
logarithmic phase. Cells were then isolated from the YPD broth via slow speed 
centrifugation and washed three times in 50 mL volumes of 1 X PBS. 
 
2.3.2. Pulmonary infection model 
2.3.2.1 Animals used  
A number of mammals have been used to study cryptococcosis including mice, rats, 
rabbits and guinea pigs [238]. There are two clear advantages of the rat model 
compared to the other mammalian model organisms. First, the rat reproduces many of 
the histopathological and serologic features of human cryptococcosis [239]. Second, 
the rat provides a size advantage over the popular mouse model. The mouse model 
would not be able to produce the fungal load required to complete global proteomics 
analyses. Inbred female Fisher-344 rats (body weight approximately 150 g) were 
obtained from the Animal Resource Centre (W.A., Australia) and maintained in 
individually ventilated cages in groups of two (care was taken to ensure that rats were 
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grouped according to inoculation type). Rats had access to food and water ad libitum 
from a top loaded food hopper and water bottle.  
 
2.3.2.2 Inoculation of rats with Cryptococcus 
Cryptococcus cells were cultured on yeast peptone dextrose (YPD) agar for at least 48 
hours at 37 °C. Fungal colonies were then transferred to sterile saline solution. Yeast 
cells were counted on a Neubauer-improved haemocytometer and the cell number 
adjusted to the appropriate concentration. Intratracheal inoculation with 0.1 mL of 107 
CFU, the minimal inoculum concentration demonstrated by Krockenberger et al. 
(2010) to produce progressive pneumonia [239], resulted in poor lesion development 
and limited disease progression. Thus, intratracheal inoculations of 0.1 mL of 108 
CFU were administered through a flexible plastic catheter that had been passed over 
the epiglottis and into the rat trachea. An otoscope was used to assist the insertion of 
the catheter into the trachea. An intranasal method of inoculation was used when the 
intratracheal route proved difficult. Intranasal inoculation involved the insertion of a 
flexible plastic catheter into the nasal passage. A 1 mL volume of air was 
administered via the inserted catheter immediately after the Cryptococcus inoculum to 
ensure that the maximal dose of Cryptococcus cells was administered and to ensure 
that the lungs were flushed with cells. Post inoculation, the rats were allowed to 
recover from anaesthesia of their own accord under a heating lamp. For this study the 
control was naïve lung, the rats being neither anesthetised nor subject to mock 
inoculations. The inoculum concentration was confirmed by back plating, whereby an 
aliquot of the inoculum was diluted, spread plated onto YPD agar plates and cultured 
at 37 °C until colonies formed.  
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Infected rats were monitored according to the University of Sydney animal ethics 
guidelines (ethics approval number: N00/10-2008/2/4810). Pulmonary infection was 
allowed to progress for 14 days (equating to early infection) and 42 days (equating to 
late infection) at which time the rats were euthanized. Prior to harvesting the rat lung, 
as much blood as possible was extracted via heart puncture with a 2 mL syringe. The 
extracted blood was allowed to coagulate at room temperature. During coagulation the 
lungs were harvested, weighed and then stored at -80 °C until required. Rat serum 
was then isolated via low speed centrifugation, aliquoted and frozen at -80 ºC until 
required. 
 
2.3.3. Pulmonary tissue homogenisation 
Control or infected lung tissue was homogenized in a 15-50 mL Ultra-turrax tube 
(IKA, Germany) with 40 mL of 1 % C7BzO, 2 M thiourea, 7 M urea, 80 mM citric 
acid, 50 mM LiCl and a complete protease inhibitor cocktail for three bursts of one 
minute at maximum speed (6,000 rpm). In between homogenization bursts the sample 
was kept on ice to prevent overheating. Processing a severely infected lung sample 
resulted in a highly viscous homogenate. To reduce viscosity the sample was divided 
into aliquots (the number of aliquots was dependent on the degree of viscosity 
observed) and diluted with 40 mL of 1 % C7BzO, 80 mM citric acid and 50 mM LiCl. 
The samples were then further Ultra-turraxed for 2 x 1 minute bursts to ensure 
complete tissue homogenization. The sample was transferred to a suitable number of 
50 mL Falcon tubes and ultra-sonicated with a probe for four bursts of 30 seconds. 
During sonication the sample was kept on ice to prevent a significant rise in sample 
temperature. The samples were then centrifuged at 4,000 g for ten minutes at 4 °C to 
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remove connective tissue, cell debris and to isolate the Cryptococcus cells. The 
supernatants were retained for the investigation of the host lung proteome and the 
pellet was retained for Cryptococcus isolation and lyophilisation.  
 
2.3.4. Isolation of Cryptococcus from pulmonary tissue and lyophilisation 
of Cryptococcus 
The pellet retained after the low speed spin (containing connective tissue, cell debris 
and Cryptococcus cells) was resuspended in 2 volumes of 1 x PBS containing a 
protease inhibitor cocktail. The sample was then carefully pippetted on the top of a 3 
mL sucrose density cushion (0.5 g/mL) in a 15 mL Falcon tube. Special care was 
taken to ensure that the sample did not mix with the sucrose density cushion. The 
sample/sucrose cushion was then centrifuged at 1,500 g for 20 minutes. Post 
centrifugation the sample differentiated into three distinct partitions: 
1. A top layer of lung supernatant 
2. An interface of C. gattii cells 
3. A pellet of pulmonary connective tissue and cell debris 
The Cryptococcus interface was carefully transferred to a 50 mL Falcon tube and the 
cells washed with 50 mL of PBS containing a protease inhibitor cocktail to remove 
excess sucrose.  The wash step was repeated twice. The washed cells were then 
resuspended in 5 mL of 1% C7BzO, 2 M thiourea, 7 M urea, 80 mM citric acid, 50 
mM LiCl and a protease inhibitor cocktail and ultra-sonicated with a probe for four 
bursts of 30 seconds. During the sonication process the sample was kept on ice. The 
sample was then centrifuged at 4,000 g for 10 minutes at 4 °C. The supernatant was 
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then transferred to a 15 mL Falcon and retained. This process was repeated and the 
supernatant pooled and retained. This repeated wash/ultra-sonication step in 
denaturing conditions was completed in an attempt to remove any proteins non-
covalently bound to the outer surface of the Cryptococcus capsule. The washed cells 
were then resuspended in a minimal volume of PBS (volume varied in accordance to 
the total volume of cells obtained from individual infected lungs) and transferred to 
the required number of lyophilisation/bead beating tubes (maximum of 500 µL per 2 
mL tube). The samples were immediately placed at -80 °C for at least 20 minutes or 
until completely frozen and were then placed in the Alpha 1-4 LDplus Freeze Dryer 
(Christ, Germany) and  lyophilized overnight.   
 
2.3.5. In vitro/in vivo Cryptococcus cellular disruption and phenol protein 
extraction 
After the lyophilisation of Cryptococcus cells the equivalent of a 500 µL volume of 3 
mm glass beads were added to the sample tubes. The sample was then dry bead beaten 
in a Fast-prep Instrument for 5 bursts of 30 seconds at maximum speed. After each 
bead beating round the samples were kept on ice to prevent them from over heating. 
Samples were then resuspended in 1 mL of 1% C7BzO, 2 M thiourea, 7 M urea, 50 
mM LiCl, 40 mM Tris and containing a protease inhibitor cocktail (Roche Applied 
Science). Further bead-beating of the sample for two x 30 second bursts at maximum 
speed was done to ensure resuspension and to promote maximal cell lysis. The 
disrupted samples were pooled in a 50 mL Falcon tube and centrifuged at 4,000 g for 
5 minutes to remove excessive bubbles. The sample was then ultra-sonicated on ice 
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with a probe for four bursts of 30 seconds and centrifuged at 4,000 g for ten minutes 
at 4 °C to remove cell debris and any un-lysed cells.  
This solution was made to 30 % sucrose and vortexed to ensure a homogenous 
mixture. An equal volume of Tris buffered phenol (10 mM Tris HCl, pH 8.0) was 
added to the protein solution and the sample mixed thoroughly for ten minutes. The 
sample was then centrifuged at 20,000 g for 10 minutes to ensure the separation of the 
organic and aqueous phases. The top organic phase (which contains the protein) was 
transferred to a suitably sized Falcon tube and the proteins precipitated by incubation 
with a 5 x volume of 100 % acetone for 30 minutes at room temperature. The 
precipitated proteins were pelleted at 4,000 g for 10 minutes at room temperature and 
the acetone discarded. The protein pellet was briefly air-dried and then resuspended in 
a suitable volume of 1 x LDS sample buffer for 1-D SDS-PAGE or 1% C7BzO, 2 M 
thiourea, 7 M urea, 50 mM LiCl, and 40 mM Tris for 2-D PAGE. Post 
resolubilisation, the sample was reduced and alkylated via 1-hour room temperature 
incubation with 10 mM TBP and 10 mM acrylamide. The reduction/alkylation 
reaction was then quenched with the addition of 10 mM DTT. 
 
2.3.6. 2-D PAGE 
To visualise the extracted lung proteome 2-D PAGE was performed [200] with the 
following  modifications. 11 cm immobilised pH gradient (IPG) strips, pH 4-7 (Bio-
Rad, USA), were rehydrated with 210 µL of sample solution pipetted under the strips. 
Isoelectric focusing (IEF) was performed using a Protean IEF Cell apparatus (Bio-
Rad, USA) at 20 ºC (Slow ramp to 5,000 V over four hours, linear gradient reaching 
10,000V over four hours, fast gradient at 10,000 V for a maximum of 150,000 kVhrs; 
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current limit set at 50 µA per strip). Prior to second dimension protein separation the 
IPG strips were equilibrated for 20 minutes in 6 M urea, 0.25 M tris-HCl pH 6.8, 
bromophenol blue and 10 % SDS (v/v). The equilibrated strips were then transferred 
onto Criterion XT Bis-Tris Precast gels, 4-12% (Bio-Rad, USA). Second dimension 
separation was carried out using a Criterion Cell apparatus (Bio-Rad, USA) at a 
constant voltage of 150 V. The gel was then removed from its casing and transferred 
into a fixing tray. 
 
2.3.7. 1-D SDS-PAGE 
In preparation for 1-D SDS-PAGE, the sample was heated at 95 °C for 10 minutes to 
maximise protein denaturation and solubilisation. The sample was centrifuged at 
16,000 g for 10 minutes to remove any insoluble particulates prior to gel loading. 
During sample heating and centrifugation, a Criterion XT Bis-Tris One Dimensional 
Precast gel and a Criterion gel running apparatus were prepared for use. The upper 
buffer chamber of the Criterion XT Bis-Tris One Dimensional Precast gel and the 
Criterion gel tank were filled with 1 x XT MES running buffer (500 mL per gel). For 
Criterion XT Bis-Tris One Dimensional Precast 12 well gels, 30 µL of the sample was 
loaded into the appropriate well/s. In addition to sample loading, 5 µL of Precision 
Plus Unstained Protein Standards (molecular weight markers) were loaded into the 
appropriate well of every sample gel. Electrophoresis performed at 160 V until the 
Precision Plus Unstained Protein Standards dye-front had reached the very end of the 
gel. The gel was then removed from its casing and transferred into a fixing tray.  
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2.3.8. Fluorescent staining and image analysis 
Protein was fixed in the polyacrylamide gel matrix via incubation in fixing solution 
for a minimum of 30 minutes. The fixing solution was then decanted and the gel was 
rinsed with ddH2O and stained with 50 mL of 1 X Flamingo™ staining solution (Bio-
Rad, USA) for a minimum of 60 minutes while wrapped in foil. All fixing and 
staining was undertaken on an orbital shaker (50 rpm) to encourage mixing of 
solutions and to expose the entire gel to each solution. The gel was imaged with a 
Typhoon TRIO (GE Healthcare, UK) gel imager using pre-set scanning wavelengths 
designed for the Flamingo™ protein stain. Scans were completed on all gels at a 
resolution of 50 µm assuming low sample intensity. 
 
2.3.9. Mass spectrometry (completed by the Australian Proteome Analysis 
Facility at Macquarie University) 
2.3.9.1. SCX HPLC 
Samples (iTRAQ labelled pulmonary material and unlabelled Cryptococcus) were 
cleaned and fractionated by SCX HPLC. The dried samples were re-suspended in 
buffer A (5 mM phosphate, 25 % acetonitrile (v/v), pH 2.7). After sample loading and 
washing with buffer A, buffer B (5 mM phosphate, 350 mM KCl, 25 % acetonitrile 
(v/v), pH 2.7) concentration increased from 10 % to 45 % over 70 minutes and then 
increased quickly to 100 % where it stayed for 10 minutes at a flow rate of 300 
µL/min. The eluent of SCX was collected every 2 minutes at the beginning of the 
gradient and at 4-minute intervals thereafter. 
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2.3.9.2. NanoLC ESI MS/MS data acquisition 
The SCX fractions were resuspended in 100 µL of loading/desalting solution (0.1 % 
trifluoroacetic acid (v/v) and 2 % acetonitrile (v/v) in ddH2O). 39 µL of the 
resuspended solution was loaded on a reverse phase peptide Captrap (Michrom 
Bioresources) and desalted with 0.1 % formic acid, 2% ACN (v/v) at 10 µL/min for 
13 minutes. After desalting, the trap was switched on line with a 150 µm x 10 cm C18 
3 µm 300 A ProteCol column (SGE Analytical Science, Australia). Buffer B (90 % 
ACN (v/v) / 9.9 % ddH2O (v/v) / 0.1 % formic acid (v/v)) concentration was 
increased from 5 % to 90 % over 120 minutes in three linear gradient steps to elute 
peptides. After peptide elution, the column was cleaned with 100 % buffer B for 15 
minutes and then equilibrated with buffer A (99.9 % ddH2O (v/v) / 0.1 % formic acid 
(v/v)) for 30 minutes before next sample injection. 
The reverse phase nanoLC eluent was subject to positive ion nanoflow electrospray 
analysis in an information dependent acquisition mode (IDA). In IDA mode a 
TOFMS survey scan was acquired (m/z 370-1600, 0.5 second), with the three most 
intense multiply charged ions (counts >70) in the survey scan sequentially subjected 
to MS/MS analysis. MS/MS spectra were acquired in the mass range m/z 100-1,600. 
 
2.3.9.3. Data processing 
The experimental MS data were submitted to ProteinPilot V4.0 (AB Sciex, USA) for 
data processing using SwissProt database and Rattus norvegicus species. All reported 
data were based on 95 % confidence for protein identification as determined by 
ProteinPilot (ProtScore ≥ 1.3). A further requirement was a protein p-value, which 
ensured protein identification and quantitation was not based on a single peptide hit.  
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2.4. Study Specific Methods: 
This thesis presents detailed descriptions of methods unique to individual studies in a 
chapter specific manner. Table 2.5 contains an index of these study specific 
methodologies. 
 
Table 2.5: Study specific methods 
Method Refer to 
section 
2-D PAGE Western blotting 3.2.8. 
1-D SDS-PAGE manual lane excision and trypsin in-gel digestion for 
mass spectrometry protein identification 
4.2.7. 
Pulmonary sample preparation for iTRAQ analysis 5.2.4. 
4-plex iTRAQ sample design 5.2.5. 
iTRAQ labelling (completed by the Australian Proteome Analysis 
Facility at Macquarie University) 
5.2.6. 
Bio-Plex Pro Rat Cytokine, Chemokine, and Growth Factor Assay 6.2.3. 
Linear regression models 6.2.4. 
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Chapter Three 
Development of proteomic protocols for the analysis 
of pulmonary infection with Cryptococcus 
The proteomic data presented in this study were the result of a significant amount of 
protocol development. This chapter presents a description and analysis of the 
experimental work undertaken to develop the study-specific protocols required for the 
proteomic investigation of pulmonary infection with Cryptococcus. 
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3.1. Technical issues are inherent to the fungal sample type 
Despite the importance of fungi to both industry and biomedicine, the proteomic 
analysis of these organisms is only just beginning. This is a direct result of the 
technical challenges associated with fungal proteomics. Protein extraction from fungi, 
and especially filamentous fungi, is difficult, largely due to the robust fungal cell wall 
that increases the structural integrity of the cell [240-242]. A number of studies have 
been undertaken to overcome the cell lysis challenges that fungal organisms pose, 
with a vast number of mechanical, chemical and enzymatic extraction methods being 
investigated. Some research groups have gone so far as to generate protoplasts (cell 
wall removed) [242], however, it is generally agreed that meaningful proteomic data 
can only be obtained when pre-lysis handling and manipulation is kept to a minimum.  
Gene expression and gene transcript changes during infection have been investigated 
in a number pathogenic fungi including Cryptococcus neoformans, Candida albicans 
and Aspergillus fumigatus [243], but there have been no studies in C. gattii. 
Additionally, to date there are no publications investigating the proteome of 
pathogenic fungi during infection. Studying fungal proteomes using animal models is 
technically challenging. The Cryptococcus model was chosen because 1) it is an 
important fungal pathogen with a suitable animal model; 2) it produces robust 
infection and was predicted to provide enough material for proteomics; and 3) as a 
yeast it was possible to purify intact infecting cells from contaminating host material. 
However, the polysaccharide capsule specific to virulent Cryptococcus species 
provided its own difficulties and using this model for proteomic analysis required 
extensive optimisation. What follows is the description of the technical difficulties 
encountered in this study and the measures taken to overcome them. 
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3.2. Methods 
3.2.1. In vitro growth conditions 
The in vitro growth conditions used were described in section 2.3.1. 
Note: C. gattii R265 (molecular type VGIIa), both cultured and obtained from 
pulmonary infection, was used for the development of protein extraction protocols. 
 
3.2.2. Pulmonary infection model 
The pulmonary infection model used was described in section 2.3.2. 
 
3.2.3. Pulmonary tissue homogenisation 
Pulmonary tissue homogenisation was completed using the method described in 
section 2.3.3. 
 
3.2.4. Isolation of Cryptococcus from pulmonary tissue and lyophilisation 
of Cryptococcus 
Cryptococcus cells were isolated from pulmonary tissue and lyophilised using the 
methods described in section 2.3.4. 
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3.2.5. In vitro/in vivo Cryptococcus cellular disruption and phenol protein 
extraction 
Cryptococcus cells were lysed and intracellular proteins extracted using the methods 
described in section 2.3.5. 
 
3.2.6. 2-D PAGE 
2-D PAGE was completed using the methods described in section 2.3.6. 
 
3.2.7. 1-D SDS-PAGE 
1-D SDS-PAGE was completed using the methods described in section 2.3.7. 
 
3.2.8. 2-D PAGE Western blotting 
Proteins separated by 2-D PAGE were transferred onto 0.45µm PVDF Immobilon-P 
Transfer Membrane (Millipore Corporation, USA) following the semi-dry method 
developed by Khyse-Anderson [244] with the following modifications. Prior to the 
completion of 2-D PAGE seven extra thick blot papers (Bio-Rad, USA) and two 
membranes were cut to the size of the 2-D PAGE gel (approximately 12 cm x 8 cm). 
The following three buffers were also prepared and cooled to 4 °C: 
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Buffer 1: SDS aids the elution of proteins from the gel matrix [245]. Amino-caproic 
acid acts as the terminating ion in the isotachophoresis ‘train’ that cleans up the 
proteins from the polyacrylamide gel [244, 246].  
o 200 mL required per gel: 20 mL of Western blot buffer 1 10X stock, 20 
mL of 100 % methanol and 500 µL of 20 % SDS made up to 200 mL with 
ddH2O. 
Buffer 2: Methanol increases protein affinity for the membrane by removing SDS 
from proteins [245]. 
o 100 mL required per gel: 10 mL of Western blot buffer 2 10X stock and 20 
mL of 100 % methanol made up to 100 mL with ddH2O. 
Buffer 3: Tris acts as a conductive strong buffering agent that maintains the 
conductivity and pH of the system during transfer [247]. 
o 50 mL required per gel: 5 mL of Western blot buffer 3 10X stock made up 
to 50 mL with ddH2O. 
Just prior to the completion of 2-D PAGE, 100 mL of buffer 1 was decanted into a 
clean plastic tray. All of buffer 2 and buffer 3 were decanted into additional individual 
clean plastic trays. Two blot papers were then placed into the tray containing buffer 1, 
four into the tray containing buffer 2 and one into the tray containing buffer 3. The 
membranes were soaked in 100 % methanol until completely wet before being 
transferred to the tray containing buffer 2 (placed under the blot papers). Upon 
completion of 2-D PAGE, the gel was removed from its cassette and placed in a clean 
tray containing ddH2O for two minutes. The ddH2O was then decanted from the 
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plastic tray and replaced with the remainder of buffer 1 and the gel equilibrated with 
buffer 1 for five minutes. When equilibrated the blot stack was assembled in a bottom 
up manner as shown below in figure 3.1: 
 
Figure 3.1: Semi-dry blotting stack for reverse polarity protein transfer 
This blotting stack differs from that described by Khyse-Anderson [244] in that the 
stack was initially formed with an additional membrane on the cathode side of the 
protein gel. Also, two blotting papers soaked in buffer 2 were in place of the standard 
two blotting papers soaked in buffer 1.  
After the gel was placed onto the membrane it was carefully inspected to ensure that 
there were no trapped air bubbles, which would prevent the transfer of protein. Once 
the stack was assembled it was carefully rolled with a plastic roller to remove excess 
buffer and any residual air bubbles. The blotting cassette was then closed and the 
instrument programmed to run at 300 mA constant for 5 minutes in the reverse 
polarity. The two blotting papers soaked in buffer 2 were then removed and discarded. 
The cathode membrane was carefully removed from the blotting stack and stained 
with direct blue 71 (DB71) for at least 5 minutes and anywhere up to an hour [248]. 
The membrane was then briefly washed with washing solution to remove excess 
DB71. The membrane was then allowed to air dry. 
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After the transfer of protein in the cathode direction, the blotting stack was 
reassembled as described by Khyse-Anderson [244], with two blotting papers soaked 
in buffer 1 in place of the two discarded blotting papers soaked in buffer 2 as shown 
below in figure 3.2:  
 
Figure 3.2: Semi-dry blotting stack for traditional polarity protein transfer 
The polarity was reset to the traditional orientation and the proteins transferred onto 
the anode membrane at 300 mA for an additional 25 minutes. Protein transfers in both 
the cathode and anode direction were completed in a 4 °C cold room. This is 
especially crucial when transferring proteins in the reverse polarity cathode direction. 
This process generates a significant amount of heat that would melt the gel into the 
membrane, resulting in poor protein transfer and high background staining.    
The anode membrane was then incubated with 5 % non-fat milk powder in PBS 
containing 0.1 % (v/v) Tween-20 (PBS-T) for 1 hour at 4 °C, in preparation for 
hybridization with sera. The blocked membrane was washed with PBS-T 5 times, for 
6 minutes each wash, and incubated with patient sera (1:20 dilution with PBS) 
overnight at 4 °C. Following another 5 washes in PBS-T, the membrane was 
incubated with alkaline phosphatase-conjugated anti-rat IgG (heavy and light chain) 
antibody (Sigma-Aldrich, 1:1000 dilution with PBS) for 1.5 hours at ambient 
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temperature. The membrane was then washed 5 times in TBS containing 0.1 % (v/v) 
Tween-20 (TBS-T).  
Colorimetric development of the immunoblot was achieved using an Alkaline 
Phosphatase Conjugate Substrate Kit (Bio-Rad, USA). 25 mL of 1 x colour 
development buffer was prepared and allowed to warm to room temperature. 
Immediately before use 250 µL of alkaline phosphatase colour reagent A and B were 
added to the 1 x colour development buffer. The anode membrane was then immersed 
in the colour development solution and incubated at room temperature on an orbital 
shaker until colour development was completed (approximately 5 minutes). The 
membrane was then washed with ddH20 for five minutes to stop colour development 
and then allowed to air dry. 
 
3.3. Results: 
3.3.1. Separating Cryptococcus from pulmonary tissue 
Mixed proteomes represented a serious technical issue to this study. The fulfilment of 
the aims of this thesis, the independent analysis of the host and infective agent 
proteomes during infection, required the separation of the host material from 
Cryptococcus and vice versa. The low-density nature of the Cryptococcus cells from 
pulmonary infection was exploited to achieve this separation via the use of sucrose 
cushion density centrifugation (figure 3.3). 
  Chapter Three 
   
 
 77 
 
Figure 3.3: Sucrose density cushion centrifugation separates Cryptococcus cells 
from host pulmonary material. 
 
3.3.2. Cell disruption, decapsulation and protein purification for 
Cryptococcus from pulmonary infection 
Protein extraction methods progressed from attempts to disrupt cells, to attempts at 
cell decapsulation from intact cells and finally to attempts at protein purification from 
cell lysates. Table 3.1 represents the techniques attempted for Cryptococcus from 
pulmonary infection. This table provides a brief description of the effect of the 
specific technique on the Cryptococcus cell or lysate, and whether the resulting 
sample was suitable for proteomic analysis platforms post-treatment.  
 
 
 
 
 
Lung pellet post 
homogenisation 
- 
Resuspended in 
PBS 
Sucrose density 
cushion!
Cryptococcus cells !
Sucrose density cushion!
Remnant Lung tissue!
PBS 
1,500 g 
Centrifugation 
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Table 3.1: Techniques attempted for Cryptococcus from pulmonary infection 
Cell lysis technique Lysis/sample buffer Outcome/Comments 
Ultrasonication 1% SDS • No cell lysis 
Ultrasonication 1% C7BzO, 7 M urea, 2 M 
thiourea, 40 mM tris 
• No cell lysis 
Boiling 1% SDS • No cell lysis 
Bead beating 1% SDS • No cell lysis 
Beat beating 1% C7BzO, 7 M urea, 2 M 
thiourea 
• Standard method for cultured material 
• No cell lysis 
Liquid nitrogen + 
bead beating 
1% C7, 7 M urea, 2 M thiourea 
 
• No cell lysis 
Chemical DMSO • Common method of Cryptococcus 
decapsulation 
• No detected decapsulation 
Enzymatic Glucanex • No detected decapsulation 
Lyophilisation + 
bead beating 
1% C7BzO, 7 M urea, 2 M 
thiourea, 40 mM tris 
 
• Cell lysis achieved 
• Large amount of non-protein 
contamination generated 
• Samples not suitable for proteomics 
analysis platforms 
Lyophilisation + 
bead beating + 
acidic extraction 
1% C7BzO, 7 M urea, 2 M 
thiourea, 80 mM citric acid 
• Cell lysis achieved 
• Acidic extraction unable to remove 
non-protein contamination  
• Samples not suitable for proteomics 
analysis platforms 
Lyophilisation + 
bead beating + 
phenol extraction 
1% C7BzO, 7 M urea, 2 M 
thiourea, 40 mM tris followed by 
phenol extraction 
• Cell lysis achieved 
• Phenol extraction removed significant 
amounts of non-protein contaminant 
• Samples suitable for proteomics 
analysis platforms 
 
3.3.3. Lyophilisation prior to mechanical disruption is essential for the 
disruption of Cryptococcus cells from pulmonary infection 
Finding the most suitable cellular disruption technique for Cryptococcus cells isolated 
from pulmonary infection required significant trial and error. It was determined that 
Cryptococcus cell lysis required drying and shrinking of the capsular polysaccharide 
structure via lyophilisation. Lysis was then achieved using bead beating with 3 mm 
glass beads (figure 3.4). 
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Figure 3.4: A) Hydrated C. gattii cells isolated from late stage pulmonary 
infection; B) the same cells post lyophilisation and beat beating.  
Image B shows the broad spectrum of cellular disruption evident post lyophilisation and beat beating, 
from complete cellular destruction to intact cells. Image B also shows the high level of cellular debris 
post lyophilisation and bead beating. 
 
3.3.4. Phenol extraction for cultured Cryptococcus 
Cellular disruption using lyophilisation coupled with bead beating generated large 
amounts of non-protein contaminants with the 2-D PAGE gel image showing poor 
protein migration/separation during IEF coupled with significant vertical streaking.  
(figure 3.5A). Phenol is one of the strongest protein-polysaccharide dissociating 
agents [249] and initial experiments with cultured Cryptococcus indicated that phenol 
could prove to be an effective sample preparation technique for Cryptococcus from 
pulmonary infection. Phenol protein extraction ameliorated the inhibitory effects non-
protein contaminants, improving protein separation during IEF and eliminating the 
majority of vertical streaking. These experiments also indicated that LiCl, the agent 
used by Jobbins et al. to dissociate protein from non-protein contaminants [232],  is 
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not required as a dissociating agent when using phenol protein extraction (figures 
3.5B and 3.5C).    
 
Figure 3.5: 2-D PAGE gel images showing the separation of proteins obtained 
from C. gattii. 
A) Cultured C. gattii cells prepared using standard alkaline protein extraction; B) cultured C. gattii 
prepared using phenol protein extraction without 50 mM LiCl; and C) cultured C. gattii prepared using 
phenol protein extraction with 50 mM LiCl. There are no observable differences between the 
migration/separation of proteins in B and C.  
 
3.3.5. Phenol protein extraction of Cryptococcus cells obtained from 
pulmonary infection 
The results of lyophilisation followed by bead beating and phenol protein extraction 
of Cryptococcus cells from pulmonary infection is shown in figure 3.6. While not 
A B 
C 
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completely removing the non-protein contamination (observable as inhibited protein 
migration in figure 3.6C), phenol protein extraction was able to improve protein 
migration and separation for 1-D SDS-PAGE to the extent that mass spectrometry 
could be attempted.  
 
Figure 3.6: 1-D SDS-PAGE gel images of C. gattii proteins. 
1-D SDS-PAGE gel image of proteins from A) cultured C. gattii and B) C. gattii obtained from 
pulmonary infection prepared using the techniques developed by Jobbins et al. (2010). C) C. gattii 
obtained from pulmonary infection prepared using phenol protein extraction. This set of images 
demonstrates that the techniques developed by Jobbins et al. (2010) are ineffective for in vivo sample 
types and that phenol protein extraction improves protein migration, separation and resolution. 
 
A B C 
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3.3.6. Exopolysaccharides in pulmonary supernatants 
Pulmonary infection with Cryptococcus resulted in the generation of large amounts of 
exopolysaccharides, which are secreted into the pulmonary spaces. This non-protein 
contaminant must be accounted for prior to the iTRAQ analysis of pulmonary 
proteins. It was determined that the application of acidic protein extraction, coupled 
with 100 kDa MWCO filtration, was readily applicable to this sample type and 
effectively removed the non-protein contaminant (figure 3.7). 
 
Figure 3.7: 2-D PAGE images showing separated lung proteins from rats 
infected with C. gattii R265 (late stage infection).  
Prepared with A) standard alkaline extraction protocol plus treatment with 50 mM LiCl and 100 kDa 
MWCO filtration and B) acidic extraction protocol plus treatment with 50 mM LiCl and 100 kDa 
MWCO filtration. A) shows the presence of non-protein contamination, observable as inhibited IEF in 
the acidic portion of the gel. B) shows that the inhibition of IEF inhibition has been rectified.  
 
3.3.7. 2-D PAGE Western blot complexity issues  
The Western blots generated by this study were far more complex than those 
generated by a similar study conducted by Jobbins et al. (2010). This introduced 
A B 
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difficulties during the alignment of protein spots of interest across the three protein 
visualisation formats (figure 3.8). Ultimately the result was the re-evaluation of the 
experimental design for this element of the study. 
 
Figure 3.8: Representative Western blot showing complexity of protein spots.  
This complexity caused difficulties when attempting to align specific protein spots across the three 
elements of the 2-D PAGE Western blot detection system. 
 
3.3.8. Non-specific binding does not cause 2-D PAGE Western blot 
complexity 
To ensure that the complexity of spots on the 2-D PAGE Western blots was not 
caused by non-specific binding the Western blot protocol was repeated without 
primary antibody (figure 3.9). The negative detection of any proteins post secondary 
antibody incubation and colourimetric development indicated that non-specific 
binding is not the cause for the observed 2-D PAGE Western blot complexity.  
2-D PAGE image – 
stained with Flamingo 
fluorescent protein stain 
Cathode membrane – 
transferred proteins stained 
with Direct Blue 71   
Anode membrane – 
transferred proteins probed 
with primary & secondary 
antibody - colorimetric 
development  
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Figure 3.9: Anode membrane generated following the previously described 
Western blot (section 3.2.8.) protocol without primary antibody.  
Negative protein detection indicates that the secondary antibody is not suffering from non-specific 
binding. 
 
3.4. Discussion 
3.4.1. Issues with the proteomic investigation of pulmonary infections 
In the simplest terms proteomics can be defined as the context driven search for 
protein purity. This is a difficult pursuit with regard to in vivo infectious diseases, and 
pulmonary infection with Cryptococcus proved particularly challenging. The initial 
concern in preparing Cryptococcus cells from pulmonary infection was the separation 
of the fungal sample from the host material, and vice versa, prior to independent 
protein identification. Previous work presented in the NHMRC grant application for 
this study demonstrated that host proteins can be removed from intact Cryptococcus 
cell obtained from murine pulmonary infection in less than 30 minutes using an Ultra-
turrax blender and 1% C7BzO, 7 M urea, 2 M thiourea, 40 mM tris buffer (figure 
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3.10) [3]. The use of repeated Ultra-turrax washes represents a very aggressive 
method of host protein removal. For this study, the physicochemical nature of the 
Cryptococcus capsule was exploited, as the increase in capsule size as a result of 
pulmonary infection, coupled with the generally low-density nature of the capsule, 
reduced the mass per unit volume ratio of the cell. In comparison, the residual lung 
material post homogenisation was tightly bound dense connective tissue. Thus, the 
overall density of the Cryptococcus cells was lower than that of the remnant 
pulmonary tissue. A density cushion (sucrose at a density of approximately 1.2 
g/cm3), which inhibited the passage of fungal cells but permitted the pelleting of the 
denser connective tissue during low speed centrifugation, was effective for separating 
the two sample types from each other (figure 3.3). This procedure was gentler on the 
Cryptococcus cells than the technique described in the NHMRC grant and also proved 
to be faster, approximately 15 minutes as opposed to 30 minutes for repeated Ultra-
turrax washes. 
 
Figure 3.10: Removal of lung tissue using an Ultra-turrax to wash the 
Cryptococcus cells. 
A) 1st extraction with residual lung material; B) pure intact C. gattii cells after 5th extraction (from [3]). 
A B 
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3.4.2. Development of an efficient protocol for in vivo Cryptococcus cell 
lysis 
Taking into consideration the effect that experimental procedures have on sample 
proteomes is paramount for comparative and quantitative proteomic analyses. 
Minimal sample manipulation is essential for the most accurate comparative 
proteomic data. Unfortunately, this proved to be extremely difficult for the 
Cryptococcus cells obtained from pulmonary infection. The major complicating factor 
was the physiochemical nature of the Cryptococcus polysaccharide capsule and its 
dynamic response to pulmonary infection, resulting in a drastic increase in capsule 
volume. The capsule resulted in three major challenges to protein isolation and 
purification: increased structural integrity of the C. gattii cells; non-protein 
contamination and associated problems with 2-D PAGE and 1-D SDS-PAGE 
resolution; and the direct binding and depletion of cryptococcal proteins.  
 
3.3.3. Cellular disruption techniques 
A number of cell lysis techniques were experimentally investigated with limited 
success (Table 3.6), including the cell lysis technique developed for cultured C. gattii 
by Jobbins et al. (2010). Jobbins et al. (2010) used bead beating in 2-D PAGE sample 
buffer coupled with ultra-sonication to achieve efficient cell disruption of cultured 
Cryptococcus cells [232]. This methodology proved to be completely inadequate for 
Cryptococcus obtained from pulmonary infection. A more aggressive cell disruption 
technique than that utilised by Jobbins et al. (2010), or sample pre-treatment to 
partially or totally decapsulate cells prior to cell disruption, was required. Dimethyl 
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sulfoxide (DMSO), a polar aprotic solvent that dissolves both polar and nonpolar 
compounds, has been previously found to remove a significant portion of the 
Cryptococcus polysaccharide capsule [250]. The removal of capsular polysaccharides 
with DMSO requires fungal cells to be incubated at room temperature for at least an 
hour, which ultimately kills the cells [96, 250, 251]. However, the resulting effects of 
the conditions necessary for decapsulation with DMSO on the proteome far outweigh 
any decapsulation that may be achieved. Additionally, DMSO decapsulation proved 
to be completely ineffective for Cryptococcus obtained from pulmonary infection 
(data not shown). 
Maxson et al. (2007) estimated that water could account for approximately 95% of the 
weight of the polysaccharide capsule of C. neoformans cells grown under capsule 
inducing conditions [252]. High water retention is a result of the acidic nature of the 
polysaccharide structure, imparted by the high content of glucuronic acid. Maxson et 
al. (2007) also established that the capsule was not a rigid boundary but is in fact 
compressible, thus capsule has the ability to absorb the shear forces created by 
mechanical disruption techniques. The compressible nature of the capsule, coupled 
with its extremely large size during pulmonary infection, explains why this sample 
type was highly resistant to mechanical cellular disruption.  
Dehydration of the capsule, via lyophilisation, resulted in the loss of its compressible 
nature, enabling mechanical cellular disruption via dry bead beating. While hydrated 
cells were uniformly unaffected by bead beating, the lyophilised sample exhibited a 
heterogeneous cell population (figure 3.2). Cellular integrity ranged from minimally 
damaged cells, to cells broken in half, to cells with varying degrees of capsule loss, to 
cells exhibiting complete fragmentation. Whilst not achieving 100% cell disruption, 
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lyophilisation followed by dry bead beating represents the most effective cellular 
disruption technique for Cryptococcus obtained from pulmonary infections attempted 
to date.   
 
3.4.4. Contaminating capsular polysaccharides 
For cultured C. gattii sample preparation, Jobbins et al. determined that standard 
protein extraction protocols resulted in the loss of high molecular weight proteins and 
significant streaking in the acidic portion of 2-D PAGE [232]. These results were 
attributed to the inability of standard extraction/sample preparation methods to deal 
with the large volumes of polysaccharide capsular material inherent to the 
Cryptococcus sample type, the components of which are small enough to enter IPG 
strips. Solubilised polysaccharides pose a major problem for IEF. They behave as 
polyanions, which are capable of binding proteins via electrostatic interactions [253]. 
The result is significant horizontal streaking at the acidic end of the 2-D PAGE gel. 
Obtaining the most complete snapshot of the Cryptococcus proteome requires the 
disassociation of proteins from capsular material and the subsequent removal of the 
capsular material from the sample.  
In 1888 Franz Hofmeister defined the series of anions and cations, known as the 
Hofmeister or lyotropic series, in order of their ability to change water structure via 
interactions between ion-protein and ion-water [254]. Anions have a larger effect than 
cations, and ions later in the series increase the solubility of non-polar molecules 
while ions earlier in the series decrease their solubility [255, 256]. Jobbins et al. 
(2010) found that lithium chloride (LiCl) was best at disrupting protein-capsule 
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interactions for cultured Cryptococcus samples, increasing the representation of high 
molecular weight proteins and improving total protein yield [232]. Lithium ions and 
chloride ions both appear towards the middle of the Hofmeister series for cations and 
anions respectively. As a result the use of this compound did not skew the data 
towards polar or non-polar proteins. Jobbins et al. (2010) concluded that the use of 
LiCl to disrupt the electrostatic interactions between protein and polysaccharide 
followed by 100 kDa molecular weight cut off (MWCO) filtration to remove capsular 
fragments eliminated the majority of artifacts from the acidic end of 2-D PAGE. 
This protocol proved ineffective at eliminating the vast amount of contaminants 
produced by the mechanical disruption of lyophilised Cryptococcus from pulmonary 
infection. For in vivo cells the capsule accounts for the majority of cell volume and 
mass. Furthermore, the physiochemical nature of the in vivo polysaccharide capsule, 
which is produced under nutrient and oxidative stress, is far more complex than the 
capsule produced following growth in rich culture media. Capsular enlargement 
results from the addition of new polysaccharide molecules near the capsule edge [96, 
257-259]. This mode of enlargement means the architecture of the capsule consists of 
multiple zones defined by their relative polysaccharide density, with the densest zone 
closest to the cell and decreasing with distance from the cell [96, 258]. It is therefore 
possible that as well as more capsular material overall, the Cryptococcus cells from 
pulmonary infection had larger amounts of polysaccharide subtypes that more readily 
and strongly associated with protein. This may have rendered LiCl ineffective at 
disassociating proteins from capsule. 
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3.4.5. Dissociating Cryptococcus capsule and proteins from pulmonary 
infection requires the stronger dissociating agent Phenol 
Phenol is the simplest aromatic alcohol, containing a polar (OH) group bound to an 
aromatic ring [260]. Phenol selectively solubilizes proteins, having little tendency to 
dissolve polysaccharides and nucleic acids. In addition to its selectivity as a solvent, 
phenol is one of the strongest dissociating agents for decreasing the molecular 
interaction between proteins and non-proteins [249]. The phenol protein extraction 
protocol was initially developed to deproteinise carbohydrates and became the 
standard procedure for removal of proteins from nucleic acid samples [261]. Hurkman 
and Tanaka (1986) were the first to discuss phenol extraction for proteomic studies 
[262]. This study, along with later studies conducted by Carpentier et al. (2005) [249] 
and Saravanan and Rose (2004) [263], established that phenol extraction was highly 
efficient at removing nucleic acids and other carbohydrate non-protein contaminants 
from protein extractions. The use of phenol extraction for protein samples has the 
added advantage of minimizing protein degradation via the denaturation and 
deactivation of endogenous proteolytic enzymes.  
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Figure 3.11: Phenol protein extraction protocol. 
 
The phenol protein extraction protocol is based on a two-phase partition principle 
(figure 3.11). The protocol couples the ability of phenol to selectively solubilize 
proteins with the immiscible nature of phenol (the organic phase) and water (the 
aqueous phase) to isolate protein from non-protein contaminants. Phenol causes 
proteins in the aqueous layer to denature via hydrogen bond interactions, effectively 
forcing the non-polar residues to the outside of the protein structure. It is this protein 
denaturation that is key to the successful isolation of protein from carbohydrates. The 
proteins become soluble in the phenol phase and less soluble in the aqueous phase 
while, crucially, the polar carbohydrate molecules remain in the polar aqueous phase.  
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3.4.6. Phenol protein extraction for in vitro Cryptococcus: a litmus test 
Preliminary experiments with the phenol protein extraction technique were conducted 
with C. gattii cultured in rich media. While this sample type is not indicative of the 
issues encountered with cells from pulmonary infection, coupled with 2-D PAGE it 
provided an effective diagnosis of the ability of phenol protein extraction to remove 
non-protein contaminants. 2-D PAGE is highly sensitive to non-protein contaminants 
(e.g. cell wall, polysaccharide, DNA etc.) [232]. Thus, a gross assessment of the 
efficiency of protein purification via phenol protein extraction can be judged on the 
quality of 2-D PAGE gel images.  
Comparison of the control gel image with that of the phenol protein extraction gel 
images indicates the potential of phenol protein extraction as a suitable sample 
preparation technique for Cryptococcus from pulmonary infection (figure 3.5). The 
control gel, prepared via standard alkaline extraction procedures without the inclusion 
of a disassociating agent or MWCO filtration, was of poor quality. This gel exhibits 
clear indications of polysaccharide contamination, observable as an acidic bias of 
protein migration and significant vertical and horizontal streaking. The acidic bias of 
protein separation results from the association of poly-anionic polysaccharides with 
the proteins in the sample. This association alters the natural pI of the proteins to a 
more acidic one, thus the observed bias of “acidic” proteins. The application of 
phenol protein extraction resulted in an amelioration of the acidic bias of protein 
migration along with an improvement in overall protein separation and resolution for 
cultured Cryptococcus. This improvement was achieved without the use of MWCO 
filtration, which was previously considered essential for C. gattii samples. It was also 
interesting to observe that the inclusion or exclusion of the disassociating agent LiCl 
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appeared to have no observable effect on the quality of protein separation by 2-D 
PAGE. The drastic improvement in gel image quality without the use of LiCl or 
MWCO filtration indicates that phenol protein extraction far exceeds the capability of 
the techniques developed by Jobbins et al. (2010) to isolate protein from non-protein 
contaminants and to subsequently remove these contaminants.  
 
3.4.7. Phenol protein extraction for in vivo Cryptococcus 
1-D SDS-PAGE was used as a diagnostic to determine the efficiency and 
effectiveness of phenol protein extraction to purify Cryptococcus from pulmonary 
infection. While not as sensitive to non-protein contaminants as 2-D PAGE, the key 
advantage of 1-D SDS-PAGE is that this technique requires significantly lower 
protein loads than 2-D PAGE. The application of Cryptococcus from pulmonary 
infection to 2-D PAGE would require the use of an entire infected lung sample per 2-
D PAGE run. This would eliminate the use of the sample for alternative proteomic 
investigations (i.e. iTRAQ) if phenol protein extraction proved effective.  
The 1-D SDS-PAGE image of C. gattii from pulmonary infection prepared using the 
techniques developed by Jobbins et al. (2010) demonstrates an inhibition and 
distortion of protein migration (figure 3.6B). This indicates that the sample 
preparation techniques utilized by Jobbins et al. (2010) are inadequate for the highly 
contaminated in vivo samples. Applying the phenol protein extraction protocol to the 
in vivo sample resulted in the marked improvement in protein separation (figure 
3.6C). While not completely removing the smearing associated with non-protein 
contamination the application of phenol protein extraction increased the total number 
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of protein bands observable and limited the degree of distortion observable in the gel 
lane. Additionally, phenol protein extraction ameliorated non-protein contamination 
to the extant that the cryptococcal proteins obtained following pulmonary infection 
were pure enough to be applied to mass spectrometric protein identification (see 
chapter 4). 
 
3.4.8. Exopolysaccharides in the lung material 
During culture, and especially during infection, C. neoformans and C. gattii 
continuously release soluble capsular material, termed exopolysaccharide, into the 
culture media [111]. While in vitro conditions stimulate capsule production, the extent 
of capsular development is much reduced compared to that observed during 
pulmonary infection. It is likely that, in accordance with an observable increase in 
capsular production, a vast amount of capsular material is released during pulmonary 
infection.  
The existing sample preparation protocols [232] were unable to eliminate the non-
protein contaminant associated with the pulmonary sample type. As with the 
cryptococcal proteins, application of extracted pulmonary proteins to 2-D PAGE 
resulted in the inhibition of IEF in the acidic portion of the gel (figure 3.7A). This is a 
result of acidic proteins remaining associated with soluble exopolysaccharides that 
were able to pass through the 100 kDa MWCO filters. The removal of soluble 
exopolysaccharide required the use of acidic protein extraction [253]. Acidic protein 
extraction exploits the principle that material close to or at its pI is at its lowest 
solubility and can be removed from solution via high-speed centrifugation. Acidic 
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protein extraction is readily applicable to the contaminated pulmonary protein sample 
as capsular polysaccharides act as poly-anions. Changing the pH buffer used during 
homogenisation from 40 mM tris (alkaline, pH ≈ 8) to 80 mM citric acid (acidic pH ≈ 
3) and increasing the duration of high-speed centrifugation to 20 minutes improved 
isoelectric focusing in the acidic portion of 2-D PAGE and eliminated the majority of 
vertical streaking (figure 3.7B). Reducing the pH of the pulmonary protein sample 
had the added advantage increasing the solubility of the majority of the pulmonary 
proteins in the sample, increasing total protein yield.  
 
3.4.9. 2-D PAGE Western blot analysis 
The identification of experimentally relevant protein spots via 2-D PAGE Western 
blot analysis required the alignment of individual protein spots across the three 
protein visualisation formats. A protein identified on the anode membrane probed 
with antibody must align with its corresponding protein on the cathode membrane and 
finally with its corresponding protein on the 2-D PAGE image prior to protein spot 
excision, trypsin digestion and identification via mass spectrometry (figure 3.8). 
Despite utilising automated systems (PDQuest, Bio-Rad, USA)) and manual 
techniques the accurate alignment of the three aspects of the 2-D PAGE western 
detection system proved problematic. The primary source of the difficulties was a 
higher than expected complexity of the Western blots (figure 3.8).  
Jobbins et al. (2010) successfully identified 37 unique cryptococcal proteins from sera 
obtained from Koalas presenting with clinical cryptococcosis. The 2-D PAGE 
Western blots presented by Jobbins et al. (2010) exhibited approximately ten 
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identifiable protein spots per anode membrane. In comparison, the work presented in 
this study detected hundreds of protein spots per anode membrane, for both control 
and disease samples. At first it was suspected that the high number of detectable 
protein spots was the result of non-specific secondary antibody binding, however, 
probing with secondary antibody in the absence of prior primary antibody resulted in 
no protein detection (figure 3.9). The differences in observable protein spots is most 
likely a result of the differences in the protocols utilised by Jobbins et al. (2010) and 
by this study to generate the 2-D PAGE Western blots.  
Jobbins et al. (2010) were forced to utilise a three-step detection system (primary, 
secondary and tertiary antibodies) for their koala infection model as alkaline 
phosphatase-conjugated anti-koala IgG is not commercially produced. In their study, 
following incubation with the koala sera, the anode membrane was incubated with an 
intermediate rabbit anti-opossum IgG antibody that was then followed by incubation 
with alkaline phosphatase-conjugated anti-rabbit IgG [232]. In contrast, the current 
study using a rat model was able to use the commercially available alkaline 
phosphatase-conjugated anti-rat IgG antibody and did not require an intermediate 
secondary antibody.  
In terms of taxonomic hierarchical classification opossums and koalas are species 
from the same Kingdom (Animalia), Phylum (Chordata), Class (Mammalia), 
Infraclass (Marsupialia) but are from different Orders (koala: Diprotodontia, 
opossum: Didelphimorphia). It is likely that the use of an antibody generated in a 
species that is similar but not identical to that of the species being analysed would 
result in both false positives and false negatives during 2-D PAGE Western blot 
analysis. Hence the intermediate anti-opossum antibody used by Jobbins et al. (2010) 
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to detect koala protein is a likely cause for the lower number of detected proteins 
compared to this study. 
In addition to protein alignment issues, Western blots could not be completed for rats 
infected with KN99α for this study. These rats were in such poor health that 
extracting enough blood to generate the required volume of serum for 2-D PAGE 
Western blots analysis proved impossible. Together, the technical limitations 
associated with the 2-D PAGE Western blot detection system forced a reassessment 
of the direction of this study to a more applicable detection system (see chapter 6). 
 
3.5. Conclusions 
This aim of this aspect of the thesis was to describe the technical issues and 
limitations encountered during this study and to highlight the progress made in 
protocol development that eventually ameliorated these significant technical 
difficulties. The majority of the technical difficulties encountered during this study 
were associated with the physiochemical nature of the capsular polysaccharides and 
exopolysaccharides that are inherent to Cryptococcus obtained from pulmonary 
infection. This study determined that cellular disruption via lyophilisation followed by 
dry bead beating and sample preparation using phenol protein extraction is most 
effective for Cryptococcus samples, including for cells obtained from pulmonary 
infection. Additional experimental investigation is required to improve protein purity 
in order to apply Cryptococcus from pulmonary infection to comparative proteomics 
techniques. Inhibited protein migration post-phenol protein extraction indicates that 
non-protein contaminants remain in cryptococcal protein samples obtained from 
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pulmonary infection (figure 3.6). The effect that these non-protein contaminants have 
on iTRAQ and other comparative proteomic techniques remains enigmatic. This 
study, however, has proven that such an endeavour may be possible and has made 
advancements towards this goal. An effective acidic protein extraction technique to 
reduce exopolysaccharide contamination of infected pulmonary protein samples was 
also identified. However, the application of phenol protein extraction to this sample 
type could prove to be more effective than acidic protein extraction at removing non-
protein contaminants. The use of phenol protein extraction would also remove the 
requirement of 100 kDa MWCO filtration, which was time consuming and possibly 
inhibited the detection of high molecular weight proteins. Unfortunately the work 
conducted on the lung proteome was completed prior to the commencement of 
experimentation focused on Cryptococcus sample preparation that resulted in the 
development of the phenol protein extraction procedure. This study also found the 
systemic analysis of the host response to infection via 2-D PAGE Western blot 
analysis to be far more complicated than observed in previous studies. Consequently, 
the Bio-Plex suspension array system was used instead of Western blotting (see 
Chapter 6).  
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Chapter Four 
Comparative proteomics of Cryptococcus 
One of the major aims of this PhD thesis was to compare clinically significant strains 
of Cryptococcus from in vitro and in vivo sources using quantitative proteomic 
techniques. The elucidation of the quantitative protein differences between cultured 
cells and cells obtained from pulmonary infection was expected to shed light on the 
biological processes of Cryptococcus pathogenesis at the molecular level. The 
technical challenges related to cell lysis and protein extraction from Cryptococcus 
obtained from pulmonary infection have been documented in Chapter 3. As a result of 
these challenges, the focus of this study shifted to performing qualitative mass 
spectrometry to compare the proteomes of cultured Cryptococcus cells and cells 
obtained from pulmonary infection. The results of this study indicate that future 
quantitative experiments with Cryptococcus from in vivo infections are achievable, 
although further protocol development will be required (see Chapter 3). Time limits 
restricted the focus of this study to C. gattii, which has been classified as a highly 
virulent primary pathogen. Despite limitations, this study detected a number of 
theoretically low abundance proteins from Cryptococcus obtained from pulmonary 
infection that are relevant to fungal pathogenesis. 
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4.1. Introduction 
Quantitative genomic and proteomic approaches are utilised to capture and monitor an 
organism’s transcriptional and translational outputs, respectively. These methods 
permit the elucidation of a pathogen’s response to varying external conditions via the 
simultaneous quantitative analysis of numerous genes or proteins. As fungal virulence 
is a multifactorial process, these approaches are particularly valuable for identifying 
the integrated expression of the different factors involved in the infection process. 
Transcriptional approaches have been applied to a number of fungal pathogens and 
significantly up- and down-regulated genes have been identified as potential virulence 
factors [1, 264-267].  
The proteome-based investigation of human-pathogenic fungi, such as C. albicans, A. 
fumigates, P. boydii and C. neoformans [7, 268, 269], is a growing area of interest. A 
significant constraint to proteomics technologies is their limited ability to detect and 
quantify low abundance proteins. Ghaemmaghami et al. (2003) demonstrated that the 
range of protein expression for Saccharomyces cerevisiae proteins expressed during 
normal growth was from fewer than 50 to more than 106 molecules per cell [212]. 
Low abundance proteins can be detected, down to hundreds of copies per cell, but 
fractionation coupled with milligram amounts of starting material are usually required 
in these cases. This amount of protein is rarely obtainable for in vivo studies using rat 
infection models. Pedersen et al. (2003) demonstrated that low abundance proteins 
make up approximately 80% of the yeast proteome [203]. The phylogenetic distance 
between Cryptococcus, a basidiomycete, and Saccharomyces, a ascomycete [270], 
questions whether Saccharomyces protein expression values represent a true 
reflection of the protein expression levels in Cryptococcus. Despite this, the studies by 
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Ghaemmaghami et al. (2003) and Pedersen et al. (2003) indicate that it is likely that a 
number of potentially interesting low abundance proteins will remain undetected by 
global proteomic investigations. 
Missall et al. (2004) published the first global examination of the Cryptococcus 
proteome. Their study used differential 2-D PAGE in an attempt to elucidate the 
proteins required for C. neoformans growth at high temperatures (37 °C). Missall et 
al. (2004) determined that the thiol peroxidases Tsa1 and Tsa3 were increased in 
expression at 37 °C and found Tsa1 is vital for growth of C. neoformans at high 
temperatures [80]. Since the Missall et al. (2004) study there have been a growing 
number of published studies analysing the C. neoformans proteome, however, it was 
not until recently that the C. gattii proteome was investigated. Jobbins et al. (2010) 
published the first examination of the global proteome of cultured C. gattii. Their 
study used immunoproteomics, 2-D PAGE Western blotting, to elucidate the key 
proteins and pathways involved in early and late stage C. gattii pathogenesis using the 
naturally occurring koala model of cryptococcosis [232]. The authors hypothesised 
that the disease-associated antigens that were identified could form future targets for 
therapy or be useful diagnostic biomarkers and indicators of prognosis. The detection 
and identification of 31 disease-associated antigens, in this case cryptococcal proteins, 
required the generation of novel sample preparation protocols. Similarly, Martins et 
al. (2013) identified 68 immunoreactive C. gattii proteins using 2-D PAGE Western 
blotting, a number of which were identified as potential targets for the development of 
immunodiagnostic tools for cryptococcosis [271]. Chong et al. (2012) used the C. 
gattii sample preparation techniques developed by Jobbins et al. (2010) to investigate 
the global response of cultured C. gattii to fluconazole treatment using a 1-D SDS-
PAGE 2-D nanoLC ESI MS/MS approach [272]. Their study hypothesised that fungal 
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proteins identified to be involved in the response to the fluconazole antifungal agent 
might be useful targets in future therapeutics. Crestani et al. (2012) investigated C. 
gattii protein expression during culture with varied levels of iron. Using 
multidimensional protein identification technology (MudPIT) and differential display 
2-D PAGE Crestani et al. (2012) found that iron deprivation affected capsule 
production, cAMP-signalling pathway, response to stress and metabolic pathways 
related to mitochondrial function [273]. 
These studies attempt to elucidate potential therapeutic and diagnostic markers using 
in vitro experimental models that are far removed from the reality of infection with 
Cryptococcus. While these in vitro studies have been able to identify proteins and 
pathways of relevance to the Cryptococcus cell, to date, no study has attempted the 
analysis of how Cryptococcus regulates protein expression in the process of in vivo 
infection. The aim of this study was to compare the proteome of Cryptococcus during 
saprophytic growth to the proteome generated during pulmonary infection using 
global comparative proteomic techniques. The underlying hypotheses of the study 
were that:  
• Fungal growth in the pulmonary environment would induce specific protein 
changes in the intracellular proteome of Cryptococcus  
• Comparative proteomic analyses would identify these specific proteins 
highlighting:   
o The proteins that permit Cryptococcus to overcome host immune 
responses and establish disease. 
o The proteins that could form future targets for therapy or be useful 
diagnostic biomarkers and indicators of prognosis. 
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4.2. Methods 
4.2.1. In vitro growth conditions 
The in vitro growth conditions used were described in section 2.3.1. 
• Note: only C. gattii (R265) cells were used for this study. 
 
4.2.2. Pulmonary infection model 
The pulmonary infection model used was described in section 2.3.2. 
• Note: The C. gattii (R265) cells used for this study were obtained from late 
stage infection (42 days post infection). 
 
4.2.3. Pulmonary tissue homogenisation 
Pulmonary tissue homogenisation was completed using the method described in 
section 2.3.3. 
 
4.2.4. Isolation of Cryptococcus from pulmonary tissue and lyophilisation 
of Cryptococcus 
Cryptococcus cells were isolated from pulmonary tissue and lyophilised using the 
methods described in section 2.3.4. 
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4.2.5. In vitro/in vivo Cryptococcus cellular disruption and phenol protein 
extraction 
Cryptococcus cells were lysed and intracellular proteins extracted using the methods 
described in section 2.3.5. 
 
4.2.6. 1-D SDS-PAGE 
1-D SDS-PAGE was completed using the methods described in section 2.3.7. 
 
4.2.7. 1-D SDS-PAGE manual lane excision and trypsin in-gel digestion 
for mass spectrometry protein identification  
Post 1-D SDS-PAGE the sample gel was stained with Coomassie G250 to facilitate 
the manual cutting of protein lanes. After fixation or Flamingo™ (Bio-Rad, USA) 
staining, the sample gel was washed for five minutes in ddH2O in a fixing tray. The 
ddH2O was then decanted and Coomassie staining solutions 1 and 2 were added in a 
4:1 ratio. The tray was covered and incubated on an orbital shaker (50 rpm) for a 
minimum of 8 hours. After staining, the gel was de-stained with 1 % acetic acid (v/v) 
solution until the gel background was clear and the protein bands were clearly 
defined. Once de-staining was complete an image of the gel was taken with a flatbed 
scanner.  
The de-stained gel was then placed on a clean white light illuminator. Using a printed 
and labelled image of the gel to be cut, the appropriate gel lanes were excised with a 
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scalpel. Each gel lane was cut lengthwise into 10 uniformly sized segments. These 
segments were further cut into ≈1 mm squares and transferred to 0.65 mL Eppendorf 
tubes. The gel pieces were briefly washed with 100 mM ammonium bicarbonate 
solution to ensure that the gel pieces were at the correct pH (above pH 8) and were 
then de-stained by the addition of 400 µL of 50% acetonitrile (ACN) (v/v) in 100 mM 
ammonium bicarbonate. The samples were vortexed and incubated for 10 minutes and 
the blue de-stain solution was removed and discarded. This de-staining process was 
repeated until the gel pieces were thoroughly de-stained. For heavily stained gel 
pieces complete de-staining was rarely achieved and instead de-staining was repeated 
until the de-stain solution no longer appeared blue.  
The samples were then washed with 200 µL of 100 % ACN to completely dehydrate 
the gel pieces. The excess ACN was removed and the gel pieces air-dried in a fume 
hood until the gel pieces appeared shrunken and white. Enough trypsin solution was 
then added to cover the dehydrated gel pieces. The gel pieces were re-hydrated at 4 °C 
for a minimum of 30 minutes to limit auto-digestion and ensure that trypsin remained 
active as it was absorbed into the gel. After rehydration, 100 mM ammonium 
bicarbonate solution was added to re-cover the gel pieces. The gel pieces were then 
digested overnight in a 37 °C incubator. 
After overnight digestion, the gel pieces were incubated in a sonicating bath for 5 
minutes and then centrifuged in a microfuge. The digest supernatant was transferred 
to a clean 0.65 mL Eppendorf tube. Enough 50 % acetonitrile (v/v) / 2 % formic acid 
(v/v) solution was then added to cover the gel pieces. The samples were then 
incubated for 30 minutes with occasional vortexing, incubated for 5 minutes in the 
sonicating bath and briefly centrifuged in the microfuge. The resulting supernatant 
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was removed and pooled with the initial digest solution supernatant. This process was 
repeated once more to ensure maximal peptide extraction from the gel pieces.  
The sample digest solutions were vortexed and then placed in a Vacufuge™ 
Concentrator 5301 (Eppendorf, Germany), with caps off, until completely dry. The 
samples were resuspended with 10 µL of loading buffer (Buffer A: 5mM phosphate 
25% acetonitrile (v/v), pH 2.7) and centrifuged at 16,000 g for 10 minutes to remove 
any extraneous insoluble particulates. 15 µL of each sample was then loaded into 
auto-sampler tubes for MS processing and subsequent protein identification. 
Alternatively, samples were stored at -20 °C until MS protein identification could be 
completed.  
 
4.2.8. Mass spectrometry (completed by the Australian Proteome Analysis 
Facility at Macquarie University) 
Mass spectrometry was completed using the methods described in section 2.3.9. 
 
4.2.9. Codon adaptation index calculation 
Codon adaptation index values were calculated using the E-CAI calculator at the 
following website http://genomes.urv.es/CAIcal/E-CAI/. FASTA sequence (from 
Uniprot) and the codon usage table and %G+C content (from 
http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=292817) data were 
entered in the designated fields. Using the Markov method and the alternative yeast 
genetic code the CAI was automatically calculated. 
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4.3. Results 
4.3.1. Macroscopic observation of rats infected with C. gattii R265 
Table 4.1: Rat lung weights 
Infection time point Mean control lung weight 
(±SD) 
Mean infected lung weight 
(±SD) 
14 days post 
infection  
0.88 g (0.035) 5.00 g (1.700) 
42 days post 
infection 
0.88 g (0.035) 4.79 g (1.676) 
 
Early stage infection: At the 14-day time point rats displayed symptoms typical of 
cryptococcosis. Rats infected with R265 demonstrated ruffled fur, lethargy and 
laboured breathing. Infected lungs were greatly increased in size compared to control 
lungs due to the development of large, multifocal gelatinous lesions (table 4.1). 
Infected lungs demonstrated extensive consolidation of lung fields, with little normal 
lung material remaining. 
 
Late stage infection: At the 42 day time-point rats displayed a similar degree of 
cryptococcosis-associated symptoms as observed at 14 days post infection. Similarly, 
lung weights, the extent of lesion development and the degree of lung field 
consolidation were comparable to the observations made at the 14 day time-point, 
however, the lungs were lighter at 42 days than at 14 days. Figure 4.1 shows lungs 
and cryptococcal cells isolated from infected rats at 42 days post infection.  
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Figure 4.1: Images of uninfected and infected lungs and Cryptococcus cells 
obtained from pulmonary infection. 
A) Typical, uninfected Fisher-344 rat lungs; B) Fisher-344 rats lungs at 42 days (late stage infection) 
post inoculation with 0.1 mL of 108 CFU of C. gattii R265; C) C. gattii R265 cells isolated from 
pulmonary tissue 42 days post inoculation. Note the drastic physical changes to lung tissue and 
Cryptococcus capsule as a result of pulmonary infection. 
 
4.3.2. In vitro and in vivo Cryptococcus mass spectrometry results 
1-D SDS-PAGE nanoLC ESI MS/MS qualitative proteomics was used to compare 
proteins expressed by C. gattii grown in culture (overnight in YPD broth) versus those 
expressed by C. gattii from late stage of pulmonary infection. This technique 
identified 1,164 non-redundant Cryptococcus proteins expressed in rich medium 
culture, 114 non-redundant Cryptococcus proteins expressed during late stage 
pulmonary infection and 470 Rattus norvegicus proteins co-identified with 
Cryptococcus proteins obtained from cells during late stage pulmonary infection 
(Table 4.2). Due to the identification of a significantly higher number of 
Cryptococcus proteins from culture than from pulmonary infection, it was 
hypothesized that any proteins unique to the pulmonary infection sample type would 
be of significance during infection. Despite using sample preparation methods 
designed to remove host contaminants from Cryptococcus cells obtained from 
A B C 
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pulmonary infection, far more Rattus norvegicus proteins were identified than 
Cryptococcus proteins. This indicates that sample preparation for Cryptococcus cells 
obtained from pulmonary infection remains a work in progress.  
 
Table 4.2: Mass spectrometric data obtained from cultured Cryptococcus and 
Cryptococcus from pulmonary infection 
Cryptococcus 
Sample Type 
Database searched Matched 
Spectra  
Distinct 
Peptides 
Proteins 
Detected 
In vitro  Filobasidiella/Cryptococcus 
neoformans species complex 
73522 21300 1164 
In vivo  Filobasidiella/Cryptococcus 
neoformans species complex 
11276 6174 114 
In vivo  Rattus norvegicus 45238 10640 470 
 
4.3.3. Host proteins co-purified with Cryptococcus proteins from 
pulmonary infection 
Table 4.3 represents biologically relevant Rattus norvegicus proteins, based on 
biological function, that were co-purified with Cryptococcus proteins obtained from 
cells from pulmonary infection. The proteins listed in this table exhibit an array of 
different biological and molecular functions. This indicates that during infection the 
Cryptococcus capsule does not associate with any particular class of proteins but 
instead appears to bind proteins randomly. 
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Table 4.3: Biologically relevant Rattus norvegicus proteins co-purified with 
Cryptococcus proteins from cells obtained from pulmonary infection 
Accession 
number 
Protein name Function 
P08426 
 
Cationic trypsin-3 Involved in the degradation of dietary trypsin 
inhibitors; the premature activation of 
mesotrypsinogen could contribute to the 
pathogenesis of human pancreatitis [274] 
O08837 
 
Cell division cycle 5-
related protein  
Cell cycle regulator important for G2/M 
transition, acts as a positive regulator of cell 
cycle G2/M progression 
Q3B7D0 
 
Coproporphyrinogen-III 
oxidase, mitochondrial  
Involved in the sixth step of porphyrin 
metabolism in the haem and chlorophyll 
biosynthetic pathways 
P23965 
 
Enoyl-CoA delta 
isomerase 1, 
mitochondrial  
Involved in beta-oxidation of unsaturated fatty 
acids with double bonds at odd-numbered 
carbon positions. 
Q64625 
 
Glutathione peroxidase 
6  
Catalyses the reduction of hydrogen peroxide 
and other peroxides, generated during normal 
metabolism or oxidative stress, to their 
corresponding alcohols using glutathione as a 
substrate  
P84586 
 
Heterogeneous nuclear 
ribonucleoprotein G 
retrogene-like  
RNA-binding protein that plays several role in 
the regulation of pre- and post-transcriptional 
processes.  
Q99PS8 
 
Histidine-rich 
glycoprotein  
 
Involved in innate immunity, ex vivo, HRG-
containing plasma as well as fibrin clots exert 
antifungal effects. In vivo, Hrg−/− mice were 
susceptible to infection by C. albicans, in 
contrast to wild-type mice, which were highly 
resistant to infection [275] 
Q63692 
 
Hsp90 co-chaperone 
Cdc37  
Cdc37is involved in tau (a protein associated 
with microtubules) stability and perhaps 
pathobiology by multiple mechanisms [276] 
P22791 
 
Hydroxymethylglutaryl-
CoA synthase, 
mitochondrial  
An intermediate in both cholesterol synthesis 
and ketogenesis 
D3ZHV2 Microtubule-actin 
cross-linking factor 1  
 
MACF1 null endodermal cells exhibit defects 
in microtubule dynamics. MACF1 is important 
for guiding microtubules on actin filaments. 
Essential for microtubule rearrangement during 
trauma/wound healing. [277] 
F1LP90 
 
Misshapen-like kinase 1  
 
Is known to regulate cytoskeletal organization 
and oncogene-induced cell senescence. 
MINK1 is essential for cytokinesis [278] 
Q9Z2J4 
 
Nexilin  Loss of nexilin function induces Z-disk 
damage and heart failure [279] 
B4F7E8 Niban-like protein 1  May play a role in apoptosis suppression, may 
promote melanoma cell invasion in vitro. 
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P48679 
 
Prelamin-A/C  
 
Implicated in various functions, including 
nuclear stability, transcriptional control, cell 
cycle regulation, nucleo-cytoplasmic interplay, 
cellular signalling, and heterochromatin 
dynamics[280] 
Q63639 
 
Retinal dehydrogenase 
2  
Vitamin A (retinol) is a critical factor in 
protective immunity, retinol synthesis is 
dependent on the three retinal dehydrogenases 
(Raldh1-3) [281] 
Q62868 
 
Rho-associated protein 
kinase 2  
Involved in regulating the shape and movement 
of cells by acting on the cytoskeleton, regulates 
actin filament organisation and contractility 
P04774 
 
Sodium channel protein 
type 1 subunit alpha  
Essential for the generation and propagation of 
action potentials, chiefly in nerve and muscle.  
Q9ERH3 
 
WD repeat-containing 
protein 7  
 
Perform a wide range of cellular functions 
including; signal transduction, RNA 
synthesis/processing, chromatin assembly, 
vesicular trafficking, cytoskeletal assembly, 
cell cycle control and apoptosis [282]. 
 
 
4.3.4. Proteins ‘unique’ to Cryptococcus cells obtained from pulmonary 
infection 
Table 4.4 lists the biologically relevant proteins identified from Cryptococcus cells 
obtained from pulmonary infection that were not identified from cultured 
Cryptococcus. The majority of these proteins were found to have functions relevant to 
fungal pathogenesis. Where possible the likely abundance of these proteins, expressed 
as protein molecules per cell, was estimated by cross-referencing protein homologs to 
the Sacchromyces protein abundance work completed by Ghaemmaghami et al. 
(2003) [212]. 
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Table 4.4: Biologically relevant in vivo Cryptococcus proteins 
Accession 
number 
Protein Name Function Estimated 
number of 
protein 
molecules 
per cell 
(yeast data 
from [212]) 
E6R936 
 
Adenylate cyclase 
(ATP pyrophosphate-
lyase), putative 
 
Capsule biosynthesis in C. 
neoformans, a major virulence factor, 
is dependent upon adenylyl cyclase 
activity [283] 
<50  
 
E6R0R2 
 
Alpha tubulin, putative 
 
Cytoskeleton, a component of C. 
neoformans “virulence bags” [232, 
284] 
5.59E+03 
 
E6QYP5 
 
ATP-binding cassette 
transporter protein 
YOR1, putative 
Functions to regulate Tat2 
endocytosis, loss of the multidrug 
transporter Yor1 from cells induces a 
strong increase in phytosphingosine 
tolerance [285] 
3.61E+03 
 
Q5K7W2 
 
ATP:ADP antiporter, 
putative  
 
Appears to be involved in energy 
parasitism [286] 
No 
identifiable 
homolog 
 
Q5KIC0 
 
Calcium-transporting 
ATPase, putative  
 
Functions to remove Ca2+ ions from 
the cytosol, transporting them to 
internal stores and avoiding calcium 
toxicity [287] 
6.90E+03 
 
E6REF5 
 
Cell wall integrity 
protein scw1, putative  
 
Regulation of fungal septation and 
cell wall structure. Acts in opposition 
to the septation initiation network as 
a negative regulator of cell-
wall/septum deposition [288] 
5.73E+03 
 
Q5KER6 Clathrin-coated vesicle 
protein, putative 
 
Involved in Clathrin-mediated 
endocytosis, the uptake of material 
into the cell from the surface using 
clathrin-coated vesicles 
No 
identifiable 
homolog 
 
E6RC32 
 
Extracellular 
elastinolytic 
metalloproteinase, 
putative  
Possibly involved in fungal invasion 
of lung tissue due to its ability to 
hydrolyze elastin [289] 
No 
identifiable 
homolog 
 
E6R7S2 
 
Formin binding protein 
3, putative 
 
Regulator of actin polymerization 
machineries, presumably critical for 
the production of different 
organizations of actin filaments, e.g. 
at the leading edge of migrating cells 
[290] 
No 
identifiable 
homolog 
 
E6RCU9 
 
Glycolipid 
mannosyltransferase, 
putative 
Involved in O-glycosylation of cell 
wall and secreted proteins, important 
for adherence to host surfaces and for 
virulence [291] 
No 
identifiable 
homolog 
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E6R2Q4 
 
Nonmuscle myosin 
heavy chain b, putative  
Fundamental roles in a number of 
different biological events such as 
cell division, alteration of cell shape 
and protein synthesis and secretion 
[292] 
No 
identifiable 
homolog 
E6RAV5 
 
Phosphatidylinositol 4-
kinase, putative  
Involved in the maintenance of 
vacuole morphology by controlling 
membrane channels or transporters 
required for osmotic control. 
Potential role in the regulation of 
vacuole fusion and/or fission [293] 
No 
identifiable 
homolog 
Q5KB69 
 
Phosphoenolpyruvate 
carboxykinase, putative  
 
An enzyme in the metabolic pathway 
of gluconeogenesis. A key player of 
part of the C. albicans metabolic 
programming that allows fungal 
persistence after phagocytosis by host 
cells and during systemic disease 
[294] 
No detected 
expression 
 
E6R9V4 
 
Polyamine transport-
related protein, putative 
 
Binds polyamines and other related 
molecules (the uptake of 
environmental polyamines is crucial 
for full expression of virulence in 
vivo). Expression is increased in 
response to oxidative and temperature 
stress, choline limitation and during 
murine bacteremia. Systemic 
immunization with recombinant 
protein results in a vigorous antibody 
response in mice that protects against 
invasive pneumococcal infections 
[295] 
No detected 
expression 
 
E6R1W0 
 
Response to drug-
related protein, putative  
 
Function unknown 
 
3.86E+02 
 
E6R9B8 
 
Serine/threonine 
protein kinase, 
putative; (SOK-1) 
(Ste20-like kinase)  
 
Activated by oxidative stress and 
chemical anoxia, regulates cell death 
in stressed cells. Its down-regulation 
by RNA interference enhances cell 
survival. Induces death when 
overexpressed [296] 
No detected 
expression 
 
E6RBT4 
 
STE20 Plays evolutionarily conserved 
functions in cellular volume sensing 
and regulation. Yeast Ste20 initiates a 
shrinkage activated MAPK cascade 
that regulates organic osmolyte 
accumulation. May also function in 
systemic osmotic homeostasis and to 
link cell-cycle events with cell 
volume [297] 
2.59E+02 
 
E6RE09 
 
Thioredoxin 
peroxidase, putative  
 
Defence against oxidative and 
nitrosative stress, survival inside 
macrophages, C. neoformans 
virulence in mice [80] 
 
3.78E+05 
 
E6R9F2 
 
UDP-glucuronic acid 
decarboxylase Uxs1p  
 
Converts UDP-glucuronic acid to 
UDP-xylose, capsule synthesis in C. 
neoformans [284] 
No 
identifiable 
homolog 
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4.4. Discussion 
4.4.1. Experimental design “Catch 22”  
A caveat to the experimental design of this study is that the inoculation of rats with 
0.1 mL of 108 CFU of Cryptococcus cells is exceptionally high and does not represent 
a natural infection. Initial experiments with inoculums of 0.1 mL of 107 CFU, the 
minimal inoculum concentration demonstrated by Krockenberger et al. (2010) to 
produce progressive pneumonia [239], resulted in poor lesion development and 
limited disease progression. Since the goal of this thesis was to obtain sufficient 
fungal burdens, and thus fungal protein yields, for comparative proteomic analyses it 
was decided that a high inoculum would be required. As proteomics lacks an 
equivalent to the PCR amplification technique utilized by genomics and 
transcriptomics there was no alternative to this approach. The data presented in this 
chapter, and the subsequent chapters of this thesis, should be interpreted in the light of 
this caveat.  
 
4.4.2. 1-D SDS-PAGE NanoLC ESI MS/MS can detect Cryptococcus 
proteins expressed during rat pulmonary infection 
Chapter 2 demonstrated that phenol protein extraction purified C. gattii samples to the 
extent that cultured samples can be applied to 2-D PAGE and that samples from 
pulmonary infection can be applied to 1-D SDS-PAGE. The identification of 
Cryptococcus proteins via mass spectrometry post protein fractionation provides 
strong evidence of the effectiveness of the proteomic sample purification techniques 
developed for this analysis. Prior to this study, mass spectrometry protein detection 
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and identification had not been achieved for C. gattii cells from pulmonary infections. 
Here a 1-D SDS-PAGE nanoLC ESI MS/MS qualitative proteomics approach was 
used to determine if intracellular Cryptococcus proteins from cells obtained from 
pulmonary infection could be identified. This protocol was chosen to provide 
evidence of whether sample preparation techniques were efficient, rather than to 
identify the maximal number of proteins. 
1-D SDS-PAGE nanoLC ESI MS/MS resulted in the detection and identification of 
114 non-redundant intracellular in vivo Cryptococcus proteins. This is the first 
successful extraction and identification of intracellular proteins from Cryptococcus 
sourced from mammalian pulmonary infection. In addition, the current study detected 
and identified 1,164 non-redundant intracellular proteins from cultured C. gattii. In 
comparison, Chong et al. (2012), who also used 1-D SDS-PAGE nanoLC ESI 
MS/MS to investigate the global response of cultured C. gattii to fluconazole 
treatment, identified a total of 195 non-redundant intracellular proteins. Using 
MudPIT, a shotgun proteomic technique that uses the combination of strong cation 
exchange with reverse phase chromatography, Crestani et al. (2012) identified 1,080 
non-redundant C. gattii proteins from low iron media culture conditions and 1,135 
from low iron media plus iron culture conditions [273]. The current study, which used 
techniques similar to Crestani et al. (2012), provides one of the most comprehensive 
snapshots of the in vitro C. gattii proteome achieved to date.   
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4.4.3. The persistence of contaminating rat proteins 
Despite incorporating a number of steps aimed at preventing the carry-over of host 
proteins there was persistent contamination of the sample with a significant number of 
Rattus norvegicus proteins. Indeed, the number of identified non-redundant rat 
proteins (470) in this sample was considerably greater than the number of non-
redundant Cryptococcus proteins identified (114). One consideration, given the skew 
towards rat proteins, was that host proteins overloaded the MS and suppressed 
Cryptococcus protein detection. This does not appear to be case, however, because the 
total number of rat proteins identified (584) was well below the totals observed in 
many LC-MS experiments, where thousands of proteins can be identified [298, 299]. 
This is a technical issue inherent to in vivo sample types and indicates the purification 
methods were unable to completely disrupt the association of host proteins with the 
porous polysaccharide capsular matrix. 
 
4.4.4. Contaminating host proteins are non-specific 
The majority of the 470 Rattus norvegicus proteins co-identified with Cryptococcus 
proteins from cells obtained from pulmonary infection were also identified in the 
iTRAQ experimentation on rat lungs described in Chapter 5 of this thesis and only 33 
(7 %) were unique. The suite of Rattus norvegicus proteins identified in the 
Cryptococcus sample were largely representative of the protein groupings exhibited 
by the iTRAQ data and included antioxidants and antifungals as well as proteins 
involved in tissue modification and metabolism. These results indicate that 
Cryptococcus does not selectively associate with host proteins with particular 
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functions during the infective process, but instead randomly binds with an assortment 
of relatively abundant host proteins. The most likely source of host protein 
contamination is serum proteins and leakage from damaged lung cells.  
Jobbins et al. (2010) established that protein and capsular polysaccharides are capable 
of forming strong associations with each other. During infection the cryptococcal 
polysaccharide capsule is surrounded by and saturated with host proteins. It is very 
likely that a significant amount of these host proteins are incorporated into the 
polysaccharide matrix of the capsule. It is also possible that these proteins remain 
associated, and effectively ‘trapped’, in this matrix until liberation during fungal cell 
lysis, leading to the subsequent co-identification of host proteins with fungal proteins 
during mass spectrometry. The resolution of this issue would require the development 
of a cellular de-capsulation technique that is compatible with comparative proteomics. 
Such a technique has yet to be developed for Cryptococcus cells from pulmonary 
infections. Until the mixed proteome issue is satisfactorily addressed global 
quantitative proteomics comparing cultured Cryptococcus with cells obtained from 
pulmonary infection remains problematic. 
While the persistence of a mixed proteome represents a significant technical problem, 
the biological consequence of host protein association with fungal polysaccharide 
capsular material is of interest. The capsule is the external component of the fungal 
surface and is the primary site of interaction between fungus and host. Capsular 
structures have been found to mediate interactions between Cryptococcus and the host 
and are involved in evasion of the host immune system and promotion of 
pathogenesis [16]. The capsule provides Cryptococcus with powerful immune 
avoidance strategies including masking of pathogen-associated molecular patterns, 
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inhibition of fungal opsonisation, structural heterogeneity and inhibition of 
phagocytosis [16, 90]. The co-identification of significant numbers of host proteins 
with Cryptococcus proteins from cells obtained from pulmonary infection could be 
evidence of a further complementary host immune system avoidance strategy in 
antigenic masking. This avoidance strategy has been suggested for various species of 
trypanosomes where host immunoglobulin has been observed to become associated 
with the protozoan cell surface [300]. It has been suggested that these antibodies may 
prevent immune recognition of the parasite by the host, but this has not been 
conclusively demonstrated. It is possible that incorporation of extensive amounts of 
host proteins on the outside and within the matrix of the Cryptococcus polysaccharide 
capsule could act to mask the pathogen from the host immune system. This theory 
requires further extensive investigation to determine its validity for virulent 
Cryptococcus.  
  
4.4.5. The selection of biologically relevant proteins from proteomics 
datasets 
The disparity between the numbers of proteins identified from cultured Cryptococcus 
grown and cells obtained from pulmonary infection restricted comparative 
quantitative proteomics. Instead, the analysis of differences between the Cryptococcus 
proteomes focused on unique proteins, rather than differential protein expression 
level, as the primary selection criterion for identifying biologically relevant fungal 
proteins. Since the detected in vivo proteome represents approximately 10 % of the 
detected in vitro proteome, it was considered likely that any proteins identified 
exclusively in the in vivo sample would be biologically relevant. Qualitative 
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proteomics, although generally used in tandem with quantitative proteomics, can 
provide in-depth sample analysis and has been exploited in the search for biomarkers 
and drug targets [301, 302]. 
 
4.4.6. Protein function as a selection criterion and the danger of using 
automated systems to assign function 
A further selection criterion used to identify proteins of interest was determination of 
their specific function in the context of both fungal proteins in general and fungal 
pulmonary infection/trauma. However, significant limitations were encountered when 
using automated computer algorithms to apply gene ontology terms/protein functions 
to the C. gattii dataset. The use of these systems is a standard method of assigning 
biological functions to large data sets of identified proteins. While these systems are 
rapidly able to provide relevant information regarding the general function of a given 
protein, they lack the disease or infection context needed to provide the most relevant 
information for the function of a specific protein in the particular biological system 
that is being investigated. For example, Gene Ontology assigned seven different 
biological processes or functions for fatty acid-binding protein, epidermal (E-FABP), 
while the DAVID Bioinformatics Database provided over 20 different biological 
processes or functions. There is no straightforward way to filter those functions by 
relevance to infectious disease.  
The idea that one gene encodes for one protein with one function has been superseded 
by the identification of proteins that exhibit multiple functions [303-305]. The 
multifunctional ability of “moonlighting” proteins is not a result of gene fusion, 
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homologous proteins, splice variants or non-specific enzyme activity. Nor are they 
proteins that have the same function in different cell types or sub-cellular location. 
Rather, moonlighting proteins are defined as single polypeptide chains that exhibit 
two or more functions. The identification of moonlighting proteins is crucial in 
assigning correct functions to the thousands of proteins that have been identified by 
the ever-growing number of genome projects being undertaken. Furthermore, the 
identification and improved understanding of this important class of proteins could 
influence the selection of target proteins during drug development, where it may be 
crucial to selectively inhibit one or more of the functions of a multifunctional protein. 
The assignment of protein function is a far from straightforward process given the 
complexity associated with moonlighting proteins and proteins that have very similar 
functions. For this study, proteins were assigned biological and molecular function 
based on information available in the literature concerning the broad field of fungal 
pathogens. While this proved to be a laborious procedure, determining the specific 
role of a given protein in the context of lung ailments is far more accurate than a 
general search for function without restriction to this particular niche. 
 
4.4.7. Protein abundance as an indicator of biological relevance 
In 2003 Ghaemmaghami et al. published a study that investigated global protein 
expression in Saccharomyces cerevisiae during log phase growth [212]. This study 
involved the creation of a Saccharomyces cerevisiae fusion library, where each open 
reading frame was tagged with a high-affinity epitope and expressed from its natural 
chromosomal location. The absolute level of protein expression (as protein molecules 
per cell) was then measured via immunodetection of the common tag. The study 
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found that about 80% of the Saccharomyces cerevisiae proteome was expressed under 
normal growth conditions, with the abundance of proteins ranging from fewer than 50 
to more than 106 molecules per cell.  
In general, global proteomic analysis techniques, even with high sensitivity MS, are 
limited to detecting and quantifying abundant and hydrophilic non-membrane proteins 
with isoelectric points below pH 8. It is unusual to identify proteins present at less 
than 104 copies per cell in an unfractionated LC-MS experiment. It has been predicted 
that low abundance proteins make up 80% of the yeast proteome [203]; thus, the 
majority of the proteome remains undetectable by conventional proteomic 
experimental platforms. It was interesting to find that the majority of the unique in 
vivo Cryptococcus proteins that had Saccharomyces homologs were predicted to be of 
low abundance. For example, adenylate cyclase (ATP pyrophosphate-lyase), a protein 
that functions as a CO2 chemosensor in C. albicans and C. neoformans [283], is 
expressed at less than 50 protein molecules per cell in Saccharomyces. Similarly, the 
putative “response to drug-related protein” and Ste20 were found to be expressed at 
approximately 102 protein molecules per cell in Saccharomyces and are considered to 
be of low abundance. This study also detected proteins, such as phosphoenolpyruvate 
carboxykinase, polyamine transport-related protein and serine/threonine protein 
kinase, whose expression could not be detected by Ghaemmaghami et al. (2003) in 
yeast. Although an obvious caveat of using protein abundance measurements made 
for Saccharomyces to estimate those in Cryptococcus is that the cellular machinery 
and physiochemical nature of these two species are markedly different, the fact that 
they were also not seen in cultured Cryptococcus suggests they have been increased in 
expression in response to the infection process. 
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4.4.8. Codon usage bias as a predictor of protein abundance 
Codon usage bias is based on the probability that only one of several possible codons 
will be used in coding DNA. Until recently the accepted dogma was that proteins 
from genes with codon bias indices (CBI) or codon adaptation indices (CAI) of less 
than 0.2 are usually poorly transcribed and therefore likely to be found in low 
abundance [188]. Despite an established correlation of codon bias and gene 
expression, it has recently been suggest that mRNA structure rather than CAI affects 
protein expression, and thus protein abundance, levels [306, 307]. The codon bias 
figures for the unique Cryptococcus proteins from cells obtained from pulmonary 
infection in this study were calculated to be greater than 0.8 (indicating high 
abundance) and there are no literature to suggest that protein expression would be 
inefficient. It is more likely that they are found in low abundance during in vitro 
growth because they are not required for growth in rich medium and low-stress 
normoxic conditions.  
 
4.4.9. Fungal response to hypoxia and stress during infection 
A number of fungal pathogens are capable of anaerobic fermentation during culture in 
rich media. However, molecular oxygen continues to be thought of as essential for the 
synthesis of ergosterol, NAD and heme, molecules that are likely to be in short supply 
in the host [308]. Thus, Cryptococcus is considered to be an obligate aerobic 
pathogen. The conditions encountered during early stage lung infection will be 
partially hypoxic and less favourable than the usual planktonic culture. After infection 
is established the lung environment becomes inflammatory and severely hypoxic. 
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Inflammatory sites such as those found in infected lung tissue contain many immune 
cells that metabolise available oxygen and obstruct blood vessels, creating an oxygen-
depleted environment.  In theory hypoxia represents a greater challenge to fungi than 
bacteria, and bacterial pathogens have alternative, oxygen independent pathways to 
synthesize NAD and heme and do not synthesise sterol [308]. To infect tissue fungal 
pathogens must be able to adapt to a hypoxic environment. Chun et al. (2007) 
demonstrated that C. neoformans mutants in either the SREBP pathway (cholesterol 
biosynthesis regulatory pathway) or the Tco1 pathway (fungal-specific hybrid 
histidine kinase family member) were less virulent and unable to proliferate in murine 
host tissue [308]. The authors suggest that targeting the components of the hypoxia 
response could yield more effective treatments for infections with Cryptococcus. 
The likely explanation for the induced expression of some in vivo Cryptococcus 
proteins is a coordinated response to the stress and hypoxia during pulmonary 
infection. Adenylate cyclase (ATP pyrophosphate-lyase) represents a perfect example 
of a Cryptococcus protein likely to be increased in expression during infection. The 
Cryptococcus capsule significantly increases in thickness in response to pulmonary 
infection and adenylate cyclase activity is essential for capsular biosynthesis in C. 
neoformans [283]. In addition, phosphoenolpyruvate carboxykinase (a key player in 
C. albicans metabolic programming that allows fungal persistence after phagocytosis 
by host cells and during systemic disease [294]), polyamine transport-related protein 
(the uptake of environmental polyamines is crucial for full expression of virulence in 
vivo [295]) and serine/threonine protein kinase (activated by oxidant stress and 
chemical anoxia, regulates cell death in stressed cells [296]) all represent proteins that 
are likely be up-regulated in response to fungal pulmonary infection.  
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4.4.10. Low abundance Cryptococcus proteins from cells obtained from 
pulmonary infection as potential drug targets 
An investigation of the literature indicated that a number of theoretically low 
abundance  (as predicted by [212]) Cryptococcus proteins from cells obtained from 
pulmonary infection represent potential drug and/or inhibition targets. Included in this 
select group are adenylate cyclase, elastinolytic metalloproteinase, glycolipid 
mannosyltransferase, enolpyruvate carboxykinase and polyamine transport-related 
protein. 
 
4.4.10.1. Adenylate cyclase 
Adenylate cyclase functions in a conserved signal transduction pathway that has been 
demonstrated to be responsible for the regulation of cyclic AMP production, hyphal 
differentiation and virulence in Cryptococcus [309]. Klengel et al. demonstrated a 
conserved link between cyclic AMP signalling and CO2/HCO3- sensing in fungi. It 
was further demonstrated that CO2 sensing plays a essential role in mediating fungal 
pathogenesis including capsule biosynthesis and melanin production, key virulence 
factors that are vital to cryptococcosis pathogenesis [283]. It is well known that 
acapsular cryptococcal cells are avirulent whilst encapsulated isolates have varying 
degrees of virulence [82, 83]. As Cryptococcus adenylate cyclases are only modestly 
related to mammalian adenylate cyclases [310], the development of novel therapeutic 
agents that target the adenylate cyclase-cyclic AMP signalling pathway could be 
useful in limiting Cryptococcus pathogenesis via the inhibition of vital virulence 
factors such as capsular biosynthesis.  
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4.4.10.2. Elastinolytic metalloproteinase 
Elastin, an insoluble hydrophobic molecule, is the major component of elastic fibres 
and functions to maintain structural and functional integrity in the lungs. The 
degradation of elastin, which is highly resistant to proteolysis, is pivotal in the 
development of pulmonary dysfunction. Matrix metalloproteinases (MMP) have the 
ability to degrade elastin. Raulo et al. (2000) determined that MMP elastinolysis 
expression was increased in horses with chronic obstructive pulmonary disease 
(COPD), indicating that excessive elastinolytic activity is involved in the 
pathogenesis of COPD [311]. These authors further determined that MMP 
elastinolytic activity was significantly inhibited by chemically modified tetracycline-3 
(CMT-3) in vitro [311]. The increased expression of Cryptococcus elastinolytic 
metalloproteinase may be associated with the pulmonary tissue destruction observed 
during severe pulmonary infection. Whether or not the inhibitory effects of CMT-3 
can be translated to the treatment of human obstructive lung diseases or could be used 
to inhibit Cryptococcus elastinolytic activity during severe pulmonary infections has 
not been tested. Nonetheless, efficient MMP inhibitors may represent a future class of 
valuable drugs for use in neutralising destructive elastinolytic activity.  
 
4.4.10.3. Glycolipid mannosyltransferase 
Glycolipid mannosyltransferases are involved in the O-glycosylation of cell wall and 
secreted proteins. The cell surface acts as the immediate point of contact between the 
fungus and the host. The outer cell wall layer is enriched in mannoproteins (mannose 
containing glycoproteins). Both the protein and carbohydrate components of 
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mannoproteins have been demonstrated to be involved in fungal adhesion to host 
cells. O-glycosylation has been demonstrated to be necessary for the full development 
of C. albicans virulence and plays vital roles in fungal cellular adhesion and the 
immunomodulation of host reposes [291]. The targeted inhibition of glycolipid 
mannosyltransferase could limit or halt fungal cellular adhesion and host 
immunomodulation, which are key to pathogenesis. Coupled with antifungal 
treatment, glycolipid mannosyltransferase inhibition represents a future antifungal 
therapeutic option that could augment the ability of the host to deal with the fungal 
pathogen and could limit the spread of infection in the lung.  
  
4.4.10.4. Phosphoenolpyruvate carboxykinase 
Phosphoenolpyruvate carboxykinase is a central control point for the regulation of 
gluconeogenesis (the synthesis of glucose of from metabolic precursors). To survive 
and thrive in mammalian host environments fungal pathogens must be able to 
assimilate carbon and other available nutrients [294]. This requires a sufficient level 
of metabolic flexibility. It has been demonstrated that C. albicans has the ability to 
up-regulate the expression of genes involved in amino acid biosynthesis when 
growing in biofilms and to shift from fermentative to non-fermentative metabolism 
following exposure to human neutrophils and/or macrophages [312-315]. Mammalian 
infection has been shown to generate a high degree of metabolic heterogeneity within 
fungal cell populations in vivo. During the early stages of infection, when access to 
glucose is limited and as a response to phagocytosis, C. albicans activates 
gluconeogenesis. During the later stages of infection and tissue colonisation, 
glycolytic colonisation predominates [294]. The evidence suggests that fungal 
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pathogens regulate central carbon metabolism in a niche-specific manner. The 
targeted inhibition of gluconeogenesis, during early stage infection, via the inhibition 
of phosphoenolpyruvate carboxykinase activity, could therefore represent a 
therapeutic option if infection can be detected early. Unfortunately, the diagnosis of 
cryptococcosis is often delayed, particularly for C. gattii, which causes sporadic 
disease, although close monitoring of immunosuppressed patients may enable early 
detection of C. neoformans. The inhibition of fungal metabolism as a therapeutic 
antifungal option still demands future investigation. 
 
4.4.10.5. Polyamine transport-related protein 
Polyamines are small organic compounds with a hydrocarbon backbone and multiple 
positively charged amino groups spaced at regular intervals. Polyamine acquisition 
and biosynthesis are vital for the development of full virulence in both prokaryotic 
and eukaryotic human pathogens [316, 317]. Polyamine transport protein D (PotD) is 
a membrane-associated periplasmic substrate binding protein that binds polyamines 
and facilities their uptake via transmembrane proteins. Two studies by Shah et al. 
(2006 and 2009) indicated the important role of PotD in pneumococcal pathogenesis 
and immunity. Similar to Cryptococcus, Streptococcus pneumonia is an encapsulated 
human pathogen with pathogenesis initiated following colonisation of the upper 
respiratory tract [318]. These studies demonstrated that both the systemic and mucosal 
immunisation of mice with recombinant PotD resulted in a vigorous and specific 
antibody response that was protective against invasive pneumococcal infection [295, 
319]. Mucosal immunisation resulted in significantly reduced nasopharyngeal 
carriage and prevented invasive disease following challenge with virulent 
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Streptococcus pneumonia serotypes [295]. This ability to inhibit prokaryotic disease, 
coupled with the known importance of PotD and polyamines in eukaryotic human 
pathogens, indicates the potential of this protein as a component of an effective next-
generation fungal vaccine. 
 
4.4.11. From biologically relevant protein to drug target 
While these qualitatively identified proteins appear interesting with regard to protein 
abundance and function, their potential as drug targets relies on whether or not a 
protein homolog exists in the host organism. Protein sequence and structure homology 
is widely utilised in the scientific literature as evidence of shared protein function 
between species. The lack of a homologous protein in the host strongly indicates that 
the specific function of the fungal protein of interest could be modulated without 
affecting the host. There are a myriad of automated homology detection tools in 
existence, however the difficulties associated with homology-based function 
prediction have been well described in the literature [320]. Automated strategies for 
the assignment of protein function depend on function transfer via protein sequence, 
structure and interaction based inference methods.  
Accurate function prediction requires the coupling of genomic, transcriptomic and 
proteomic sequence and expression information with prediction algorithms. The 
primary issue with function prediction techniques is whether inferences made by 
similarity comparisons actually provide a true representation of functional relatedness 
[321]. Thus, function prediction via homology based inference remains a significant 
challenge. The work completed in this study was limited by the poorly annotated 
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nature of the Cryptococcus sequence databases. Very few Cryptococcus proteins have 
been extensively modelled or indeed researched at all beyond simple amino acid 
sequence information and the provision of a protein name. Indeed, the vast majority 
of Cryptococcus proteins listed on UniProt are ‘Predicted’. UniProt provides five 
levels of evidence of protein existence. These are, in descending strength, are 
‘evidence at protein level’, ‘evidence at transcript level’, ‘inferred from homology’, 
‘predicted’ and ‘uncertain’. ‘Predicted’ proteins represent detected proteins for which 
there is no evidence for protein existence at the protein, transcript, or homology levels 
(http://www.uniprot.org/manual/protein_existence). The lack of comprehensive 
protein structural modelling and protein interactions for Cryptococcus protein 
databases severely limits the comprehensiveness of any conducted homology based 
function prediction.  
The most stringent method of defining protein function, and thus, the potential of an 
identified protein as a drug target, is via in vitro and in vivo experimentation. These 
experiments are performed to confirm the exact function of an identified cryptococcal 
protein. In addition, in vitro and in vivo experimentation can deduce the physiological 
effects of Cryptococcus protein function modulation (ranging from function deletion 
to recombinant protein supplementation) on both the animal model utilised and on 
fungal pathogenesis. In vitro experimentation involving the fungal pathogen is useful 
for determining how modulating protein function affects the fungal organism, with the 
key question being: does protein modulation inhibit key features of pathogenesis? In 
vitro experimentation can then be followed by in vivo experiments in an animal 
model. These experiments can determine whether deletion of the mammalian 
homolog of the fungal protein, or introduction of recombinant fungal protein, affects 
the host cellular machinery. Subsequently, in vivo experiments involving both the host 
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and the infective agent can determine whether the modulation of fungal protein 
function successfully attenuates fungal pathogenesis and thus enables the host 
immune system to successfully deal with the pathogenic threat. While these 
experimental processes are time consuming and demanding on resources expenditure, 
the results obtained would provide comprehensive insight into the function of an 
identified protein and its potential as an anti-fungal drug target. 
 
4.5. Conclusions 
Unfortunately validation studies fell outside of the scope this study, largely because of 
the technical difficulties associated with C. gattii that delayed progress and hampered 
further studies, and also because the Cryptococcus databases crucial to proteomic 
analyses area as yet poorly annotated. Despite the impediments to experimentation, 
the identification of significant numbers of non-redundant Cryptococcus proteins 
from cultured cells and cells from pulmonary infection provided interesting 
qualitative datasets that offered insights into fungal pathogenesis at the protein level 
and highlighted a number of potentially exciting Cryptococcus proteins that could be 
exploited as drug targets. However, the proof of concept for global ‘–omics’ analysis 
of this technically challenging sample type provided by this study should lead to 
further analysis, and potentially quantitative analysis, of fungal pathogens under in 
vivo conditions, along with continued development of novel therapeutic and 
diagnostic options for pathogenic fungi. 
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Chapter Five 
Elucidating the rat host protein response to 
pulmonary infection with Cryptococcus 
Despite the recognition of the lung as a primary site of Cryptococcus infection, very 
little is understood about the global molecular mechanisms of the pulmonary host 
response to fungal inhalation and pathogenesis. This study provides the first attempt 
at global quantitative proteomic investigation of the host response to pulmonary 
cryptococcosis. The elucidation of the global host protein response to pulmonary 
infection with Cryptococcus was technically challenging due to the physiochemical 
nature of Cryptococcus exopolysaccharide. Advances in sample preparation 
described in chapter 3 permitted the use of isobaric tag for relative and absolute 
quantification (iTRAQ) analysis to quantitatively compare the proteomes of rat lungs 
infected with virulent strains of Cryptococcus, using naïve control lungs as a baseline. 
The quantitative data obtained shows how the host adapts to fungal insult and 
highlights potential diagnostic and therapeutic targets. 
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5.1. Introduction 
The lung is the essential respiration organ of mammals [322]. The primary function of 
the lung is to transport oxygen from the atmosphere into the bloodstream and to 
release carbon dioxide from the bloodstream into the atmosphere (figure 5.1). The 
lung serves other vital functions, including but not limited to, protecting the host 
against air-borne infection via mucociliary escalator actions [323] and maintaining 
sterility by producing mucus containing antimicrobial agents [324]. Breathing is 
driven by muscular action with gas exchange taking place in the alveoli, the terminal 
end of the respiratory tree (figure 5.1). The approximately 300 to 500 million alveoli 
in the human lung provides the large surface area (roughly 70 m2) required for 
efficient gas exchange [325].  
 
Figure 5.1: Schematic of the mammalian respiratory structures. 
A) The location of the respiratory structures in the body. B) An enlarged view of the airways, alveoli 
and capillaries. C) Gas exchange between the capillaries and alveoli (from [326]).  
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The lung is susceptible to microbial pathogens that are transmitted through the air via 
aerosols of dust or liquids. The bodily secretions of an infected individual represent a 
likely source of pathogen-containing aerosols. While the zoonotic transmission of 
Cryptococcus has been documented [19, 20] it is very rare and human-to-human 
transmission remains undocumented. Cryptococcus infectious propagules are most 
likely to be desiccated yeast cells or basidiospores transmitted via environmentally 
generated aerosols. For example, infection with C. neoformans is commonly 
associated with the disturbance of soil contaminated with bird droppings, especially 
pigeon droppings, and C. gattii infection, especially the Vancouver Island outbreak, is 
associated with forestry [327-329]. Effective host defence against airborne pathogens 
depends on the rapid mechanical clearance of inhaled infective agents via the action 
of airway turbulence and the mucociliary escalator [330, 331]. Cryptococcus displays 
the ability to circumvent these upper airway defences and become deposited in the 
respiratory spaces of the lung. The success or failure of host defence against deposited 
Cryptococcus is critically regulated by cell-mediated immunity and especially T 
lymphocytes [35, 86, 141-144]. The predominant synthesis of Th1 and Th17 
cytokines over Th2 cytokines protects mice from cryptococcal infection [147-149]. 
Virulent Cryptococcus strains are then able to circumvent the non-specific innate 
immune system defences, leading to fungal proliferation and metastasisation [332]. 
While previous studies have determined the type of innate immune response effective 
for the elimination of Cryptococcus from the host, the elucidation of the global 
molecular responses to Cryptococcus infection remains enigmatic. Hirsch et al. 
(2004) acknowledged the potential of proteomics to acquire an understanding of the 
complex responses of lung exposure to stimuli [333]. This review of proteomic 
methods of pulmonary research also acknowledged that the pulmonary sample type, 
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due to its inherent complexity, represented a challenging target to proteomics. Zhao et 
al. (2012) demonstrated that meaningful comparative proteomic data could be 
obtained from in vivo pulmonary infection models [334]. This study investigated the 
host response to viral infection using 2-D DIGE to compare the proteomes of 
uninfected and infected murine lung tissue. Similarly, Ohlmeier et al. (2010) 
demonstrated that differential display 2-D PAGE coupled with Western blot analysis 
could be utilised to identify potential human protein biomarkers involved in the 
pathogenesis of chronic obstructive pulmonary disease [335]. With regard to the 
analysis of fungal pathogens, Fekkar et al. (2012) investigated the ability of 
proteomics to discover novel diagnostic biomarkers for invasive aspergillosis using 2-
D DIGE to analyse murine bronchoalveolar lavage and sera. This study was able to 
provide evidence for an in vivo complement evasion mechanism during invasive 
aspergillosis and provided insight the inflammatory host response to invasive 
aspergillosis in both the lung and sera, providing new insight into the pathophysiology 
of the disease [336]. Combined, these studies provide evidence for the ability of 
global comparative proteomics to interpret the host responses to infection and to 
highlight potential biomarkers. In the case of pulmonary fungal infection, analysis to 
date has been limited to bronchoalveolar lavage and sera.  It is likely that the absence 
of literature concerning the comparative proteomic investigation of host pulmonary 
tissue during fungal infection is a result of the technical challenges associated with 
this sample type (discussed in chapter 3). 
The work undertaken in this study attempted to utilise global comparative proteomic 
approaches to analyse differential gene expression at the whole organism level. 
Specifically, this study attempted to compare the host responses of animals infected 
with high virulence C. gattii strain R265 and low virulence C. gattii strain R272 and 
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the responses of animals infected with the two different virulent species of 
Cryptococcus (C. neoformans vs. C. gattii). This is the first global quantitative 
proteomic investigation of how the rat reacts to pulmonary infection with 
Cryptococcus. The underlying hypotheses of the study were that: 
• Fungal growth in the pulmonary environment would induce specific protein 
changes in the lung proteome  
• iTRAQ comparative proteomic analyses would identify these specific proteins 
highlighting:   
o The lung proteins that respond to infection with Cryptococcus of 
different species and different virulence levels. 
o The proteins that could form future drug targets, biomarkers and 
diagnostic markers. 
 
5.2. Methods 
5.2.1. Cryptococcus strains and number of rats infected 
Table 5.1: Cryptococcus strains and number of rats infected 
Cryptococcus strain Number if rats infected 
Early stage 
infection 
Late stage 
infection 
KN99α (C. neoformans molecular type VNI) 10 N/A 
R265 (C. gattii molecular type VGIIa, high 
virulence) 
10 10 
R272 (C. gattii molecular type VGIIb, low 
virulence) 
10 10 
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5.2.2. Pulmonary infection model 
The pulmonary infection model used was described in section 2.3.2. 
 
5.2.3. Pulmonary tissue homogenisation 
Pulmonary tissue homogenisation was completed using the method described in 
section 2.3.3. 
 
5.2.4. Pulmonary sample preparation for iTRAQ analysis 
Supernatants retained from 2.3.3. were divided among a suitable number of 50 mL 
Falcon tunes and the proteins precipitated by incubation with a 5 x volume of 100 % 
acetone for 30 minutes at room temperature. Following centrifugation at 3,000 g for 
10 minutes, the acetone was discarded and the protein pellet solubilised in a suitable 
volume of 1 % SDS (v/v), 100 mM TEAB. The sample was then transferred to 100 
kDa MWCO filters (250 µL per filter, Pall Scientific, USA) and centrifuged at 10,000 
g until all of the solution had passed through the filter (approximately 8 hours). The 
sample was then buffer exchanged into 0.1 % SDS (v/v), 250 mM TEAB using Micro 
Bio-Spin 6 chromatography columns (Bio-Rad, USA) to remove residual LiCl prior to 
iTRAQ analysis.  
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5.2.5. 4-plex iTRAQ sample design 
Tables 5.2, 5.3 and 5.4 describe the specific iTRAQ labels used to label uninfected 
control and infected lung protein samples for KN99α, R265 and R272 respectively. 
Experiments with KN99α used the 4 labels available for 4-plex iTRAQ, while 
experiments with R265 and R272 used 3 of the 4 the labels in each run. 
 
Table 5.2: 4-plex iTRAQ sample design for pulmonary infection with KN99α  
4-plex run #1 (two biological replicates in the same run) 
Sample   Lung weight iTRAQ label  
Uninfected control #1  0.85 g 114 
Uninfected control #2  0.90 g 115 
Early stage infection #1 7.03 g 116 
Early stage infection #2 7.33 g 117 
 
Table 5.3: 4-plex iTRAQ sample design for pulmonary infection with R265 
4-plex run #1 (1st biological replicate) 4-plex run #2 (2nd biological replicate) 
Sample Lung 
weight 
iTRAQ 
label  
Sample  Lung 
weight 
iTRAQ 
label  
Uninfected 
control 
0.85 g 115 Uninfected 
control 
0.90 g 115 
Early stage 
infection  
3.80 g 116 Early stage 
infection  
6.19 g 116 
Late stage 
infection  
3.60 g 117 Late stage 
infection  
5.97 g 117 
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Table 5.4: 4-plex iTRAQ sample design for pulmonary infection with R272 
4-plex run #1 (1st biological replicate) 4-plex run #2 (2nd biological replicate) 
Sample Lung 
weight 
iTRAQ 
label  
Sample Lung 
weight 
iTRAQ 
label  
Uninfected 
control 
0.85 g 115 Uninfected 
control 
0.90 g 115 
Early stage 
infection  
2.10 g 116 Early stage 
infection  
1.81 g 116 
Late stage 
infection  
0.94 g 117 Late stage 
infection  
0.81 g 117 
 
5.2.6. iTRAQ labelling (completed by the Australian Proteome Analysis 
Facility at Macquarie University)  
iTRAQ was used to quantitatively profile the lung proteome during infection. 100 µL 
aliquots of protein samples were delivered to the Australian Proteome Analysis 
Facility as a liquid in 0.1 % SDS at a concentration of approximately 1 µg/µL 
(determined by the comparison of protein standards run on 1-D SDS-PAGE). The 
samples were reduced with 5 mM TCEP for 1 hour at 60 °C and alkylated with 10 
mM MMTS at room temperature for 10 minutes. The protein sample was digested 
overnight with trypsin at 37 °C at a trypsin to protein ratio of 1:20. Digested samples 
were labelled with the iTRAQ reagents following the protocol provided by the vendor 
(Applied Biosystems, Foster City, CA). Briefly, one vial of iTRAQ labelling reagent 
was used for every 100 µg of protein. Ethanol was used to solubilise the iTRAQ 
reagent then added to the peptide sample ensuring a final organic concentration of at 
least 60 % (v/v). After 1 hour of iTRAQ labelling, the reaction was quenched by 
adding 50 µL of water. The samples were then mixed at equal ratios and dried by 
centrifugal evaporation.  
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5.2.7. Mass spectrometry (completed by the Australian Proteome Analysis 
Facility at Macquarie University)  
Mass spectrometry was completed using the methods described in section 2.3.9. 
 
5.3. Results 
5.3.1. Rat lung weights pre and post infection 
Table 5.5 lists the mean weights of lungs from control and infected rats according to 
the specific Cryptococcus strain used for infection and the infection time point.  
 
Table 5.5: Rat lung weights 
Cryptococcus strain Infection 
time point  
Mean control 
lung weight 
(±SD) 
Mean infected 
lung weight 
(±SD) 
KN99α  (C. neoformans 
molecular type VNI) 
14 days 0.88 g (0.035) 7.18 g (0.212) 
42 days N/A N/A  
R265 (C. gattii molecular 
type VGIIa) 
14 days 0.88 g (0.035) 5.00 g (1.700) 
42 days 0.88 g (0.035) 4.79 g (1.676) 
R272 (C. gattii molecular 
type VGIIb) 
14 days 0.88 g (0.035) 1.96 g  (0.205) 
42 days 0.88 g (0.035) 0.86 g  (0.092) 
 
5.3.2. Inoculation resulted in strain specific lesion formation in rat lungs 
The progression of infection and lesion formation was assessed by the general 
appearance and health of the rats prior to euthanasia and by the macroscopic scale 
inspection of their lungs post euthanasia. The extent of lesion development observed 
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at the early and late stage infection time points was found to be highly dependent on 
the Cryptococcus strain used for pulmonary infection.   
 
5.3.2.1. Rats infected with KN99α  (C. neoformans molecular type 
VNI) 
Early stage infection: At the 14 day time-point rats displayed symptoms typical of 
cryptococcosis. The rats were hunched, lethargic with ruffled fur and squinted eyes 
and were visibly struggling to breathe. Infected lungs were greatly increased in size 
compared to control lungs due to the development of large, multifocal gelatinous 
lesions. Infected lungs demonstrated extensive consolidation of lung fields, with little 
normal lung material remaining. Based on these observations, and the requirements 
for ethical animal treatment, experiments involving late stage infection with KN99α 
were abandoned. All rats infected with KN99α were humanely euthanized at day 14 
(early stage infection) as per the Animal Ethic Committee protocol to prevent 
suffering. 
 
5.3.2.2. Rats infected with R265 (C. gattii molecular type VGIIa) 
Early stage infection: At the 14 day time-point rats appeared less lethargic than those 
infected with KN99α. Their fur was ruffled and breathing strained, but less so than in 
infections with KN99α. The dissected lungs were considerably larger than control 
lungs, although less so than in infection with KN99α. Compared to KN99α, lesion 
development was slightly reduced and there was a greater amount of apparently 
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normal lung material. Based on these observations, experiments designed for late 
stage infection with R265 were permitted to proceed to the 42-day time point. 
Late stage infection: At the 42 day time point rats appeared hunched, lethargic with 
ruffled fur and squinted eyes and were visibly struggling to breathe, but less so than in 
the 14 day infections with KN99α. The dissected lungs were considerably larger than 
the control lungs, although less so than in infection with KN99α. Lesion development 
and amounts of normal tissue was similar to those observed at the 14 day time-point, 
however, the lungs were lighter at 42 days than at 14 days.  
 
5.3.2.3. Rats infected with R272 (C. gattii molecular type VGIIb) 
Early stage infection: At the 14 day time point rats appeared in normal health. Rats 
were active with apparently normal breathing patterns. The lungs were slightly larger 
than control lungs, though considerably smaller than 14 day R265 and KN99α. 
Lesion development was sparse with the majority of the lung tissue appearing normal.  
Late stage infection: At the 42-day time-point rats appeared in normal health. Rats 
were active with apparently normal breathing patterns. The lungs were not statistically 
different in weight compared to the uninfected controls; however, they were 
significantly smaller than 14-day infections with R272. The lungs were considerably 
smaller than lungs infected with KN99α and 14 and 42 day R265. Lesion 
development was not observed and the lung tissue appeared normal.  
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5.3.3. Global comparative quantitative analysis of control and infected 
lungs 
The soluble proteomes of control and infected rat lungs were compared utilizing 
iTRAQ. Table 5.6 details the mass spectrometric results obtained with respect to the 
Cryptococcus strain used for pulmonary infection. 
 
Table 5.6: iTRAQ mass spectrometry results 
Pulmonary 
infection strain 
KN99α  R265 R272 
4-plex run 1 1 2 1 2 
Mass 
spectrometer 
Triple TOF 
5600 (AB 
Sciex) 
Qstar XL 
(AB Sciex) 
Triple 
TOF 5600 
(AB Sciex) 
Triple 
TOF 5600 
(AB Sciex) 
Triple 
TOF 5600 
(AB Sciex) 
Spectra 
identified 
238103 38581 197661 144955 173678 
Distinct 
peptides 
26927 9560 26213 18037 16486 
Proteins 
detected 
1152 876 1344 1017 897 
 
5.3.4. Differentially expressed proteins common to infected lungs 
Table 5.7 lists the differentially expressed proteins that were detected across all 
pulmonary infections with KN99α, R265 and R272. Accept for Alpha-1B-
glycoprotein, the proteins were consistently increased or decreased in expression 
across all pulmonary infection datasets. A number of these proteins were found to 
have functions involved in the host immune response to infection.  
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Table 5.7: Differentially expressed proteins common to the pulmonary infection 
datasets 
Accession 
number: 
Protein name: Expression  
Q9EPH1 Alpha-1B-glycoprotein Ambiguous 
P10760 Adenosylhomocysteinase Decreased 
Q63495 Advanced glycosylation end product-specific 
receptor 
Decreased 
P47853 Biglycan Decreased 
B0BNN3 Carbonic anhydrase 1 Decreased 
P27139 Carbonic anhydrase 2 Decreased 
P16303 Carboxylesterase 3 Decreased 
Q9EPT8 Chloride intracellular channel protein 5 Decreased 
P31430 Dipeptidase 1 Decreased 
P23764 Glutathione peroxidase 3 Decreased 
P08010 Glutathione S-transferase Mu 2 Decreased 
Q63279 Keratin, type I cytoskeletal 19 Decreased 
P48679 Lamin-A Decreased 
O35763 Moesin Decreased 
Q63425 Periaxin Decreased 
P35704 Peroxiredoxin-2 Decreased 
P85125 Polymerase I and transcript release factor Decreased 
Q9Z1J8 SEC14-like protein 3 Decreased 
Q8VIF7 Selenium-binding protein 1 Decreased 
P06761 78 kDa glucose-regulated protein Increased  
Q6RY07 Acidic mammalian chitinase Increased 
P24268 Cathepsin D Increased 
P55053 Fatty acid-binding protein, epidermal Increased 
P04642 L-lactate dehydrogenase A chain Increased 
Q6AYC4 Macrophage-capping protein Increased 
P35248 Pulmonary surfactant-associated protein D Increased 
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5.3.5. Biologically relevant differentially expressed proteins 
Table 5.8 and 5.9 list lung proteins selected from the list of differentially expressed 
proteins common to the KN99α, R265 and R272 datasets (table 5.7) according to the 
selection criteria for proteins of interest outlined in this study (section 4.4.6.). The 
proteins listed in table 5.8 increased in expression with infection while those in Table 
5.9 decreased.   
 
Table 5.8: Biologically relevant proteins with increased expression  
Accession 
number: 
Protein name: Protein function: 
P06761 78 kDa glucose-regulated 
protein 
Maintenance of cellular homeostasis 
and protection from cell lysis. 
Q6RY07 Acidic mammalian chitinase Degrades chitin, promoter of 
allergic inflammation. 
P24268 Cathepsin D Blocks alveolar epithelial cell 
apoptosis. 
P55053 Fatty acid-binding protein, 
epidermal 
Involved in the synthesis of 
functional surfactant. 
Q6AYC4 Macrophage-capping 
protein 
Involved in macrophage motility 
and phagocytosis. 
P35248 Pulmonary surfactant-
associated protein D 
Pattern recognition molecule 
involved in opsonisation for 
enhanced phagocytosis. 
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Table 5.9: Biologically relevant proteins with decreased expression 
Accession 
number: 
Protein name: Protein function: 
Q63495 Advanced glycosylation end 
product-specific receptor 
Maintains the correct morphology 
of alveolar type I cells. 
P47853 Biglycan Anti-fibrotic. 
B0BNN3 Carbonic anhydrase 1 Carbon dioxide transport out of the 
lungs. 
P27139 Carbonic anhydrase 2 Carbon dioxide transport out of the 
lungs. 
P23764 Glutathione peroxidase 3 Antioxidant. 
O35763 Moesin Innate immune response, TLR4-
mediated pattern recognition, 
promotes expression of pro-
inflammatory cytokines. 
Q63425 Periaxin Maintenance of peripheral nerve 
myelin. 
P35704 Peroxiredoxin-2 Antioxidant. 
Q9Z1J8 SEC14-like protein 3 Indicator of airway inflammation 
progression. 
 
5.3.6. Proteins that are marginally outside the selection criteria 
The proteins listed in Table 5.10 were significantly different in expression in five out 
of six biological replicates. These proteins represent a data subset marginally lower 
than the filtered ‘common proteins’ in the hierarchy of stringency (section 5.4.2.), 
indicating that this subset represents regulated proteins with a high likelihood of being 
biologically relevant in the context of pulmonary ailment. 
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Table 5.10: Differentially expressed proteins marginally outside the selection 
criteria 
Legend: 
⇑  Significantly up-regulated in both biological replicates 
↑  Significantly up-regulated in one of two biological replicates 
⇓  Significantly down-regulated in both biological replicates 
↓  Significantly down-regulated in one of two biological replicates 
Accession 
number: 
Protein name: Regulation 
state: 
Function: 
P00697 
 
Lysozyme C-1  ⇑ R272, 
KN99α  
↑R265 
Antibacterial protein, glycoside hydrolase 
that damages the bacterial cell wall [337], 
associated with Plasmodium parasite 
persistence during mosquito infection 
[338].  
P50116 
 
Protein S100-A9  ⇑ KN99α, 
R265  
↑R272 
Major antifungal agent of neutrophil 
extracellular traps [339]; chelates divalent 
cations essential for fungal growth [340], 
promotes the inflammatory response [341], 
inhibits the function of wound repairing 
fibroblasts [342]. 
P08699 
 
Galectin-3 ⇑ KN99α, 
R265 
↑R272 
Capable of binding a wide range of 
oligosaccharide structures (including C. 
albicans and cryptococcal 1,2-linked 
sugars, promotes fungal cell death by both 
indirect and direct fungicidal mechanisms 
[343-346].  
Q9EQP5 
 
Prolargin  ⇓R265, R272  
↓ KN99α 
Possess antimicrobial peptides that bind to 
negatively charged bacterial membranes 
promoting membrane destabilisation and 
consequent bacterial killing without 
effecting host cells [347, 348].  
O35244 
 
Peroxiredoxin-6  ⇓ KN99α, 
R265  
↓R272 
Antioxidant enzyme highly expressed in 
the lungs and a major player in the defence 
of lungs under oxidative stress in the lung 
[349, 350], catalyses the reduction of H2O2, 
E-FABP hyperoxides and phospholipid 
hyperoxides in cell membranes, protecting 
cells against apoptotic death [351].  
P04764 
 
Alpha-enolase  ⇓R265, 
KN99α 
↓R272 
It has been suggested that the expression of 
alpha enolase on the surface of mammalian 
cells, and also pathogenic organisms, could 
function to concentrate plasminogen on the 
surface of cells, enhancing the cells ability 
to digest fibrous tissue and/or invade 
through stroma [352]. 
Q66H98 
 
Serum 
deprivation-
response protein 
⇓ R265, 
KN99α  
↓r272 
Involved in caveolae formation and 
stabilisation [353, 354]. The loss of 
caveolae results in severe 
pathomorphological defects in large 
sections of lung alveolar septa, the tissue 
location where gas exchange takes place.  
P85972 Vinculin ⇓ Maintains the mechanical integrity of the 
cytoskeleton and cell shape control, cells 
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 KN99α,R272  
↓R265 
lacking vinculin are unable to produce 
stable lamellipodia the motor that pulls the 
cell forward during migration and acts as a 
steering device during chemotaxis [355-
358].  
P23785 
 
Granulins  ⇑R272, R265  
↑ KN99α 
In wound fluids granulins acts as an anti-
inflammatory via the inhibition of TNF-α 
activation of inflammatory cells [359].  
 
5.3.7. Ambiguous interesting proteins 
Table 5.11 lists the proteins that are more ambiguous in their statistical significance 
and corresponding regulation state. One or more of the biological replicates for these 
proteins were found to have expression that was not statistically significant (p-value 
>0.05), did not meet the >1.2 or <0.8 level of differential expression (as compared to 
the control lung baseline) or were not detected by the mass spectrometer. Despite the 
ambiguous nature of the data, the biological functions that these particular proteins 
represent are interesting and therefore worth mentioning. 
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Table 5.11: Proteins with ambiguous expression states among biological 
replicates 
Legend: 
⇑  Significantly up-regulated in both biological replicates 
↑  Significantly up-regulated in one of two biological replicates 
⇓  Significantly down-regulated in both biological replicates 
↓  Significantly down-regulated in one of two biological replicates 
↔  Not differentially expressed 
×  Not detected by the mass spectrometer 
Accession 
number: 
Protein 
name: 
Regulation 
state: 
Function: 
P55009 
 
Allograft 
inflammatory 
factor 1  
⇑ KN99α 
↑R272 
×R265 
Plays a crucial role in the survival, 
migration and proinflammatory activity of 
macrophages [360].  
P07151 
 
Beta-2-
microglobulin  
⇑ KN99α 
↑R265, R272  
Essential for the cell surface expression of 
MHC class I, the stability of the peptide-
binding groove, antigen presentation and 
subsequent cytotoxic T cell activation 
[361], factor in the genesis of pulmonary 
fibrosis [362-364].  
P04762 
 
Catalase  ⇓ KN99α, 
R272  
↔R265 
Catalyses the decomposition of hydrogen 
peroxide to water and oxygen, functions to 
prevent damage to cells and tissues as a 
result of exposure to hydrogen peroxide.  
O88767 
 
Protein DJ-1  ⇓R265  
↓ KN99α 
↑R272) 
A stabilizer of Nuclear factor elytroid 2-
related factor (NRF2). NRF2 plays a 
protective role during lung diseases that 
involve oxidative stress and inflammation 
via the regulation of the antioxidant 
defence system [365, 366].  
P07632 
 
Superoxide 
dismutase 
[Cu-Zn]  
⇓R265  
↓ KN99α 
↑ R272 
Catalyses the dismutation of superoxides 
into oxygen and hydrogen peroxide, is 
strongly correlated with an increased 
production and release of hydrogen 
peroxide from alveolar macrophages 
represents a novel mechanism for the 
pathogenesis of pulmonary fibrosis [367].  
P41350 
 
Caveolin-1  ⇓R265 
↑R272 
↑↓ KN99α 
Involved in caveolae formation and 
stabilisation [353, 354]. The loss of 
caveolae results in severe 
pathomorphological defects in large 
sections of lung alveolar septa, the tissue 
location where gas exchange takes place.  
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5.4. Discussion 
5.4.1. An observable strain hierarchy in response to infection 
Observations of general rat health and the progression of lesion development at the 
early infection time-point revealed a hierarchy of infection severity. KN99α was 
found to be the most lethal Cryptococcus strain to Fisher-344 rats, followed by R265 
with R272 being the least lethal. The severity of pulmonary infection with KN99α 
was so extreme that these infections were not permitted to proceed to the 42-day ‘late 
stage infection’ time point. Repeat infections were not possible within the timeframe 
of this study, however, considerably lower cell numbers would be recommended in 
any future KN99α inoculations. The lethality hierarchy remains consistent at the late 
stage infection time-point. While KN99α infection would presumably result in rat 
death, pulmonary infections with R265 were able to persist through to late stage 
infection. For rats infected with R272 general health remained stable, with no 
apparent lesion formation and lung weights similar to control weights. This indicates 
the possible resolution of infection. These macroscopic examinations are interesting 
and appear to display a strain-based hierarchy of infection. It was hypothesised that 
these strain-based differences in the degree of infection reflected the level of host 
immune responses and were associated with different immunological and 
physiological processes. The investigation of this hypothesis required the analysis of 
the molecular processes involved in the host response to pulmonary infection with 
Cryptococcus. 
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5.4.2. The selection of biologically proteins from datasets generated by 
iTRAQ 
Only proteins found significantly altered in expression in both biological replicates 
(represented by individual 4-plex iTRAQ runs (5.2.5.)) of rats infected with KN99α, 
R265 or R272 were included as biologically relevant quantitatively different proteins. 
For this study statistical significance was judged according to the p-value calculated 
by the ProteinPilot software (AB SCIEX, USA). P-values were used as an initial 
indicator of whether a protein had any significance in the context of the iTRAQ 
investigation of pulmonary infection. The next level of selection criteria used to refine 
the list of biologically relevant quantitatively different proteins was whether or not 
they changed in expression >1.2 or <0.8 fold of their level compared to the uninfected 
control. These are the standard fold change cut-offs used by the Australian Proteome 
Analysis Facility, where the iTRAQ labelling, mass spectrometry and data acquisition 
and processing for this study were undertaken. Whilst this study uses the term ‘up or 
down regulation’ to describe proteins detected in increased or decreased abundance, 
there are a number of possible reasons for changes in protein abundance. A change in 
gene expression is one possibility, but protein abundance in a particular cell extract 
may also be altered by post-translational modification, degradation or intra-cellular 
localization.  
The application of these two selection criteria revealed a correspondence between the 
previously described hierarchy of Cryptococcus strain lethality (5.4.1.) and a 
hierarchy associated with the total number of quantitatively different proteins. Rats 
infected with KN99α, which generated most severe pulmonary infections, generated a 
list of 170 quantitatively different proteins using the uninfected control lung as a 
baseline. The less severe infections associated with R265 resulted in 121 
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quantitatively different proteins while least severe infections with R272 generated the 
smallest protein list, with only 75 quantitatively different proteins being identified. 
This observed hierarchy occurred despite the fact that the total number of proteins 
identified for each iTRAQ run, representing the lungs infected with the different 
Cryptococcus strains, were relatively similar (table 5.6).  
 
5.4.3. Protein function as a selection criterion 
The final selection criterion for ranking proteins of interest was the determination of 
the specific function of an identified protein in the context of pulmonary infection and 
trauma. While increased or decreased protein expression coupled with statistical 
significance provides crucial indications as to the effect infection is having on the 
lung, the degree of expression does not provide a great deal of information about the 
likely biological effect of this regulation. An accurate assessment of the degree of 
protein regulation requires additional analysis to ensure accuracy. Due to the limited 
amount of protein obtained, this additional analysis would be difficult or impossible 
for the majority of our samples. In this context, to ensure that considerable time was 
not spent analysing irrelevant proteins, the specific function of an identified protein 
has been given a greater weight than the degree of positive or negative regulation. 
 
5.4.4. Differentially expressed proteins common to infected lungs 
The search for proteins of relevant function revealed that at the early infection time-
point there was a subset of proteins that were common to pulmonary infections with 
KN99α, R265 and R272 (table 5.7). These were significantly differentially expressed 
in all biological replicates across all infections. Interestingly, it was observed that all 
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but one of these identified proteins (Alpha-1B-glycoprotein) was uniformly regulated 
in abundance, meaning they were consistently increased or decreased in expression in 
all pulmonary infection datasets. This finding strongly suggests that the basic 
responses to pulmonary infection with Cryptococcus of different species and different 
virulence levels are uniform, regardless of the disease outcome.  
Reviews of infectious disease literature suggest that the changes in host gene 
expression changes are different for bacterial and fungal infections [368, 369], 
however, the proteins detected in this experiment represent a subset of the host innate 
immune system involved in the non-specific response to insult. What follows is a 
discussion of the function of the identified ‘interesting common’ proteins and what 
the potential consequences of therapeutic intervention against or with recombinant 
forms of these proteins could be in the context of pulmonary insult and infection. The 
proteins have been divided into groups according to the direction of protein 
expression and function. It should be noted that while there are clearly proteins 
involved in host defence within this common list, this group of proteins alone was not 
sufficient to define the host response to the various strains of Cryptococcus. 
Additionally, this group of proteins did not indicate whether the eventual host 
responses were going to be successful in controlling and eliminating the infection.  
 
5.4.5. Differentially expressed proteins that increased in expression 
5.4.5.1. Proteins involved in tissue protection after insult 
5.4.5.1.1. 78 kDa glucose-regulated protein  
78 kDa glucose-regulated protein (GRP78) is a resident stress protein of the 
endoplasmic reticulum that belongs to the Hsp70 multi-gene family. In contrast to the 
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stress proteins Hsp60 and Hsp70, whose surface expression promotes the lysis of 
injured, pathogen-infected or transformed cells, the surface expression of GRP78 
confers resistance to cell lysis by cytotoxic T lymphocytes and TNF [370]. GRP78 
has also been demonstrated to protect cells from death via the suppression of oxygen 
free radical accumulation and the stabilisation of mitochondrial function [371]. There 
is also evidence that the induction of GRP78 up-regulation has the potential to 
counterbalance the effects of idiopathic pulmonary fibrosis [372]. The observed up-
regulation of GRP78 across all Cryptococcus infections suggests that the host is 
attempting to protect itself from unrelenting cellular destruction as a result of 
infection-associated stress. It is possible that the development and administration of a 
recombinant form of GRP78 could help to ameliorate the tissue destruction that 
occurs during pulmonary infection with Cryptococcus.  
 
5.4.5.1.2. Cathepsin D  
Cathepsin D is a lysosomal aspartyl protease that has been found to be up-regulated 
during pulmonary injury by bleomycin, a glycopeptide antibiotic, in primary cultures 
of rat alveolar epithelial cells [373]. Bleomycin induces sensitivity to oxygen toxicity 
that results in pulmonary fibrosis, impaired lung function and apoptosis. Li et al. 
(2004) demonstrated that apoptosis of alveolar epithelial cell due to exposure to 
bleomycin required the autocrine expression and proteolytic processing of 
angiotensinogen to angiotensin II [373]. These authors also provided evidence that 
cathepsin D is required for the proteolytic processing of angiotensinogen to 
angiotensin II, and that the blockage of cathepsin D could prevent alveolar epithelial 
cell apoptosis. The anti-apoptotic activity of cathepsin D could limit the extent of lung 
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injury, which indicates the potential suitability of this protein as a target for 
recombinant protein therapy. 
 
5.4.5.2. Proteins involved in the antifungal response and 
inflammation 
5.4.5.2.1. Acidic mammalian chitinase 
C. neoformans has a tendancy to induce and promote the progression of allergic 
inflammation in animal models. Goldman et al. (2006) demonstrated that chitinases 
act as important mediators of IL-13-associated allergic inflammation and airway 
hyper-responsiveness during chronic infection with C. neoformans [374]. Vicencio et 
al. (2008) demonstrated an increased expression of acidic mammalian chitinase 
(AMCase), a hydrolytic enzyme that degrades chitin via the digestion of glycosidic 
bonds, in airway epithelial cells and macrophages during chronic pulmonary infection 
with  C. neoformans [375]. These results strongly suggest that AMCase acts as an 
important promoter of allergic inflammation during cryptococcal infections. AMCase 
has also emerged as a potential diagnostic maker for pulmonary infection with fungal 
organisms. Vicencio et a (2008) demonstrated an increased expression of AMCase 
during chronic pulmoary infection that was not present with systemic infection [375]. 
The observable increase in AMCase protein expression has been found to act as an 
indicator of the initiation of pulmonary fungal infection [376]. The measurement of 
AMCase in patients suspected to have been exposed to infectious Cryptococcus 
species could be used as a general diagnostic for infection and a trigger for 
prophylactic antifungal treatment in high-risk cases. 
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5.4.5.3. Proteins associated with pulmonary surfactant  
Pulmonary surfactant is a surface-active lipoprotein complex produced by type II 
alveolar cells essential for reducing the surface tension in the lungs [377]. Surfactant 
functions to increase lung compliance, regulates alveolar size and reduces fluid 
accumulation in the alveoli [377]. These properties of surfactant are afforded by the 
physiochemical nature of the protein and lipid constituents of the material.  
 
5.4.5.3.1. Fatty acid-binding protein, epidermal 
In the lung fatty acid-binding protein, epidermal (E-FABP) has been identified to be 
involved in the synthesis of dipalmitoylphosphatidylcholine. 
Dipalmitoylphosphatidylcholine is the most abundant phospholipid component of 
lung surfactant and contributes the majority of its surface tension reduction properties 
[378]. Resultantly, E-FABP has been established as an essential factor required for the 
synthesis of functional surfactant [379].  The up-regulation of E-FABP during 
infection indicates that the host is either actively increasing the secretion of surfactant 
to ameliorate the consequences of infection or is being forced to do so by the infective 
agent. In the latter case, increased surfactant secretion could act as vital supply of 
nutrients for the infective agent.  
5.4.5.3.2. Pulmonary surfactant-associated protein D  
Pulmonary surfactant-associated protein D (SP-D) is a hydrophilic surfactant protein 
that possesses important immune functions for host defence. SP-D, a member of the 
collectin family of proteins, functions as a pattern recognition molecule involved in 
the opsonisation of fungal cells for enhanced phagocytosis. This innate immune host 
response should lead to the destruction of the majority of the microorganism burden. 
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Cryptococcus cells, however, have been shown to survive within and be liberated 
alive from macrophages after phagocytosis, which is an important aspect of their 
infection process [53, 54]. The observations made in this study correlate with results 
produced by Geunes-Boyer et al. (2009) who determined that pre-treatment with SP-
D prior to infection with C. neoformans increased both fungal phagocytosis and 
fungal growth in the presence of macrophages [380]. With the knowledge that 
infection progresses past the 14-day time point for KN99α and R265, it could be 
concluded that these strains represent examples where the host’s immune system 
could be enhancing fungal pathogenesis and dissemination. 
 
5.4.5.4. Proteins involved in tissue and cell structural modulation 
5.4.5.4.1. Macrophage capping protein 
The forces required for cell motility in non-muscle cells are provided via regulated 
dynamic shifts in the concentration and length of actin filaments. Macrophage 
capping protein (CAP-G) belongs to the gelsolin/villin family of proteins that function 
to regulate these dynamic shifts. These proteins serve to control the growth and 
assembly of actin filaments and are capable of determining where new forces for 
directional cell movement are generated [381]. CAP-G is widely expressed in 
mammalian cells but is most abundant in macrophages. Macrophages require barbed 
end actin filament assembly and regulation in order to form pseudopods to ingest and 
destroy foreign organisms. Witke et al. (2001) determined that CAP-G plays an 
important role in macrophage motility and phagocytosis and that the loss of 
macrophage capping protein function while not being lethal, resulted in the significant 
decrease in phagocytosis rates [382].  
  Chapter Five 
 
 157 
5.4.6. Differentially expressed proteins that decreased in expression 
5.4.6.1. Molecular indicators of reduced ventilation and poor health 
5.4.6.1.1. Carbonic anhydrase 1 and 2 
Carbonic anhydrases, a large family of zinc metalloenzymes, catalyse the 
interconversion of carbon dioxide and water to bicarbonate and protons [383]. 
Carbonic anhydrases function in a number of vital biological processes including the 
transport of carbon dioxide out of the lungs, cellular respiration and acid-base 
balance. Coupled with our observation that infected animals were struggling to breath 
that indicates physical limitations to ventilation, a result of obstruction and/or the 
destruction of the lung tissue due to fungal infection, the down regulation of carbonic 
anhydrase 1 and carbonic anhydrase 2 would likely lead to the development of 
respiratory acidosis. If not adequately expelled through alveolar ventilation, carbon 
dioxide rapidly accumulates in the lungs. This causes body fluids to become overly 
acidic and the onset of symptoms including confusion, fatigue, lethargy and shortness 
of breath [384], which are all observed in rats during severe infection with 
Cryptococcus. The consistent down-regulation of carbonic anhydrase 1 and 2 coupled 
with the observed physical difficulties with breathing indicates that chronic infection 
with Cryptococcus reduces ventilation at a physical and molecular level. 
 
5.4.6.1.2. Sec14-like protein 3 
Sec14-like protein 3, a water-soluble 45 kDa protein secreted by alveolar epithelial 
cells, functions to maintain airway epithelial cell homeostasis. It has recently been 
demonstrated that sec14-like protein 3 expression is strongly and inversely associated 
with the progression of airway inflammation [385]. The decrease in sec14-like protein 
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3 expression in diseased lung tissue may be caused by damage to the epithelium. 
Indeed it is believed that the changes in sec14-like protein 3 expression may be 
triggered by neutrophils and then exacerbated by the infiltration of other 
inflammatory cells. A practical aspect of this inverse relationship is that the degree of 
down-regulation of sec14-like protein 3 acts as a quantitative indicator/biomarker of 
the progression of respiratory inflammation and tissue damage during pulmonary 
cryptococcosis.  
 
5.4.6.1.3. Periaxin  
Periaxin is a cytoskeleton-associated protein that appears to be required during the 
early deposition and maintenance of peripheral nerve myelin. It appears that periaxin 
functions to enhance the structural stabilisation of myelin [386]. Mice lacking 
periaxin, while being able to ensheath and myelinate peripheral axons, where found to 
subsequently develop severe demyelinating neuropathy [387]. The impairment of the 
transmission of peripheral nerve impulses can have severe consequences, such as the 
peripheral nerves being less able to activate muscles, or impairment of the relay of 
information from sensory cells to the brain. The possible impairment of the 
transmission of nerve impulses from the brain to the lung and vice versa would have a 
detrimental effect on the control of respiration. 
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5.4.6.2. Proteins involved in the antifungal response 
5.4.6.2.1. Moesin  
Moesin is a member of the ERM superfamily of proteins that are associated with the 
submembranous cytoskeleton. ERM proteins are widely expressed and localized to 
membranous protrusions that are important for ligand recognition, signal transduction 
and motility. Moesin is primarily found in the core of microextensions of leukocytes 
and endothelial cells where it functions in the dynamic changes in cell shape that take 
place during attachment, spreading and cell movement. While traditionally being 
identified as a structural protein, it has recently been proposed that moesin plays an 
important role in the innate immune response and TLR4-mediated pattern recognition. 
Tohme et al. (1999) and Zawawi et al. (2011) demonstrated that moesin acts as a 
second, independent receptor for LPS on the surface of human monocytes and that 
LPS binding stimulates a biological response, with the expression of pro-
inflammatory cytokines [388, 389]. These data also suggested that moesin acts as a 
necessary co-receptor for the transduction of the CD14 signal, that is, the recognition 
of pathogen associated molecular patterns. The observed down regulation of this 
protein across the three infection types indicates that pulmonary infection with 
Cryptococcus is detrimentally affecting at least one mode of non-host material 
recognition.  
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5.4.6.3. Proteins involved in tissue and cell structural modulation 
5.4.6.3.1. Advanced glycosylation end product-specific 
receptor 
Advanced glycosylation end product-specific receptor (RAGE) is a 35 kDa 
transmembrane receptor of the immunoglobulin super family that functions as a 
pattern recognition receptor [390]. The lungs exhibit a high basal level of expression 
for RAGE, especially in alveolar type I cells [391, 392]. The interaction between 
RAGE and its ligands has been demonstrated to activate a proinflammatory effect in 
innate immunity [393]. RAGE, via an association with the basal cell membrane, 
promotes and maintains the spread-out morphology of alveolar type I cells. This 
morphology ensures optimal gas exchange and alveolar stability. The disruption of 
RAGE has been implicated in the development of a number of pulmonary disorders 
including cancer and fibrosis [391, 394]. RAGE presents itself as a potential target for 
therapeutic use, whereby the development and administration of recombinant RAGE 
could function to maintain pulmonary structure and gas exchange homeostasis during 
infection. 
 
5.4.6.4. Proteins involved in tissue protection after insult 
5.4.6.4.1. Peroxiredoxin-2  
In order to minimize damage and death, cells rely on the scavenging of reactive 
oxygen species by enzymatic and non-enzymatic antioxidant defences. 
Peroxiredoxins are ubiquitously expressed enzymes that play protective roles against 
oxidative stress via the reduction of hydrogen peroxide and other reactive oxygen 
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species [395]. Peroxiredoxin 2 is a relatively abundant, predominant cytoplasmic 
peroxiredoxin found in mammalian cells that belongs to the 2-Cys subgroup [351]. 
The observation that peroxiredoxin 2 is downregulated during severe pulmonary 
infection strongly indicates the occurrence of an oxidant/antioxidant imbalance as a 
result of infection with Cryptococcus. 
 
5.4.6.4.2. Glutathione peroxidase 3  
Glutathione peroxidases are widely distributed enzymes that catalyse the reduction of 
hydrogen peroxide and other peroxides, generated during normal metabolism or 
oxidative stress, to their corresponding alcohols using glutathione as a substrate [395]. 
Glutathione peroxidase 3 is found in the plasma (it is the only known Glutathione 
peroxidase that exists in the extracellular space) and plays a role in maintaining the 
vasorelaxant and antithrombotic properties of the vascular endothelium [396]. The 
observed down-regulation of glutathione peroxidase 3 in all infections with 
Cryptococcus strongly indicates an imbalance in the oxidant/antioxidant system that 
exists during the early stages of pulmonary infection. 
 
5.4.6.4.3. Biglycan 
It has been demonstrated in vitro that the small leucine-rich proteoglycans decorin and 
biglycan have the inherent ability to bind to and inhibit the profibrotic function of 
TGF-β [397]. The anti-fibrotic function of decorin identified in vitro carries over to in 
vivo animal models. This is not the case for biglycan; indeed under certain conditions 
it has been suggested that biglycan could act as a profibrotic agent [397, 398]. The 
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divergent in vivo function of these two similar molecules is a result of their differing 
tissue localisations. Decorin is bound to collagen where it binds TGF-β and prohibits 
its interaction with cellular receptors. Biglycan is more closely associated with the 
pericellular space and cell surface. At this cellular location, biglycan binds TGF-β but 
does not inhibit its interaction with receptors. Inhibition of the profibrotic function of 
biglycan and the development and administration of recombinant decorin could act to 
inhibit the development of excessive fibrous connective tissue during pulmonary 
infection with Cryptococcus. 
 
5.4.7. The case of proteins that fall outside of the selection criteria 
Despite the observed hierarchy in the number of statistically significant quantitatively 
different proteins for the three differing strains of Cryptococcus, the total numbers of 
identified proteins from the lung material from these infections were relatively 
similar. Furthermore, the identified proteins evident in the original unfiltered lists 
were surprisingly similar. This was despite the differing infective strains used and the 
marked differences in ultimate disease outcome. The reasons for the vast majority of 
identified proteins being excluded from the ‘common list’ of proteins is largely a 
result of our experimental design and the methodology used. The decision to 
specifically target proteins that were statistically significant in all biological 
replications was intended to increase the stringency of the subsequent analysis. The 
reality of this approach is the loss of significant amounts of ambiguous but potentially 
interesting protein data.  
The omitted data is ambiguous in that despite being iTRAQ labelled, identified by the 
mass spectrometer and exhibiting a fold change that falls within the designated 
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parameters of >1.2 or <0.8, the differential expression of these proteins was not 
significant (p-value > 0.05) in one or more of the biological replicates. This 
phenomenon can arise due to a number of factors, including biological variations in 
peptide levels due to in vivo degradation, or artefacts of the technique such as 
inefficient trypsin digestion, variable iTRAQ labelling or variations in 
chromatography and mass spectrometric peptide fragmentation and detection. The 
fact that the p-values of these identified proteins are outside the optimal threshold 
casts doubt on whether or not the regulation state of the proteins as indicated by 
iTRAQ labelling are indeed a true representation of the biological states of these 
proteins during infection.  
The iTRAQ samples were prepared using a robust and validated method. iTRAQ has 
been found to be reproducible when samples are processed together and then analysed 
in a single iTRAQ run. The experiences encountered in this study are similar to those 
of other experienced iTRAQ users, including the Australian Proteome Analysis 
Facility, where our analyses were performed [399]. It is tempting, therefore, to 
conclude that the proteins identified with high confidence in one strain, but not in 
another are differentially processed or degraded during the course of the infection. 
Given the very different outcomes from the three Cryptococcus strains it is not 
unreasonable to conclude that the lung remodelling processes will also be quite 
different. Despite the ambiguous nature of this specific subset of the obtained data, 
the question remains as to whether any of these identified proteins could be used to 
provide either an indication of the host response to infection or therapeutic targets to 
combat infection. Speculations made from the analysis of this data sub-set require 
further investigation and experimental validation, as do any deductions made from the 
‘common list’ of proteins. The same criteria of functional relevance were applied to 
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this protein group (section 5.4.2.), and their potential association with lung infection is 
discussed below.  
 
5.4.8. Proteins with one or more biological replicates that was not 
significant 
The application of the selection criteria limited the scope of analysis to 26 potentially 
interesting proteins. Table 5.10 lists proteins that are biologically significant in five 
out of six biological replicates. This data subset includes antifungal agents (Lysozyme 
C-1, Protein S100A9, Galectin-3, Prolargin), proteins involved in tissue protection, 
(Peroxiredoxin-6, Granulins), proteins involved in tissue and cell structure 
stabilisation (Serum deprivation-response protein, Vinculin) and a protein that is 
potentially involved in tissue invasion (Alpha enolase). Table 5.11 represents proteins 
that are more ambiguous in their statistical significance and corresponding regulation 
state. One or more of the biological replicates for these proteins were found to have 
expression that was not statistically significant (p-value >0.05), did not meet the >1.2 
or <0.8 level of differential expression (as compared to the control lung baseline) or 
were not detected by the mass spectrometer. Despite the ambiguous nature of the data, 
the biological functions that these particular proteins represent are interesting. For 
example, they include proteins involved in the survival of macrophages (Allograft 
inflammatory factor 1), antigen presentation (Beta-2-microglobulin) and tissue 
protection (Catalase, Protein DJ-1, Superoxide dismutase [Cu-Zn], Caveolin-1 
Caveolin-1). While representing interesting proteins in the context of pulmonary 
infection, whether these data are trustworthy is questionable. The lack of statistical 
significance across all the replicates indicates that there is a higher chance that their 
assigned expression state may be the result of factors other than a true biological 
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response to Cryptococcus pulmonary infection. It is also possible that the clarification 
of the molecular processes involved in the host response to Cryptococcus pulmonary 
infection requires significantly more biological replicates to “catch” the dynamic 
response of the host, especially given the variable extent of infection observed across 
the biological replicates by this study.  
 
5.4.9. Experimental design constrains the elucidation of the host response 
to infection 
This project represents the first attempt at the global elucidation of the host response 
to Cryptococcus pulmonary infection using quantitative proteomic analysis 
techniques. There have been large scale analyses carried out on lung infections and 
diseases, however, these were gene expression studies rather than proteomics. The 
complete lack of large-scale quantitative proteomics studies of lung infection 
probably reflects the technical difficulties associated with sample preparation. In 
addition, high quality, reproducible and cost effective proteomic techniques such as 
iTRAQ have only been widely available in the last 5 years. The experimental design 
of this PhD project, however, was targeted at the investigation of fungal pathogenesis 
during pulmonary infection. This required synchronised pulmonary infections with 
high fungal burdens to ensure maximal fungal cell numbers and the highest possible 
protein yields. A limitation of this experimental design, in terms of the elucidation of 
the host response to infection, was that the induction of such severe infection required 
inoculation with unnaturally large fungal loads followed by relatively long periods of 
infection. An experimental design that would enable a more realistic appraisal of the 
host response to Cryptococcus infection demands considerably increased animal 
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numbers and a re-evaluation of fungal load, timing of euthanasia and the analysis 
platforms utilised.  
A more suitable infection model for the targeted study of the host response to fungal 
infection would include inoculations with more environmentally realistic doses of the 
infective agent and the inclusion of earlier, and potentially more, time-points for 
analysis. The common response to infection indicated by the majority of the iTRAQ 
data obtained indicates that this technology platform may not be ideally suited to 
interpreting the host response to Cryptococcus infections. It is likely that iTRAQ is 
not sensitive enough to identify relevant proteins that are present at low abundance in 
a very complex sample. It is also likely that analyses at time-points between 14 days 
and 42 days will be important in elucidating the strain-specific responses after the 
initial common response period. The integration of transcriptomic technology 
platforms into the experimental design may increase the analytical potential in future 
studies. Transcriptomics involves quantitative analysis of mRNAs using high-
throughput techniques based on DNA microarray technology or next generation 
sequencing. Furthermore, transcriptomics is more applicable to the relatively small 
sample types generated by our experimentation as mRNA can undergo PCR 
amplification. Proteins and proteomics lack a PCR equivalent, and thus demand high 
fungal burdens. 
Despite the limitations in the experimental design, a number of proteins have been 
identified that could potentially act as targets for recombinant protein treatment. There 
are a growing number of recombinantly expressed and purified proteins being 
investigated as clinical therapeutic agents for a myriad of diseases. One such example 
is the intravenous administration of angiotensin-converting enzyme 2 to inactivate 
angiotensin II, which resulted in the amelioration of LPS induced acute lung injury in 
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piglets [400]. Coupled with the administration of a suitable antifungal, such as the 
fungistatic fluconazole, the administration of recombinantly generated and purified 
forms of proteins could aid in both the inhibition of fungal pathogenesis and the 
amelioration of lung injury. We have identified a number of proteins that were 
downregulated during infection and would fall into this class of potential therapeutics. 
The include moesin (involved in the innate immune system), advanced glycosylation 
end product-specific receptor (involved in the maintenance of the lung architecture), 
carbonic anhydrase 1/carbonic anhydrase 2 (involved in lung homeostasis) and 
biglycan, glutathione peroxidase 3 or peroxiredoxin-2 (involved in tissue protection). 
 
5.4.10. An observable increase in ambiguity at the late stage infection 
time-point 
Inconsistent protein expression is an inherent phenomenon of quantitative proteomics 
using animal models and is generally indicative of the biological variation between 
individual members of the animal population being analysed. What was notable in the 
current analysis was that inconsistency dramatically increased in late stage infection 
compared with early stage infection. In the early stage infections with R265, 3 of the 
136 (2%) significantly differentially expressed proteins were alternatively regulated in 
the biological replicates. The rate for R272 was slightly higher with 8 of 88 (9%) 
significantly differentially expressed proteins alternatively regulated. At the late stage 
of infection this increased to 23 of 102 identified proteins (23%) for R265 and 31 of 
46 (67%) identified proteins for R272. Note that infections with KN99α were too 
aggressive to be permitted to continue to the late stage infection time point.  
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What is the cause of the rise in inconsistently regulated proteins at the late stage 
infection time point? Is it a consequence of the differing biological responses of 
individuals to the stress of infection or differing rate of recovery from infection at the 
late stage of infection?  Unfortunately the experimental design does not permit an 
adequate answer to this question. At the early stage infection time-point, the 
proteomic analyses agree with the literature suggesting the host mounts a common 
response to infection regardless of strain. Between the early and late stages of 
infection the course of the infections preceded very differently, with KN99α animals 
requiring early euthanasia, R265 animals progressing to severe but not lethal infection 
and R272 infections resolving. It is highly likely that the time-point where the 
response to infection changes from synchronous to asynchronous has been missed. In 
a similar fashion to the issues with early stage infection, the rectification of this issue 
requires an improvement to experimental design to better target the host response to 
infection. This improved design would feature pulmonary infections initiated with 
more realistic inoculation sizes and an increased number of time-points, especially in 
the earlier stages of infection and between the early and late stage infection time-
points. 
 
5.5. Conclusions 
While limited by a number of experimental design issues this study has provided 
evidence that a global analysis of the complex biological interactions between host 
and infective agent is possible. The analysis permitted inferences to be drawn 
regarding the potential therapeutic use of a number of differentially expressed 
proteins, most likely in a dual role with commercially available antifungal agents, 
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which could be exploited to ameliorate lung injury as a result of infection. While this 
study shows that global proteomic analyses of the host response to pulmonary 
infection with Cryptococcus are possible, further comprehensive analysis requires the 
inclusion of additional infection time points as well as integration of quantitative 
analytical techniques that are more sensitive than iTRAQ. 
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Chapter Six 
The systemic response to pulmonary infection with 
Cryptococcus 
The previous result chapters were restricted in focus to the investigation of 
Cryptococcus pathogenesis (chapter 4) and the host responses to pathogenesis  
(chapter 5) in the context of the pulmonary environment. The aim of the following 
study was to explore the systemic host response to pulmonary infections with 
Cryptococcus. The experimental design was focused on the quantitative analysis of 
cytokines, chemokines and growth factors during pulmonary infection with virulent 
Cryptococcus, using naïve control lung as the baseline. This analysis was achieved 
using the Bio-Plex suspension array system (Bio-Rad, USA). 
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6.1. Introduction 
Profiling serum cytokine expression levels has been described as a powerful tool that 
links the systemic host immune defence system with disease pathogenesis [401]. 
Cytokines are cell-signalling proteins expressed and secreted by a myriad of cells, 
including those of the immune system. The host immune response to invading 
pathogens involves a tightly regulated balance between the Th1 (a proinflammatory 
response that stimulates the cellular immune system), Th17 (recruitment, activation 
and migration of neutrophils) and Th2 (a generally anti-inflammatory response that 
stimulates the humoral immune system) patterns of cytokine production. The outcome 
of infection is heavily dependent on the specific cytokine response mounted by the 
host after exposure to Cryptococcus [86]. The appropriate cytokine production profile 
promotes removal of the invading pathogen and damaged cells while minimalizing 
the detrimental impact to the host via the repair of the injured tissue.  It has become 
apparent that the predominant synthesis of Th1 and Th17 cytokines over Th2 
cytokines protects mice from cryptococcal infection [147-149]. The detection and 
quantitative measurement of these immune proteins could provide insight to the 
physiological state and the responses of the host to cryptococcal infection. 
Circulating cytokines levels are generally in the low pg/mL range and are below the 
detection limit of mass spectrometry-based proteomics. Whilst cytokines can be 
detected by traditional immunoassays such as ELISA, obtaining data on many 
cytokines is time consuming and expensive. Multiplexed methods of cytokine 
detection and quantification provide a number of advantages over traditional single-
cytokine measurement systems. The detection and quantification of single cytokines 
is of limited value given the fact that many cytokines have closely related or 
overlapping functions. Multiplexed methods also reduce the cost and time of analysis 
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and use samples more effectively than single-cytokine measurements. The Bio-Plex 
suspension array system, using xMAP technology licensed from Luminex Corp. by 
Bio-Rad [402], is one such multiplex analysis system. The technology is based on the 
flow cytometric analysis of fluorescently colour-coded magnetic microspheres that 
possess distinct spectral addresses (figure 6.1). The assay is essentially an 
immunoassay, similar in principle to a sandwich ELISA, supplied on colour coded 
magnetic beads.  
 
Figure 6.1: Magnetic microsphere architecture (from [234]) 
 
The Bio-Plex suspension array system is the most cited xMAP assay in the world 
[402, 403]. It has been used to analyse cytokine levels in human, mouse and rat 
biological fluids and tissues including: plasma, serum, adipose interstitial fluid, 
bronchoalveolar lavage fluid, blister fluid, cerebrospinal fluid, nasal lavage fluid, 
peritoneal fluid, synovial fluid, colon tissue, kidney tissue, nervous system tissue, 
spleen tissue and tissue culture supernatant [403]. Bio-Plex has also been used to 
analyse the supernatants of murine lung tissue homogenates generated following 
pulmonary infection with C. neoformans and C. gattii strains. Wormley et al. (2007) 
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investigated the cell-mediated immune responses that are generated during pulmonary 
infection with C. neoformans (H99γ), a strain engineered to produce host Th1 type 
cytokine interferon gamma (IFN-γ). This study demonstrated that the pro-
inflammatory Th1 pattern of cytokine production was significantly higher, while the 
anti-inflammatory Th2 pattern of cytokine production was significantly lower, in mice 
infected with H99γ than those infected with wild type H99. This Th1-skewed 
response resulted in the elimination of primary infection and provided subsequent 
protection against secondary pulmonary challenge with wild type C. neoformans. 
Similarly, Wozniak et al. (2011) used the Bio-Plex suspension array system to 
demonstrate that while IL-17 may be important for the optimal protection of the host 
from pulmonary infection with C. neoformans (H99γ), the Th1 pattern of cytokine 
expression is sufficient for protection against infection [404]. Wang et al. (2011) also 
employed the Bio-Plex system to determine the contribution of MyD88 dependent 
receptors to host defences during pulmonary infection with C. neoformans (H99) 
[405]. MyD88 is an adaptor molecule required for IL-1 and IL-18 signalling pathways 
and is utilised by toll-like receptors for signalling [405-407]. MyD88 is vital for host 
defence against infection with Cryptococcus, with MyD88-deficient mice exhibiting 
decreased survival and increase pulmonary fungal burdens [408, 409].  
Using lung tissue homogenates, Cheng et al. (2009) demonstrated that at 7 days post 
infection, acknowledged as the time that coincides with the onset of cell-mediated 
immunity in the mouse model [410], C. gattii strain R265 induced considerably lower 
levels of neutrophil infiltration and reduced inflammatory cytokine production during 
murine pulmonary infection compared to C. neoformans [411]. Cytokine analysis 
indicated the absence of a clear Th1 type immune response, however they were also 
not able to find evidence for the development of a Th2 type immune response. The 
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authors suggested that the hypervirulent C. gattii strain responsible for the outbreak of 
cryptococcosis on Vancouver Island was inducing less protective immunity or 
suppressing the protective immune responses in mice, permitting the pathogen to 
thrive in an environment that normally limits the progression of disease. 
It has been acknowledged that mice and rats differ in their susceptibility and their 
immune responses to infection with Cryptococcus [133, 411, 412]. Furthermore, the 
rat model appears to be more similar to humans in susceptibility to pulmonary 
cryptococcosis than the mouse, and to exhibit some of the clinical features of human 
pulmonary cryptococcosis [238, 239]. While the previously described studies provide 
important insights into Cryptococcus virulence and the host immune responses to 
pulmonary infection, all were conducted in the mouse host model. The aim of the 
work undertaken in this study was to reveal the cytokines, chemokines and growth 
factors that play a role in the rat host response to Cryptococcus pulmonary infection. 
The underlying hypotheses of the study were that: 
• Rats infected with Cryptococcus strains of assumed differing virulence would 
express significantly different cytokine expression profiles.  
• The Bio-Plex suspension array system would identify specific cytokines, 
chemokines and growth factors that highlight:  
o Differences in overall cytokine expression profiles evoked by 
Cryptococcus strains of differing virulence;  
o Specific cytokines or cytokine responses that promote or eliminate 
infection;  
o Cytokines that could form potential future drug targets, biomarkers and 
diagnostic markers. 
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6.2. Methods 
6.2.1. In vitro growth conditions 
The in vitro growth conditions used were described in section 2.3.1. 
 
6.2.2. Pulmonary infection model 
The pulmonary infection model used was described in section 2.3.2. 
 
6.2.3. Bio-Plex Pro Rat Cytokine, Chemokine, and Growth Factor Assay 
6.2.3.1. Sample preparation 
Aliquoted serum samples, prepared in section 6.2.2., were removed from -80 °C 
storage and defrosted. At the same time the buffer components of the Bio-Plex kit 
were removed from 4 °C storage and warmed to room temperature. The magnetic 
beads, standard, detection antibody and streptavidin-PE tubes were kept on ice. The 
standard was reconstituted with 500 µL of sample diluent and left on ice for 30 
minutes. 75-100 µL of serum was then transferred to a 0.2 µm Nanosep MF 
Centrifugal Device with Bio-Inert Membrane (Pall Scientific, USA) and centrifuged 
at 9,000 g for five minutes (note: 50 µL is required per well and a loss of 5-10 µL is 
expected as a result of filtration). After centrifugation the columns were checked to 
ensure that all of the solution had passed through the filter. If not, the centrifugation 
process was repeated until the entire sample had passed through the filter. Samples of 
each filtrate were analysed using the Bio-Plex Pro™ Rat Cytokine, Chemokine and 
Growth Factor 24-plex Assay (Bio-Rad, USA) according to the manufacturer’s 
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instructions. This assay kit included the following cytokines, chemokines and growth 
factors: 
Pro-
inflammatory 
Growth 
factors 
Chemokines Anti-
inflammatory 
Dual role 
cytokines 
IFN-γ IL-7 IL-5 IL-4 IL-2 
IL-1α EPO  GRO/KC IL-10 IL-6 
IL-1β G-CSF MIP-1α IL-13  
IL-12 (p70) GM-CSF MIP-3α   
IL-17 M-CSF RANTES   
IL-18 VEGF    
IFN-γ     
TNF-α     
 
6.2.3.2. Wash station preparation 
All washing procedures were performed on the Bio-Plex Pro II magnetic wash station 
(Bio-Rad, USA). Following the rinse procedure provided by Bio-Rad, 100 mL of 
ddH2O was used to flush the wash station. The wash station was then primed using 30 
mL of the Bio-Plex wash buffer.  
 
6.2.3.3. Coupled magnetic bead preparation 
Each well required 50 µL of 1 x coupled beads. The 10 x coupled beads were gently 
resuspended before transferring the required volume (variable depending on number 
of wells used during analysis). The beads were then diluted to the working solution 
with assay buffer and kept on ice in the dark. 
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6.2.3.4. Serial dilution of standards 
Eight tubes were labelled S1 to S8 for the standard dilutions. 128 µL of reconstituted 
standard was added to the first tube (labelled S1) with 72 µL of standard diluent. The 
sample was then vortexed gently for 1-3 seconds. 50 µL of S1 was then transferred to 
S2 with 150 µL of standard diluent and then vortexed. This process was repeated until 
completion of the 8-tube dilution series.  
 
6.2.3.5. Assay procedure 
The diluted standards, samples and controls were equilibrated at room temperature for 
20 minutes prior to use. The coupled beads were vortexed for 30 seconds at medium 
speed and then 50 µL transferred to the designated wells of the provided 96-well 
plate. The 96-well plate was then placed on the magnetic wash station and the coupled 
beads washed twice with Bio-Plex wash buffer. The diluted standards, samples and 
controls were briefly and gently vortexed and 50 µL of each were added to the 
designated wells. The plate was covered and incubated on a shaker at room 
temperature for one minute at 1,100 rpm. The shaker speed was then reduced to 300 
rpm and the samples were incubated for a further 60 minutes. 
Ten minutes prior to the completion of the incubation the detection antibody was 
prepared. Stock 10 x detection antibody was vortexed at medium speed for 20 seconds 
and diluted to a 1 x working solution (25 µL required per well) with detection 
antibody diluent.  After the completion of the 60 minute shaking incubation (above) 
the plate was washed three times using the Bio-Plex wash station. Detection 
antibodies were briefly and gently vortexed and 25 µL transferred to each well. The 
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covered plate was then placed on the incubating shaker for one minute at 1,100 rpm, 
followed by 30 minutes at 300 rpm. 
During this incubation period the Bio-Plex machine was set up, calibrated and the 
streptavidin-PE prepared. Stock 100 x streptavidin-PE was vortexed for 20 seconds at 
medium speed. A 1 x working solution of streptavidin-PE was then prepared with 
assay buffer (50 µL required per well). Finally, the Bio-Plex software was set up. The 
identification details for each sample were entered and all calculated standard values 
were double-checked to match the table supplied with the standard vial.  
After completion of the antibody incubation the 96 well plate was placed on the 
magnetic wash station and the coupled beads washed three times with the Bio-Plex 
wash buffer. The working solution of streptavidin-PE was vortexed vigorously and 50 
µL added to each well. The covered plate was then placed on the incubating shaker 
for one minute at 1,100 rpm followed by 10 minutes at 300 rpm. The plastic seal was 
removed, the plate placed on the magnetic wash station and the beads washed three 
times with the Bio-Plex wash buffer. 125 µL of assay buffer was then added to each 
well, and the plate was covered and placed on the incubating shaker at 1,100 rpm for 
1 minute. The plate was now ready for reading. Data were acquired using the Bio-
Plex 200 system with version 5.0 software (Bio-Rad, USA). 
 
6.2.4. Linear regression models 
Cytokine expression data were loaded into RStudio (RStudio Inc, USA) and a linear 
regression model fitted to the data using the following functions and command lines: 
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6.2.4.1. Loading data 
The data function specifies the data file to be loaded into RStudio and the format of 
the data file. 
• data=read.csv(“filename.csv”, header=T, as.is=T) 
 
6.2.4.2. Stacking vectors from a Data Frame 
The stack function is used to transform the data from a separate column form 
(produced by the Bio-Plex 200 system with version 5.0 software (Bio-Rad, USA)) 
into a single column. Essentially, stacking vectors concatenate multiple vectors into a 
single vector. Factors can be added to indicate where each data point, or data point 
subgroup, originated. The colnames function applies a character vector to the generic 
stacked data. 
• datastack=stack(data[,x:y]) 
• datastack$Strain=rep(cyto$Strain,y) 
• datastack$Time=rep(cyto$Time,y) 
• datastack$Strain=as.factor(datastack$Strain) 
• colnames(datastack)[2]=“Cytokine” 
• colnames(datastack)[1]=“Fluorescence” 
 
6.2.4.3. Fitting a linear model 
The lm function is a sophisticated command that computes a linear model that fits the 
data. The summary function produces result summaries of the model fitting functions. 
• datatrend=lm(Fluorescence~Time*Strain, subset=(Strain %in% c(“KN99”, “R272”, “R265”))  
• summary(datatrend) 
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6.2.4.4. Plotting the linear model  
The plot function is a generic command for the plotting of R objects, such as the 
linear regression model (lm). The points function is a generic command that draws a 
sequence of points at the specified coordinates.  
• plot(Fluorescence~Time, subset=(Strain==“R265”), data=datastack, col=1) 
• points(Fluorescence~Time, subset=(Strain==“KN99”), data=datastack, col=2) 
• points(Fluorescence~Time, subset=(Strain==“R272”), data=datastack, col=3) 
 
6.2.4.5. Adding straight lines (intercept/slope form) to the plot  
The abline function adds one or more straight lines, specifying the line in 
intercept/slope form, through the specified coordinates. 
• abline(datatrend(Fluorescence~Time, subset=(Strain==“R265”), data=datastack), col=1) 
• abline(datatrend(Fluorescence~Time, subset=(Strain==“KN99”), data=datastack), col=2) 
• abline(datatrend(Fluorescence~Time, subset=(Strain==“R272”), data=datastack), col=3) 
 
6.2.5. Data analysis 
The average concentration of each cytokine was calculated from the biological 
replicates. The results are presented as the mean ± standard error of the mean (SEM). 
A two-tailed t-test was used to test the significance between the average 
concentrations of each cytokine in the disease samples compared to the control 
samples. P-values <0.05 were considered statistically significant. Only the cytokines 
that were observed at significantly different concentrations between control and test 
conditions are presented. 
  Chapter Six 
 
 181 
6.3. Results 
6.3.1. Cytokine response to pulmonary cryptococcosis: global trends 
The fitting of linear regression models to the entirety of the cytokine expression data 
indicated that the systemic host response to pulmonary infection with C. gattii R265 
(high virulence) generated a statistically similar cytokine expression profile to that of 
C. gattii R272 (low virulence) (figure 6.2). This was of interest given the differing 
pulmonary fungal burdens and disease outcomes for animals infected with R265 or 
R272. Rats infected with R272 appeared in general good health throughout the six-
weeks of infection and had minimal lesion development at early stage infection and 
the complete lack of observable lesions at late stage infection. In contrast, animals 
infected with R265 exhibited poor health and had large multifocal gelatinous lesions 
with little remaining normal lung tissue in the affected lungs at both the early and late 
stage infection time points (section 5.3.2.). Pulmonary infection with C. neoformans 
strain KN99α generated cytokine, chemokine and growth factor expression levels that 
were significantly higher than those generated by R265 and R272 (figure 6.2). This 
coincides with the extreme progression of pulmonary infection observed for rats 
infected with the KN99α.  
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Figure 6.2: Plot generated by RStudio after fitting a linear regression model to 
the global cytokine, chemokine and growth factor expression data for control 
and infected rat lung.  
P-values refer to whether the slopes, which provide an indication of the cytokine expression trend, are 
significantly different when comparing strains.  
 
6.3.2. Pro-inflammatory cytokine expression during pulmonary infection  
Linear regression models indicated that rats infected with KN99α had significantly 
higher expression of pro-inflammatory cytokines than those infected with R265 and 
R272 (figure 6.3). Similar to the global cytokine, chemokine and growth factor data, 
the expression level of pro-inflammatory cytokines for infections with R265 and 
R272 were statistically indistinguishable (figure 6.3). These data indicate that a pro-
inflammatory environment is promoted by pulmonary infection with virulent strains 
of Cryptococcus.  
Comparison* Mode* P/Value*
R265%R272' Slope' 0.757'
R265%'KN99α'' Slope' 0.042*'
R272%'KN99α' Slope' 0.024*'
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Figure 6.3: Plot generated by RStudio after fitting a linear regression model to 
the pro-inflammatory cytokine expression data for control and infected rat lung.  
P-values refer to whether the slopes, which provide an indication of the cytokine expression trend, are 
significantly different when comparing strains. 
 
6.3.3. Anti-inflammatory cytokine, chemokine, growth factor and dual 
role cytokine expression during pulmonary infection 
No significant differences in the overall expression of anti-inflammatory, growth 
factor or dual role cytokines were seen across infections (figure 6.4). There was a 
significant difference in chemokine expression trends between KN99α and R272 
(figure 6.4). For the dual role cytokines, the comparison of KN99α with R265 (p-
value 0.069) and R272 (p-value 0.062) were close to statistical significance. 
Comparison* Mode* P/Value*
R265%R272' Slope' 0.906'
R265%'KN99α'' Slope' 0.007**'
R272%'KN99α' Slope' 0.004**'
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Figure 6.4: Plots generated by RStudio after fitting linear regression models to 
the anti-inflammatory, chemokine, growth factors and dual role cytokine 
expression data for control and infected rat lung.  
P-values refer to whether the slopes, which provide an indication of the cytokine expression trend, are 
significantly different when comparing strains. 
 
6.3.4. Differentially expressed cytokines as a result of pulmonary infection 
with Cryptococcus 
There was a trend of increased expression for each of the 23 cytokines analysed in 
rats infected with KN99α, at the early infection time point, although not all cytokines 
increased significantly. This observed system-wide disruption of normal cytokine 
expression indicates that aggressive pulmonary infection with KN99α disrupts the 
systemic homeostasis of the infected animal. The cytokines significantly increased in 
expression were IL-1α, IL-17, IFN-γ, MIP-1α and TNF-α (figure 6.5). Similar to the 
Comparison* Mode* P/Value*
R265%R272' Slope' 1.000'
R265%'KN99α'' Slope' 0.502'
R272%'KN99α' Slope' 0.491'
Comparison* Mode* P/Value*
R265%R272' Slope' 0.748'
R265%'KN99α'' Slope' 0.077'
R272%'KN99α' Slope' 0.048*'
Comparison* Mode* P/Value*
R265%R272' Slope' 1.000'
R265%'KN99α'' Slope' 0.069.'
R272%'KN99α' Slope' 0.062.'
Comparison* Mode* P/Value*
R265%R272' Slope' 0.896'
R265%'KN99α'' Slope' 0.396'
R272%'KN99α' Slope' 0.348'
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KN99α dataset, only a small subset of the cytokines analysed at early and late stage 
infection with strain R265 were significantly different in expression. These cytokines 
were IL-5, IL-17, GRO/KC and MIP-1α, all of which were increased in expression 
(figure 6.5). The subset of cytokines significantly different in expression for R272 
was smaller than for KN99α or R265 and included IL-β, IL-12 and RANTES, all of 
which were increased in expression (figure 6.5).  
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Figure 6.5: Cytokines, chemokines and growth factors found to be significantly 
different in expression when comparing serum from rats with pulmonary 
Cryptococcus infection to serum from naïve rats.  
The cytokines graphed are presented as mean ± standard deviation (n=5) for the control and each 
infection time point. # indicates the statistically significant strains and time points. 
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6.4. Discussion 
6.4.1. Experimental design considerations 
Wormley et al. (2007), Wozniak et al. (2011) and Wang et al. (2011) demonstrated 
the ability of the Bio-Plex suspension array system to provide valuable insights to the 
murine immune responses to pulmonary infection with C. neoformans [145, 404, 
405]. The vital difference between this study and the aforementioned studies was the 
severity of pulmonary infection. Wormley et al. (2007), Wozniak et al. (2011) and 
Wang et al. (2011) did not report the extreme degree of pulmonary fungal burden as 
observed for virulent strains of Cryptococcus for this study. Given that rats have been 
observed to be more resistant to pulmonary infection than mice in models of fungal 
pneumonia [133], the heightened severity of infection observed for this study is likely 
due to the use of an infectious inoculum aimed a producing maximal pulmonary 
disease. Krockenberger et al. (2010) determined that rats consistently became ill or 
died following inoculation with ≥ 107 CFU mL-1 [239]. The experimental design of 
this thesis was primarily concerned with obtaining sufficient Cryptococcus for 
quantitative proteome analysis. This led to compromises with respect to obtaining 
pulmonary tissue samples and datasets. Thus, this study used inoculations of 108 CFU 
mL-1 to ensure that pulmonary infection was severe enough to generate fungal 
burdens sufficient for downstream quantitative proteomic analysis. In contrast, the 
mouse based studies used inoculation concentrations (104 to 105 CFU mL-1), 
consistent with the generation of standard infection in mice. The use of such a high 
inoculum in this study has resulted in a more progressive pulmonary infection than 
previously observed [145, 404, 405]. The consequence of increased fungal cell 
numbers, especially in the pulmonary environment, is the generation of significant 
amounts of capsular polysaccharide and exopolysaccharide.  This is a possible 
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explanation for the absence of any detailed polysaccharide contamination noted by 
previous studies. 
Cytokines exist at nanomolar to picomolar concentrations that vary significantly in 
response to trauma or infection. Considering the severe technical issues previously 
encountered with Cryptococcus capsular polysaccharides and exopolysaccharides 
(chapters 3, 4 and 5) it was likely that any cytokine data obtained from lung 
homogenates of severely infected rat lungs would be compromised by polysaccharide 
contamination. It was predicted that the attempted replication of the analysis of 
supernatants from tissue homogenates would introduce serious analytical challenges. 
In the place of tissue homogenates, the serum of uninfected control and infected rats 
was analysed using the Bio-Plex suspension array system. While this did not provide 
localised tissue information regarding the cytokine profile of the lungs during 
infection, it had the advantage of providing insight to the systemic response to 
pulmonary fungal infection. 
 
6.4.2. Linear regression models and the cytokine response to infection 
To interpret the general trend of cytokine expression, globally and according to 
functional categories, linear regression models were fitted to the data. Linear 
regression models are a type of trend estimation that fits a linear model to the data, 
independently of anything known about the system being analysed. This provides 
inferences about the general direction of cytokine expression over time, whether the 
trend is random or not, and permits comparisons and interpretations on specific sub-
populations of the data. 
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It was originally hypothesized that the systemic cytokine expression profiles 
generated in response to pulmonary infection with strains of C. gattii assumed to be of 
low (R272) or high (R265) virulence would be significantly different. It was further 
hypothesized that these differences would provide an indication of the specific 
cytokine profile that induces the progression or regression of pulmonary infection. 
The fitting of linear regression models to the cytokine expression data revealed that 
that the reality of infection does not fit this hypothesis. Linear regression models 
indicated that the host generates statistically similar overall cytokine expression 
profiles in response to pulmonary infections with C. gattii strains of either high or low 
virulence. A clear limitation to the fitted linear regression models is that they do not 
provide an explanation for the differences in pulmonary fungal burden and disease 
outcome observed for rats infected with these differing strains of C. gattii.  
This study also hypothesized that there would be an observable difference in the 
systemic cytokine expression profiles generated in response to pulmonary infection 
with C. gattii vs. C. neoformans. The linear regression models fitted to these datasets 
demonstrated a significant increase in global cytokine, pro-inflammatory cytokine and 
chemokine expression in response to pulmonary infection with C. neoformans strain 
KN99α compared to infection with C. gattii strains. Increases in the expression of 
cytokines involved in generating an inflammatory environment can be correlated to 
the extreme degree of symptoms observed for rats infected KN99α. What linear 
regression models fail to provide is insight with regard to the specific molecules that 
are responsible for the observable trends and biological outcomes of cytokine 
expression.  
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6.4.3. More than regression models 
Linear regression models were used to provide general information about the trend of 
cytokine, chemokine and growth factor expression over time in a strain-specific 
manner. While expression trends can provide useful inferences about how changes 
observed during experimentation correlate with the data generated, this form of 
statistical analysis does not provide specific information that aids in the elucidation of 
what is causing the correlation. Specifically, this study found that pulmonary 
infections with R265 and R272 resulted in markedly different pulmonary fungal 
burdens and disease outcomes, but the linear regression models applied to the 
cytokine expression data indicated that the host generated similar cytokine expression 
profiles. It was therefore hypothesised that the analysis of individual cytokines 
significantly changed in expression would provide insight to the molecular 
mechanisms responsible for the cytokine expression trends and biological outcomes 
associated pulmonary cryptococcosis. What follows is the analysis and discussion of 
the significantly differentially expressed cytokines. 
 
6.4.3.1. IL-1α  
IL-1α expression is central to the initiation and persistence of inflammation and the 
promotion of fever and sepsis [413]. IL-1α is produced largely by activated 
macrophages; however, neutrophils, epithelial cells and endothelial cells also produce 
IL-1α. Botelho et al. (2011) determined that IL-1α is central to the initiation and 
exacerbation of smoke-induced neutrophilic inflammation, independently of IL-1β 
[414]. Botelho et al. (2011) also provided evidence that IL-1α is expressed in stable 
chronic obstructive pulmonary disease (COPD) but that IL-1α expression is increased 
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in correlation to COPD exacerbation [414]. The current study demonstrated that IL-
1α expression was significantly increased at the early stage infection time point of 
pulmonary infection with KN99α compared to uninfected controls. This suggests the 
possibility that, in concert with a suitably effective antifungal agent being used to 
eliminate the fungal pathogen, the targeted inhibition of IL-1α could represent a 
therapeutic option for the amelioration of the excessive inflammation observed during 
severe pulmonary infection with highly virulent strains of Cryptococcus. 
 
6.4.3.2. IL-1β  
Produced by activated macrophages as a pro-protein, IL-1β is proteolytically 
processed to its active form by caspase 1. The expression of IL-1β is strongly 
correlated with the expression of the pro-inflammatory cytokine TNF-α in alveolar 
macrophages. IL-1β is a potent pro-inflammatory cytokine that is vital to processes 
such as the initial response to infection or sepsis and in systemic diseases [413]. There 
is evidence that the high expression of IL-1β is inversely related to pulmonary 
function [415]. Churg et al. demonstrated that IL-1β plays a crucial role in the 
development of murine emphysema and small airway remodelling and suggested that 
the amelioration of the IL-1β pro-inflammatory response could limit the amount of 
tissue damage associated with COPD [416]. Similar to COPD, pulmonary infections 
with virulent strains of Cryptococcus are associated with significant tissue 
remodelling and damage. This study demonstrated that IL-1β expression was 
significantly increased at early and late stage infection with R272. As with IL-1α, 
with a suitably effective antifungal agent, the targeted inhibition of IL-1β function 
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during pulmonary infection with Cryptococcus could act to ameliorate the tissue 
damage associated with the pro-inflammatory response to fungal infection.   
 
6.4.3.3. IL-5 
IL-5 is a chemokine (cytokines that have the ability to induce directed chemotaxis in 
nearby responsive cells) generated by Th2 cells and mast cells. IL-5 has been 
identified as a key player in the recruitment of eosinophil granulocytes to the site of 
physiological stimulus during immune responses to respiratory allergens and 
infections [417]. Eosinophils are not found in the lung under normal conditions and 
the observation of pulmonary eosinophilia is generally indicative of disease [418]. 
Eosinophil activation and subsequent degranulation leads to the release of a number 
of cationic granule proteins, reactive oxygen species, lipid modulators, enzymes, 
growth factors and cytokines that are either directly toxic to the infective agent, and 
the host, or promote a toxic environment for pathogen eradication. Eosinophils have 
also been implicated in antigen presentation to T-cells [419]. 
Domachowske et al. (2002) demonstrated that phenotypically normal eosinophils 
could be recruited to sites of physiological stimulus in an environment completely 
devoid of IL-5 [420]. This suggests the presence of distinct subsets of IL-5-dependent 
and independent eosinophils at the site of physiological stimulus under normal 
physiological conditions. Similarly, Foster et al. (2001) concluded that IL-5 is 
primarily responsible for the allergen-induced expansion of pre-existing eosinophil 
populations [421]. Coupled, these findings suggest that IL-5 plays a prominent role in 
eosinophil activation, maturation and survival rather than in direct eosinophil 
recruitment. Domachowske et al. (2002) even speculated that IL-5 might play a role 
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in the more negative aspects of eosinophil biology. IL-5 has been implicated in 
eosinophil overproduction and the prolonged viability of eosinophils in asthmatic and 
allergic lung tissue. This study demonstrated that the expression of IL-5 was 
significantly increased at early stage infection with R265. An improved understanding 
of the role of IL-5 in eosinophil recruitment and function could permit the future 
regulation of the eosinophilic inflammatory response to the benefit of the host.  
 
6.4.3.4. IL-12 p70 
IL-12 p70 is a heterodimeric cytokine, consisting of the two subunits p35 and p40, 
produced by dendritic cells and phagocytes after microbial or cytokine stimulation 
[422]. IL-12 p70, which is also known as T cell stimulating factor, is directly involved 
in the differentiation of naïve T cells into Th1 cells and the subsequent generation of a 
proinflammatory environment [423]. IL-12 p70 induces the production of IFN-γ and 
TNF-α from T cells (CD8+ cytotoxic T lymphocytes) and natural killer cells. This 
cytokine also reduces IL-4, an anti-inflammatory cytokine that induces the 
differentiation of naïve helper T cells to Th2 cells. The production of IFN-γ leads to 
both the killing of targeted cells, be it foreign or host cells, and anti-angiogenic 
activities [424]. 
Duckett et al. (2005) demonstrated that intact IL-12 p70 was pivotal for the protection 
of mice against pulmonary infection with the gram-negative bacterium F. tularensis 
[425]. Pre-treatment with exogenous IL-12 p70, which acts as a strong inducer of 
IFN-γ in the lungs, provided increased protection against lethal respiratory bacterial 
infections. Inoculation with IL-12 p70 did not prevent dissemination nor did it 
influence survival during an already established infection [425]. The protective 
immunity provided by IL-12 p70 pre-treatment was dependent on the presence of 
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IFN-γ and CD8 cells. While the precise mechanisms for IL-12 p70 activated CD8 T 
cell protection from intracellular bacterial infection remains enigmatic, it has been 
speculated that infection is controlled by the lysis of infected macrophages. Similar to 
Cryptococcus, F. tularensis is an intracellular pathogen that targets macrophages. It is 
speculated that the destruction of a niche growth environment, that is, host 
macrophages, limits the potential of infectious agent pathogenesis. Kawakami et al. 
(1996) demonstrated that the early administration of IL-12-induced IFN-γ production 
in the lungs of mice infected with C. neoformans led to increased murine survival 
rates [426]. This study demonstrated that expression of IL-12 p70 was significantly 
increased at late stage infection with R272. At this time point infection appeared to be 
resolved. These results indicate that the pre-treatment of individuals from 
environments of high infection risk with IL-12 p70 represents a potential preventative 
therapeutic option to limit Cryptococcus infection.   
 
6.4.3.5. IL-17 
IL-17, which is also known as IL-17A, is a pro-inflammatory cytokine produced by 
Th17 type cells, γδ T cells, CD8+ T cells, NKT cells, NK cells and neutrophils [404]. 
IL-17 is the defining cytokine for Th17 cells. The secretion of IL-17 generates a 
positive feedback loop causing undifferentiated CD4+ cells to differentiate into TH17 
cells. Th17 cells are potent inducers of inflammatory mediators such as TNF-α, IL-1β, 
and IL-6. IL-17 also acts as a potent mediator of chemokine production that recruits 
monocytes and neutrophils to the site of inflammation in a similar fashion to IFN-γ. It 
has been demonstrated that Th17 cells are able to bridge the innate and adaptive 
immune responses [427]. Th17 cells act as a “backstop” for the immune system in 
that they are recruited when the Th1 and Th2 cells cannot eliminate pathogens [428]. 
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The role that Th17 cells and IL-17 play with regard to susceptibility or resistance to 
fungal infections remains enigmatic. It has been demonstrated that the neutralization 
of IL-17 during oral candidiasis [429] and pulmonary aspergillosis [430] results in 
decreased neutrophil infiltration, reduced levels of chemokines and antimicrobial 
expression and increased fungal burden [427]. Conversely, it has been demonstrated 
that Th17 cell activation promotes deleterious inflammation and defective fungal 
clearance in pulmonary aspergillosis and gastrointestinal candidiasis [431, 432]. 
Wormley et al. (2007) demonstrated that mice infected with IFN-γ-producing, but not 
wild type, C. neoformans (H99) had an increased production of IL-17 that elicited 
protective host immunity against pulmonary cryptococcosis [145]. Wozniak et al. 
(2011) confirmed that IL-17 expression, which was increased during infection and 
resulted in the resolution of acute infection with wild-type C. neoformans, was 
dependent on IFN-γ receptor signalling. Additionally, Wozniak et al. (2011) suggest 
that the observed immune response to infection with C. neoformans was more likely 
associated with the Th1 type immune response than the Th17 type immune response 
[404]. This study demonstrated that IL-17 expression was significantly increased at 
early stage infection with KN99α and R265 and at late stage infection with R265. The 
observed increase in IL-17 expression may represent an attempt by the host to provide 
a “backstop” or supplementary effector for the immune system due to the failure of 
the Th1 type host response to effectively eliminate the most virulent infective agents.  
 
6.4.3.6. GRO/KC 
GRO/KC expression was significantly increased in expression at late stage infection 
with R265. GRO/KC, which is also known as CXCL1, is a potent neutrophil 
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chemoattractant that has been found to be essential to the recruitment of neutrophils to 
the lungs during pathogen infection [433]. Inbred SJL/J mice generate a heightened 
pro-inflammatory response to infection and are resistant to infection with 
Cryptococcus. Guillot et al. (2008) determined that inbred SJL/J mice significantly 
increased the expression of TNF-α and KC/GRO during infection [434]. As 
previously discussed, the Th1 type immune response is protective against infection 
with Cryptococcus. While it is known that TNF-α is a proinflammatory cytokine that 
promotes the Th1 type immune response, the exact role of the neutrophil chemokine 
KC/GRO in host defence against fungal infection is far from clear.  
 
6.4.3.7. IFN-γ 
IFN-γ is a crucial pro-inflammatory cytokine whose expression defines Th1 type 
immune cells and promotes the Th1 type immune response. IFN-γ is produced by a 
myriad of cells including CD4+ T helper cell type 1 lymphocytes, CD8+ cytotoxic 
lymphocytes, NK cells, B cells, NKT cells and professional antigen presenting cells 
(i.e. macrophages, dendritic cells) [435].  An increase in IFN-γ production is generally 
associated with a greater resistance to bacterial, viral and fungal infections. IFN-γ 
production is initiated by macrophage pathogen recognition that induces macrophage 
secretion of both IL-12 and chemokines. The chemokines recruit immune cells to the 
site of inflammation while IL-12 secretion promotes IFN-γ synthesis by these 
recruited immune cells. The expression of IL-12 and IL-18 further promotes the 
synthesis of IFN-γ in macrophages, NK cells and T cells [435]. 
Using strains of C. neoformans engineered to produce host IFN-γ, Wormley et al. 
(2007) [404] and Hardison et al. (2010) [436] independently demonstrated that the 
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expression of IFN-γ stimulated the local Th1-type cell mediated immunity. The result 
was the development of protective host immunity against pulmonary infection. 
Conversely, animals infected with wild type strains of C. neoformans generated a 
Th2-type response to infection, resulting in the progression of disease [145, 436]. This 
study found IFN-γ to be significantly increased in expression at early stage infection 
with KN99α. The induction of IFN-γ production, or the development of a 
recombinant IFN-γ therapeutic, to generate the Th1-type response to infection has the 
potential to act as a therapeutic option for protection against pulmonary infection with 
virulent strains of Cryptococcus. 
 
6.4.3.8. MIP-1α  
Macrophage Inflammatory Protein 1-alpha (MIP-1α) expression was significantly 
increased at early stage infection with KN99α and late stage infection with R265. 
MIP-1α is a pro-inflammatory chemokine generated by macrophages, dendritic cells 
and lymphocytes after stimulation by pathogen endotoxins. MIP-1α plays a major 
role in the recruitment and activation of a myriad of immune cells, including 
granulocytes (such as neutrophils, eosinophils and basophils) as well as T cells and 
natural killer cells, to the site of physiochemical stimulation [437]. MIP-1α also 
induces the synthesis and expression of other proinflammatory cytokines such as IL-1, 
IL-6 and TNF-α from fibroblasts and macrophages. Fittingly, MIP-1α is crucial for 
the effective and efficient immune response towards infection and inflammation 
[438].  
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6.4.3.9. RANTES 
Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) was 
increased in expression at early stage infection with R272. RANTES is a vital pro-
inflammatory chemokine that acts to recruit leukocytes to the site of infection and/or 
inflammation. RANTES appears to have a dual role with regard to Th1 and Th2 type 
immune responses. This chemokine has been implicated in both the IFN-γ dominant 
Th1 response and also in eosinophilic disease that is driven by Th2 type responses 
[439-441]. There is, however, strong evidence that RANTES is essential for driving 
inflammation during respiratory syncytial virus infection [441] and in the recruitment 
of Th1 cells to the lungs for protective granuloma formation during pulmonary 
infection with Mycobacterium tuberculosis [442]. Blocking the action of RANTES 
could be beneficial in mitigating the detrimental effects of an overbearing pro-
inflammatory immune response. Conversely, supplementing the immune system with 
RANTES during the early stages of infection could result in the more efficient 
recruitment of immune cells to the site of infection/inflammation, the promotion of 
the IFN-γ dominant Th1 response and the eradication of disease. Due to the apparent 
divergent roles of RANTES in relation promotion of either the Th1 or Th2 type 
response, the exact therapeutic potential of this cytokine for infections with 
Cryptococcus remains enigmatic. 
 
6.4.3.10. TNF-α  
Tumor necrosis factor (TNF-α) expression was significantly increased at early stage 
infection with KN99α. TNF-α is a potent pro-inflammatory protein produced by 
activated macrophages, CD4+ lymphocytes and NK cells. TNF-α is an endogenous 
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pyrogen that is involved in the regulation of immune cells and acts to induce apoptotic 
cell death, sepsis, cachexia and inflammation. The expression of TNF-α, and the 
subsequent induction of systemic inflammation, acts to inhibit pathogen replication. 
TNF-α is a key member of the group of cytokines that stimulate the acute phase 
response. The maximal production of TNF-α during fungal pulmonary infections is 
dependent on the presence of IL-12 and IL-18.  
Filler et al. (2005) demonstrated that TNF-α knockout mice are susceptible to fungal 
pulmonary infection [443]. While macrophage and neutrophil recruitment appeared 
normal, the recruited immune cells were unable to comprehensively deal with the 
pathogenic fungi. These data suggest that TNF-α is essential for the promotion of a 
Th1 type immune response and the enhancement of leukocyte killing of pathogenic 
organisms. Mehrad et al. (1999) determined that mice treated with anti-TNF-α 
antibodies exhibited diminished neutrophil recruitment to the sight of infection during 
pulmonary fungal infection [444]. Coupled, these studies suggest that TNF-α is vital 
for the recruitment of immune cells to the sight of fungal infection and for 
augmenting the antifungal capacity of the recruited immune cells.  
 
6.4. Conclusions 
The analysis of host cytokine expression in response to pulmonary infection with 
virulent Cryptococcus strains indicated that the systemic response to pulmonary 
infection is largely a Th1 type and/or Th17 type immune response. A pro-
inflammatory Th1 type cell mediated immune response, which is augmented by the 
generation of the Th17 immune response, is believed to be essential for protection of 
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the host from infection with virulent intracellular pathogens, including Cryptococcus. 
This study observed a significant increase in the expression of a number of cytokines 
reported to be fundamental to the initiation and promotion of pro-inflammatory Th1 
and Th17 immune responses. While infection with low virulence R272 was eradicated 
by late stage infection, pulmonary infections generated with the highly virulent 
KN99α and R265 strains of Cryptococcus progressed aggressively. These 
observations suggest that Th1 and Th17 type immune responses are unable to resolve 
infections with highly virulent strains of Cryptococcus.  
Similar to the study conducted by Cheng et al. (2009), this study indicated that the 
host is able to detect C. neoformans more readily than C. gattii, regardless of C. gattii 
type. Cheng et al. (2009) demonstrated that C. gattii induced lower levels of 
neutrophil infiltration and reduced inflammatory cytokine production during murine 
pulmonary infection compared to C. neoformans [411]. While lacking pulmonary 
infiltration data, the current study highlighted a significant increase in global, pro-
inflammatory cytokine and chemokine expression in response to pulmonary infection 
with C. neoformans strain KN99α compared to infection with C. gattii strains.  Cheng 
et al. (2009) correlated reduced inflammatory cytokine production during pulmonary 
infection with C. gattii to the apparent generation of the less protective Th2 type 
immune response. It is more likely in the current study that the significant increase in 
inflammatory cytokine production in response to KN99α is due to a Th1 overreaction. 
A major caveat to the findings made by this study is that infection was produced by a 
large inoculum of Cryptococcus cells, which may have overwhelmed the host 
response and triggered a damaging, overactive Th1 response. Replication of this study 
with more appropriate infective doses is required to elucidate how cytokine 
expression relates to the outcome of infection.  
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The extreme nature of the observed pulmonary fungal burdens and disease outcomes 
for infections with KN99α and R265 suggest that the Th1 and Th17 immune 
responses may actually be promoting fungal pathogenesis. It has been previously 
demonstrated that the incubation of rabbit pulmonary macrophages with TNF-α, a 
potent pro-inflammatory cytokine assumed to be paramount to host protection from 
fungal infection, led to increased A. fumigatus phagocytosis rates and enhanced fungal 
clearance [445]. Unlike A. fumigatus, Cryptococcus can survive and undergo 
phenotypic switching within macrophages, enhancing the development of the 
virulence factors paramount to fungal replication and dissemination. Unfortunately 
this study, either by the analysis of cytokine expression trends or individual cytokine 
expression, was unable to determine what affords the highly virulent KN99α and 
R265 strains with the survival advantages apparently lacking in the eradicated low 
virulence R272. Elucidation of these survival advantages requires the in vivo analysis, 
be it genomic, transcriptomic or proteomic, of the Cryptococcus infective agent, 
which has proven to be technically challenging.  
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Chapter Seven 
General discussion 
This chapter discusses the findings of this doctoral thesis and proposes further work 
that warrants pursuing. 
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7.1. Fungal pathogens - the emerging threat 
Fungal diseases represent an emerging threat to human, animal and plant health. The 
chilling statement made by microbiologist and immunologist Arturo Casadevall that 
“Fungi are the only group of organisms that have been convincingly shown to cause 
extinction” [446] exemplifies the dire consequences of unmitigated fungal disease 
[447]. C. gattii has emerged as pathogenic fungus of concern. In 1999, highly virulent 
strains of C. gattii were identified as causing widespread pulmonary infection and the 
death of otherwise healthy hosts on Vancouver Island, British Columbia, Canada 
[448]. Since 1999, C. gattii has caused an expanding epidemic of human and animal 
infection and death. As of December 2010, C. gattii was associated with 338 
confirmed human infections and 40 deaths [40, 447, 448]. The Vancouver Island 
outbreak represents the largest documented population of C. gattii infected people in 
the world [447, 449]. The initial outbreak on Vancouver Island has spread to 
mainland British Columbia and further south into the Pacific northwest of the United 
States of America [40]. Disease as a result of C. gattii infection is currently under 
public health surveillance in the United States of America, becoming reportable as of 
Autumn 2011 in Oregon and Washington [450]. This means that healthcare providers 
and laboratories must collect and retain specific information on each case and report 
the information to the appropriate public health authority.  
This study set out to identify the global proteome changes that occur in Cryptococcus 
and mammalian host lung tissue during pulmonary infection with Cryptococcus of 
different species and different virulence levels using quantitative proteomic analysis 
platforms. It was hypothesised that the identification of significantly expressed, 
biologically relevant Cryptococcus or mammalian proteins could be exploited as 
  Chapter Seven 
 
 204 
future therapeutic or diagnostic targets. The use of the mammalian model of infection 
to determine the in vivo molecular mechanisms of fungal pathogenesis and the host 
response to infection introduced several significant technical challenges. These 
technical challenges inhibited the integration of alternative “-omics” analyses, such as 
genomics and transcriptomics, with proteomics to further elucidate fungal 
pathogenesis and host-pathogen interactions. 
 
7.2. The elucidation of Cryptococcus pathogenesis and the host 
response to infection requires a holistic approach 
Combined, the emergence of highly virulent strains of C. gattii in environments 
outside their geographical niche and the limited availability of diagnostic and 
treatment strategies for infection with Cryptococcus, have prompted research into this 
previously overlooked fungal pathogen. There is particular interest in determining the 
molecular mechanisms responsible for fungal pathogenesis, and the host response to 
fungal infection. Most studies of fungal pathogenesis have taken a reductionist 
perspective, whereby a specific molecular process is studied in isolation, with limited 
analysis of the broader biological system. Understanding invasive fungal infection 
requires the comprehensive investigation of the complex interactions between host 
and the pathogen. This requires the quantitative analysis of a large number of 
functionally diverse genes, proteins and metabolites [451].  Systems biology is an 
emerging approach to biomedical and biological research. This generally involves 
biology-based interdisciplinary experimentation that focuses on the holistic analysis 
of the complex interactions within biological systems [452]. The evolution of 
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integrated, high-throughput, systems-oriented approaches to understanding the 
mechanisms that underlie infection and immune response are improving the analysis 
of these complex systems [453].  
To date the in vivo study of the interplay between fungal pathogens and the host at the 
level of the genome, transcriptome and proteome remains limited [451]. The primary 
challenges are the highly complex nature of pathogen-host interactions and the limited 
number of methods available for the separation of fungal and host material (that is, 
DNA, RNA and protein) [451]. Most “-omics” studies of fungal pathogenesis have 
focused on fungi grown under controlled in vitro or ex vivo conditions. While these 
studies have been able to use global comparative analysis platforms to identify genes 
[454-459], proteins [272, 460, 461] and pathways of relevance to human-pathogenic 
fungi, such as Aspergillus fumigatus, Candida albicans and Cryptococcus, they 
cannot capture the complexity of in vivo infection. Several studies have attempted to 
broaden their analysis by determining the proteome changes that occur in cultured 
host cells after exposure to fungal pathogens in tandem with the investigation of the 
proteome changes that occur in the fungus itself [462-464]. While increasing the 
perspective of analysis, this in vitro approach does not replicate the complex host 
environment and thus limits the interpretation of how fungi respond to in vivo 
infection. The current study attempted to use a systems biology approach, focused 
primarily on proteomic analyses, to study Cryptococcus pathogenesis and the host 
reposes to pulmonary infection using the rat model.  
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7.3. Cryptococcus protein extraction protocols - a work in progress 
The research presented in this thesis demonstrated that lyophilisation of Cryptococcus 
reduced the high level of structural integrity provided by the polysaccharide capsule, 
allowing for subsequent mechanical cellular disruption. This study also demonstrated 
that phenol protein extraction could largely prevent the inhibitory effects of non-
protein capsule contamination. Despite these advances, the optimal removal of non-
protein contaminants remains the primary issue associated with Cryptococcus 
obtained from pulmonary infection. Additionally, this study demonstrated that despite 
extensive washing procedures rat proteins continued to contaminate the preparation of 
intracellular Cryptococcus proteins from pulmonary infection. The co-identification 
of rat and Cryptococcus proteins gave clear evidence that the proteomes remained 
mixed.  
Despite these technical challenges, this is the first study to successfully extract and 
identify intracellular Cryptococcus proteins from mammalian pulmonary infection. 
One of the most significant achievements of this study was the proof of concept for 
the global “-omics” analysis of Cryptococcus obtained from in vivo sources. 
Furthermore, the qualitative comparison of in vitro and in vivo C. gattii offered 
insights into fungal pathogenesis at the protein level and highlighted a number of 
Cryptococcus proteins that could be exploited as potential drug targets, biomarkers 
and diagnostic markers. Future work from this study should include continued 
protocol development aimed at the complete amelioration of polysaccharide 
contamination and contaminating rat proteins. This requires further research to 
discover more suitable disassociating agents that can be used before and after cellular 
disruption, or the development of suitable de-capsulation techniques prior to cellular 
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disruption. The advances made should lead to future quantitative analyses of 
Cryptococcus, and other fungal pathogens, under in vivo conditions. 
 
7.4. Comparative proteomics revealed lung proteins of biological 
relevance 
During in vitro and in vivo growth Cryptococcus continuously sheds polysaccharide 
capsule into the extracellular surroundings. These exopolysaccharides represent a 
significant non-protein contaminant that inhibited the proteomic analysis of host 
tissue infected with Cryptococcus. Acidic protein extraction protocols reduced the 
effects of exopolysaccharide contamination, and it would be of interest to now 
determine whether phenol extraction of proteins could more effectively remove the 
exopolysaccharides. Unfortunately, experiments involving phenol protein extraction 
were undertaken after the completion of the work involving the iTRAQ analysis of 
control and infected host tissue. 
iTRAQ comparative proteomics suggested that the fundamental response of the host 
to pulmonary infection with Cryptococcus is uniform, regardless of infecting species, 
level of virulence, or disease outcome. This study highlighted the potential of 
inhibiting Cryptococcus pathogenesis by supplementation of the host with 
recombinant lung proteins. The work in this study provides further evidence that 
global proteomic approaches can be used to identify potential drug targets, biomarkers 
and diagnostic markers from in vivo mammalian infection models. Future work based 
on this study would involve the validation of expression states for the proteins 
identified as being biologically relevant. This can be achieved using 2-D PAGE, 
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Western blot or multiple reaction monitoring (targeted quantitative mass 
spectrometry) [465, 466]. Validation work would then be followed by in vitro and in 
vivo experimentation to deduce the physiological effects of protein function 
modulation (ranging from function deletion to recombinant protein supplementation) 
on both the animal model utilised and on fungal pathogenesis. While these 
experimental processes are time consuming and demanding on resources, the results 
obtained would provide comprehensive insight into the function of an identified 
protein and its potential as a drug target. 
 
7.5. The systemic cytokine response to infection 
In the current study, infection with C. neoformans resulted in significant increases in 
global cytokine, pro-inflammatory cytokine and chemokine expression compared to 
infection with C. gattii. This agrees with previous studies that have suggested that the 
host more readily detects C. neoformans than C. gattii [411].  Unfortunately, the 
current study was unable to determine why the highly virulent strains KN99α and 
R265 had a survival advantage over the low virulence strain R272, which was 
eradicated. Pulmonary infection with virulent Cryptococcus progressed, despite an 
increase in expression of cytokines, chemokines and growth factors that should result 
in the infection inhibition and/or eradication of infection. This study indicates that 
host response alone cannot eradicate disease with highly virulent strains of 
Cryptococcus. The eradication of infection with highly virulent strains of 
Cryptococcus requires effective diagnostic and treatment strategies. The development 
of said strategies has not kept pace with the emergence of cryptococcosis. The 
discovery of novel therapies requires an improved understanding of host-pathogen 
  Chapter Seven 
 
 209 
interactions, which could be accomplished via future integrated “-omics” analyses of 
how Cryptococcus behaves under host conditions. 
 
7.6. Is there a relationship between pulmonary Cryptococcus infection 
and COPD? 
Chronic obstructive pulmonary disease (COPD) is defined by characteristically low 
airflow on lung function tests that is poorly reversible and progressively worse over 
time [467, 468]. In reality COPD refers to two main conditions, emphysema and 
chronic bronchitis [467]. Emphysema is a long-term progressive condition where the 
tissue supporting the physical shape and function of alveolar and surrounding tissue is 
destroyed [366]. Chronic bronchitis, the chronic inflammation of the bronchi, 
increases the thickness of the walls of the airways and induces the overproduction of 
mucus, both of which can lead to airway obstruction. The severity of COPD has been 
directly linked to the presence of an oxidant/antioxidant imbalance in lungs, with an 
increased oxidant burden contributing to epithelial damage [469]. COPD has become 
a global epidemic and is likely to become the third largest cause of death worldwide 
by 2020 [470]. Traditionally, COPD is caused by the inhalation of noxious particles 
or gases that trigger abnormal inflammatory responses in the lung [471]. 
Observations made by this study, of general rat health and the progression of infection 
at the early and late stage infection time points, suggest that pulmonary infection with 
virulent strains of Cryptococcus could fall under the general description of COPD. 
Fungi are not considered classical irritants associated with the development of COPD, 
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however, pulmonary infections with virulent Cryptococcus strains generates 
symptoms consistent with COPD: 
• There is a severe limitation to the normal functions of the pulmonary system that 
gets worse over time. 
• The physiology of the lungs is affected. This was indicated by the comparison of 
uninfected control and diseased lung morphology at the macroscopic scale and by 
iTRAQ data that identified proteins involved in cell and tissue remodelling. 
Similarly to emphysema, alteration of the physical nature of the lungs induced by 
infection with Cryptococcus corresponds with a high level of tissue damage and 
destruction.  
• Similar to chronic bronchitis, infection with virulent Cryptococcus strains induces 
acute and chronic inflammation in the lung tissue and associated airways. 
Additionally, this study identified proteins (including cytokines) that indicate the 
progression of airway inflammation.  
• iTRAQ data obtained in this study indicated that there was an increased oxidant 
burden in the pulmonary environment, which is known to exacerbate COPD. 
While not entirely falling under the scope of COPD, observations by this study at the 
macroscopic and molecular level suggest that rat pulmonary infection with virulent 
Cryptococcus strains exhibit the signs and symptoms associated with COPD. This 
suggests that that pulmonary cryptococcosis could be considered a type of COPD. As 
with cryptococcosis, COPD has no cure. Furthermore, diagnosis of COPD is limited 
to lung function tests, chest X-ray or CT scans and arterial blood gas tests that only 
indicate disease once symptoms are severe [472]. The amelioration of COPD and 
cryptococcosis requires diagnostic advancements that are capable of identify early 
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stage disease. Subsequent induction of therapeutic options in early stage disease 
would limit the development of severe pulmonary tissue inflammation and destruction 
that are associated with these emerging diseases. 
 
7.7. Conclusions 
The most significant achievements made by this study were the advances in protocol 
development. This study also demonstrates that systems-oriented approaches to 
understanding invasive Cryptococcus infection have the ability to identify molecules 
of biological relevance to pulmonary cryptococcosis. It is hoped that, given continued 
protocol development, the advances made by the current study will permit future 
integration of proteomics analyses of in vivo fungal infection with genomics, 
transcriptomics and other alternative “-omics” analysis platforms. The integrated “-
omics” analysis of fungal pathogens and the host responses to infection under in vivo 
conditions should make it possible to uncover the molecular and cellular dynamics of 
the complex host-pathogen interactions. Additionally, it is hoped that these future 
integrated studies will lead to the development of novel therapeutic and diagnostic 
options that are so desperately required to meet the growing threat of emerging fungal 
pathogens. 
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